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ABSTRACT
This thesis involves two lines of investigation into aspects of coronary heart disease: 
firstly dyslipidaemia in non-insulin-dependent diabetes mellitus (NIDDM), systemic lupus 
erythematosus (SLE) and psoriatic arthritis (PA), and secondly the role and origin of human 
anti-xanthine oxidase (XO) antibodies.
Atherogenic abnormalities in fasting and postprandial lipemia were demonstrated in 
hypertriglyceridaemic subjects with NIDDM. Elevated fasting levels of large triglyceride- 
rich lipoproteins were exaggerated and prolonged postprandially in NIDDM compared to 
controls. Postprandial triglyceride response was proportional to fasting triglyceride levels in 
patients and controls. Raised levels of small, dense low density lipoprotein (LDL), reduced 
levels of high density lipoprotein (HDL) cholesterol and triglyceride-enrichment of LDL-2 
and HDL persisted postprandially in NIDDM. Both fasting and postprandial triglyceride 
were strongly associated with prevalence of small, dense LDL in diabetic patients.
Bezafibrate therapy reduced fasting and postprandial triglyceride-rich lipoproteins 
and small, dense LDL in NIDDM towards that of normolipidaemic subjects. Reductions 
were greatest in chylomicrons and large very low density lipoprotein (VLDL). In the 
postprandial state, the proportion of large VLDL in total VLDL mass and triglyceride- 
enrichment of HDL were reduced in subjects with NIDDM. Such alterations clearly reduce 
atherogenic potential.
Fasting lipoprotein subtraction distribution and composition was studied in SLE and 
PA. In both patient groups, particularly females, the proportion of small, dense LDL in 
total LDL was elevated, independent of triglyceride levels. HDL cholesterol was 
significantly reduced in PA patients and tended to be low in SLE patients compared to 
controls. These abnormalities have atherogenic implications.
To study the origin and role of anti-xanthine oxidase antibodies, such antibodies 
were measured in the serum of normal healthy subjects. Levels of IgM anti-human xanthine 
oxidase (HXO) antibodies were higher than IgM anti-bovine xanthine oxidase (BXO) 
antibodies suggesting that the immunogen was endogenous HXO rather than ingested BXO. 
IgM anti-BXO (and HXO) antibodies were higher in younger females compared to age- 
matched males and older females. Levels of IgG anti-BXO and HXO were much lower and 
showed no such age and gender differences.
IgM anti-BXO antibody levels were significantly higher in patients dying within six 
months of a myocardial infarction (MI) compared to survivors and tended to be raised in 
patients who had suffered a MI compared to controls. No difference was found between
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diabetic patients and controls. A lack of positive correlation of the extent of the MI with 
antibody levels suggests that these antibodies were not the result of the MI itself but 
produced prior to the MI, possibly due to chronic lesions of capillary endothelium exposing 
XO to the immune system. A protective role for anti-XO antibodies in heart disease, by 
neutralising XO, is consistent with the age and gender differences in healthy subjects.
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This thesis separately investigates firstly dyslipidaemia in NIDDM, SLE and PA, and 
secondly the role and origin of human anti-xanthine oxidase antibodies in certain 
populations, in view of their potential role in atherogenesis and coronary heart disease. 
Chapter one includes an introduction to lipoprotein metabolism, lipoproteins and heart 
disease and dyslipidaemia in diabetes, systemic lupus erythematosus and psoriatic arthritis. 
Also included is an introduction to the properties, distribution, function and role in 
ischemia-reperfusion injury of xanthine oxidase, and finally the relationship between anti­
xanthine oxidase antibodies and heart disease. The aims of the thesis are stated at the end 
of this Chapter. Methodology is described in Chapter 2 and results, with relevant 
discussion, are reported in Chapters 3-8. Conclusions are stated in Chapter 9.
1.1. CORONARY HEART DISEASE
Coronary heart disease (CHD) is the leading cause of death in economically 
advanced countries. In England and Wales 30% of all deaths amongst men and 22% of all 
deaths amongst women are the result of CHD (Dwyer et al, 1980), defined by the World 
Health Organisation as ‘the cardiac disability, acute or chronic, arising from reduction or 
arrest of blood supply to the myocardium in association with disease processes in the 
coronary arterial system’. CHD in middle-age is predominantly a male problem, but gender 
differences are much less with increasing age (Heller, 1978). In women, oestrogen is 
believed to have a protective effect against CHD, which disappears after the onset of the 
menopause. There are marked international differences in the rate of occurrence of CHD. 
In general, the highest coronary mortality occurs in Northern Europe and Northern 
America, while in Southern Europe and Japan rates are much lower (Marmot, 1984). 
People who have migrated from a low-risk country, such as Japan, to a high-risk country, 
such as USA, have tended to adopt the rates of CHD of the high-risk country, suggesting 
that variations between countries are often due to environmental or behavioural differences 
(Nichamen et al.,1975). Known risk factors for CHD include hypercholesterolaemia, 
smoking, hypertension, diabetes mellitus, physical inactivity, age, male sex, family history of 
CHD and obesity.
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In CHD, the reduction of flow of blood to the myocardium is caused by the 
narrowing of arteries supplying the tissue. This can be caused by thrombus formation, artery 
spasm or the thickening of the artery wall, a process known as atherosclerosis. There are 
three main clinical presentations of CHD:
1. Angina Pectoris. Usually a chronic and sometimes intermittent symptom, resulting from 
inadequate supply of oxygen to the myocardium. It is characterised by chest pain on 
exertion which is relieved by rest.
2. Myocardial Infarction. The sudden loss of sustained blood supply to the myocardium 
causes tissue injury and necrosis and prevents normal myocardial contraction. This is 
characterised by severe chest pain, and may or may not be fatal.
3. Sudden Death. Death from ventricular fibrillation may occur suddenly and without 
warning or within hours of the onset of cardiac symptoms.
Other manifestations of CHD include cardiac failure and non-fatal arrhythmias.
1.2. ATHEROSCLEROSIS
Atherosclerosis is defined as a variable combination of changes in the intima (inner 
lining) of arteries consisting of focal accumulation of lipids, other blood constituents and 
fibrous tissue, accompanied by changes in the media (middle layer) of the vessel wall. 
These features are the result of interaction between the structural and metabolic properties 
of the artery wall, composition of the blood and haemodynamic forces. Atherosclerosis 
develops over many years and may be asymptomatic. However, symptomatic 
atherosclerosis may occur in minutes and the clinical consequences can include coronary 
heart disease (angina pectoris, myocardial infarction and sudden death), cerebrovascular 
disease (stroke) or peripheral vascular disease (intermittent claudication, gangrene).
Endothelial damage, stemming from various causes including hypercholesterolaemia, 
is the initiating event in atherogenesis. Lipoproteins (LDL and VLDL/chylomicron 
remnants) become attached to the site of injury on the endothelial surface of the arteries and 
attract monocytes to the site of injury. These monocytes subsequently penetrate through 
the endothelium into the subintimal space and mature into macrophages. Macrophages 
become foam cells as they internalise lipid and accumulate resulting in formation of a fatty 
streak. Macrophages attract platelets to the site of the fatty steak which release platelet- 
derived growth factor causing smooth muscle proliferation, and the eventual conversion of a
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fatty streak into a proliferative lesion or fibrous plaque, thus narrowing the lumen of the 




Lipids are used by cells for a wide range of functions including membrane synthesis, 
hormone production and energy provision. The liver and intestine are the main sites of lipid 
synthesis and a directed and efficient transport mechanism has evolved in man and other 
species for their dispersion to other tissues. Neutral lipids (cholesterol esters and 
triglycerides) are hydrophobic and can only be transferred through the aqueous environment 
of plasma in macromolecular complexes containing protein (apolipoproteins) and polar 
lipids (phospholipids). These structures are known as lipoproteins and form a spectrum of 
particles which can be divided into a number of classes according to differing physical 
and/or chemical properties. The basic structure of lipoproteins consists of a hydrophobic 
core of triglyceride and cholesterol ester surrounded by a surface monolayer of protein and 
phospholipid. Free cholesterol spans the region intermediate between these two parts of the 
micelle structure.
The most common classification is based on hydrated density (g/ml) or their 
flotation rates, measured in Svedberg units (Sf) in the analytical centrifuge at a fixed 
background density. This approach was developed by Gofman, Lindgren and co-workers 
(Gofman et al, 1949) producing five classes of lipoprotein: chylomicrons, very low (VLDL), 
intermediate (IDL), low (LDL), and high (HDL ) density lipoproteins, each of which is 
heterogenous in terms of size, lipid composition and apolipoprotein content. Techniques 
such as electrophoresis, gradient ultracentrifiigation and affinity column chromatography 
have revealed structurally discrete subgroups within these classes. VLDL and LDL 
subfractions can be separated either by gel electrophoresis producing several bands of these 
lipoproteins, or by cumulative flotation ultracentrifiigation (CFU) commonly producing 
three VLDL and three LDL subfractions. Some lipoproteins (VLDL and HDL) can also be 
isolated using precipitation techniques. Both the CFU and the precipitation techniques are 
used in this thesis and are described in more detail in the methods section (Chapter 2).
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1.3.2. Composition
The physical and chemical properties of the major lipoprotein classes are shown in Table
1. 1.
Chylomicrons are the largest lipoprotein particles varying in diameter from 75 to 
1200nm. In normal individuals, chylomicrons are virtually absent in the fasting state. They 
are formed in the intestinal epithelial cells and their main lipid content, triglyceride, is 
synthesised from re-esterification of dietary monoglycerides and fatty acids. Triglycerides 
represent 80-90% by weight of chylomicrons and protein accounts for 1-2% of the mass. 
The remainder is composed of phospholipid, cholesterol ester and free cholesterol in 
decreasing proportion. They contain apolipoproteins B48, AI, AIV and C initially and 
apoCs and E are acquired from HDL or VLDL particles in the lymphatic or systemic 
circulation.
Very low density lipoproteins are similar to chylomicrons with triglyceride as their 
main lipid component. These particles are secreted by hepatocytes and range in size from 
30-80nm with hydrated density <1.006g/ml. Apolipoproteins B100, CII, CIII and E are the 
main protein constituents and have important regulatory roles in the catabolism of these 
particles. p-VLDL are so called because they float at d<1.006g/ml upon 
ultracentrifiigation but migrate with P-lipoproteins (LDL) on electrophoresis. P-VLDL are 
cholesterol-rich catabolic remnants of chylomicrons and VLDL, which are believed to be 
potentially atherogenic due to their receptor-mediated uptake by macrophages (Goldstein et 
al., 1980).
Intermediate density lipoproteins have a hydrated density of 1.006-1.019g/ml and 
represent a partial transition from VLDL to LDL particles as a result of the hydrolysis of the 
triglyceride moiety. The protein content of IDL is mainly apo B-100 and apo E with less 
apo C than VLDL.
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Chylomicron <0.95 >400 75-1200 Origin B48, AI, E
cn, cm
5 2 84 7 2
VLDL 0.95-1.006 20-400 30-80 Pre-P B100, Cl,
cn, cm, e
11-14 5-8 44-60 20-30 4-11
IDL 1.006-1.019 12-20 25-35 Broad p B100, E, Cl,
cn, cm
22 8 30 25 15
LDL 1.019-1.063 0-12 18-25 P B100 38 8 11 22 21
HDL 1.063-1.21 none 5-12 a AI, An, E,
ci, cn, 
cm
13 6 3 28 50
Flotation rate (Sf) is quoted against background solvent density of 1.063g/ml.
Low density lipoproteins are the main cholesterol-carrying lipoprotein in man and 
account for 70% of circulating cholesterol. These lipoproteins (hydrated density of 1.019- 
1.063g/ml) contain apo B100 as their major apolipoprotein and are formed by synthesis in 
the liver as well as catabolism of VLDL. Trace amounts of apo C and apo E are also 
present.
High density lipoproteins are the heaviest (density 1.063 to 1.21g/ml) and smallest 
(diameter 5.5-12.0nM) of the lipoproteins and contain apo AI and All as their major protein 
moieties accounting for approximately 30% of the total protein. Trace amounts of apo Cl, 
CII, CIU, D and E also present. HDL are the most abundant lipoprotein particles although 
they only carry 20% of the circulating cholesterol. They are formed from precursors 
synthesised in the liver and small intestine, or from the surface components of triglyceride- 
rich lipoproteins released during lipolysis. HDL are customarily divided into two major 
density classes: HDL2 (density, 1.063-1.125g/ml) and HDL3 (density, 1.125-1.21g/ml).
Lipoprotein (a) is an LDL-like particle, synthesised in the liver, containing 
cholesterol, phospholipid, triglycerides and apo B100, with the latter linked via a single 
disulphide bond to a second large protein termed apoprotein (a) (Utermann, 1989). The 
structure of apo (a) has a high degree of homology to plasminogen and contains a number 
of pretzel-like structures termed kringles. The molecular weight of apo (a) varies between 
450-750KD, and the relationship between molecular weight and plasma concentration is an 
inverse one (Fless et al., 1985).
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1.3.3. Apolipoproteins
The apolipoprotein moieties of plasma lipoproteins (Table 1.1) serve unique 
functions in the biogenesis, transport and metabolism of plasma lipoproteins. Eleven major 
apolipoproteins have been sequenced, and the genes responsible for their synthesis have 
been mapped in the human genome (Schonfeld, 1990; Breslow, 1991). With the exception 
of apo (a), the apolipoproteins possess an amphipathic helical region which contributes to 
their unique ability to transport lipids in an aqueous environment. Apolipoproteins (i) 
solubilise cholesterol esters and triglyceride by interacting with phospholipids; (ii) regulate 
the reaction of certain enzymes such as lecithin: cholesterol acyltransferase (LCAT), 
lipoprotein lipase (LPL) and hepatic lipase (HL); and (iii) bind to cell surface receptors 
therefore determining the sites of uptake and rates of degradation of their lipoprotein 
constituents. With the exception of apo B48, B100, and apo (a), all the apolipoproteins 
appear capable of dissociating from one lipoprotein and moving to another. This movement 
of apolipoproteins between lipoproteins not only serves to enhance processing of a given 
lipoprotein particle, but also prolongs the residence time of the apolipoproteins in plasma.
Apo AI is synthesised in the liver and intestine. It accounts for 70% of the total 
protein of HDL. Its main metabolic roles are as cofactor for the enzyme LCAT, and in 
promoting cholesterol efflux from the tissues. Apo All is mainly synthesised in the liver and 
is the second commonest protein in HDL, although its function of has not been determined. 
Apo AIV is synthesised only in the small intestine and is a minor component of HDL and 
chylomicrons. It may play a role in the activation of LCAT.
Apo B48 is essential for the assembly and secretion of chylomicrons. It is so called 
because it constitutes 48% of the amino terminal end of apo B100 (Powell et al, 1987). It 
appears that apo B48 is generated from the same gene and messenger RNA as apo B100, 
but that only approximately half of the gene is translated into the protein in the intestine. 
Once the chylomicron has been secreted from the small intestine, it appears that apo B48 
has no other role in the plasma metabolism of this lipoprotein or in the removal of 
chylomicrons from the plasma by the liver.
Apo B100 is the largest apolipoprotein (500KD), produced largely in the liver and 
secreted in VLDL particles on a 1:1 molar basis. It is essential for assembly and secretion 
of VLDL and as the ligand for the LDL receptor. The receptor binding domain of apo
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B100 is absent from apo B48. Recent evidence suggests that variants of apo B100 which 
bind poorly to receptors may be an important cause of hyperlipidaemia in the population 
(Innerarity et al., 1990).
There are three C apolipoproteins (Cl, II and III) all of which are synthesised in the 
liver. Apo CII has an important role as a cofactor for LPL which hydrolyses triglycerides in 
VLDL and chylomicrons, whereas Apo CIII is an inhibitor of LPL activity. The exact 
function of Apo Cl is unknown.
Apo E is synthesised in the liver and is found on all the lipoproteins. Apo E on 
LDL and VLDL remnants bind to the LDL receptor. It regulates the removal of
chylomicron remnants from the plasma by the liver, although the exact mechanism of this 
activity is unknown. The receptor responsible for the removal of these remnant particles 
appears to be distinct from the LDL receptor, and has apo E alone as its ligand (Hoeg et al., 
1985).
As previously noted apo (a) is a protein associated with Lp (a). Apolipoprotein D is 
a minor component of HDL and its function is unknown.
1.4. LIPOPROTEIN METABOLISM
The wide variation in lipid and lipoprotein levels within and between populations 
suggests that the homeostatic mechanisms regulating plasma lipoprotein levels are not under 
tight control. Many factors can influence plasma lipoprotein levels including genes, 
hormones and diet. Abnormalities in lipoprotein metabolism are known to be associated 
with atherosclerosis and have been the subject of thorough investigation in recent years. 
The liver plays a crucial role in the homeostasis of lipoproteins by controlling their secretion 
and removal from the plasma. Lipoprotein metabolism can be considered as endogenous 
and exogenous pathways. The exogenous pathway is concerned with the absorption and 
transport of dietary fat and the endogenous pathway transports lipoproteins synthesised in 
the liver to the periphery.
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1.4.1. The exogenous pathway
Nearly all the dietary cholesterol and triglyceride are transported by chylomicrons. 
Ingested triglycerides are hydrolysed in the intestine, releasing free fatty acids which are 
then re-esterified to form triglycerides in the intestinal mucosal cell and are assembled with 
apolipoprotein B48 and other apolipoproteins. During secretion from the enterocyte, these 
assembled particles enter the lymphatic circulation and then the blood stream where they 
acquire apo C and E from HDL and transfer apo AI and All to HDL. In the plasma, the 
triglyceride is rapidly hydrolysed by lipoprotein lipase which resides on the surface of the 
capillary endothelium.
As triglyceride is hydrolysed from the chylomicrons, phospholipid, free cholesterol 
and apo A and C are transferred to HDL producing a triglyceride depleted and cholesterol 
enriched chylomicron remnant. These remnants are believed to be cleared by the liver by 
the binding of apo E to a protein similar to the LDL receptor (Beisiegel et al, 1989), called 
the LDL-receptor-related protein (LRP). The remnants enter liposomes in the liver from 
which cholesterol can enter metabolic pathways or be excreted into the bile.
1.4.2. The endogenous pathway
I.4.2.I. Very low density lipoprotein metabolism
VLDL are triglyceride-rich lipoproteins secreted by the liver and transport 
triglyceride to the peripheral tissues. Many factors influence the secretion of hepatic VLDL 
including nutrient intake, and plasma concentrations of free fatty acids, insulin, glucagon 
and epinephrine. The size of VLDL seems to be determined mainly by the amount of 
triglyceride available (Ginsberg et al., 1985). If triglyceride availability is reduced the liver 
may actually secrete IDL or LDL. VLDL are metabolised in a similar manner to 
chylomicrons by LPL, liberating fatty acids for uptake by the peripheral tissues. VLDL 
acquire additional apo C and E by transfer from HDL, in exchange for free cholesterol 
which is esterified by the enzyme LCAT and then returned to VLDL by cholesterol ester 
transfer protein (CETP) in exchange for triglyceride. As VLDL becomes triglyceride 
depleted, a portion of the surface including apo C and E and phospholipids are transferred 
to HDL. Smaller triglyceride-depleted VLDL particles (VLDL remnants or IDL) can either 
be removed from the circulation by receptors in the liver, including apo B/E receptors and
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possibly LRP, or further metabolised by hepatic lipase (HL) to form LDL. Smaller more 
dense VLDL (S f 20-60) are more efficiently converted to LDL via IDL, whereas larger 
VLDL (Sf 60-400) are more likely to be converted to a form of IDL which is removed by 
the liver (Packard et al., 1984).
I.4.2.2. Low density lipoprotein metabolism
LDL is the major cholesterol-carrying particle present in plasma and, metabolically, 
LDL may be regarded as the end product of VLDL metabolism. The only apolipoprotein 
present in LDL is apo B and only one molecule of apo B is present per particle. Clearance 
of LDL is mediated by a specific receptor (apo B/E or LDL receptor) present on the surface 
of both liver and peripheral cells. The identification of this receptor and its role in 
cholesterol homeostasis was recognised by Goldstein and Brown (1977) for which they 
were awarded a Nobel prize.
After binding to the receptor, the LDL are internalised and the influx of free 
cholesterol sets into motion a cascade of events to control the cholesterol content of the 
cell: (i) esterification of cholesterol is stimulated by activation of acyl-coenzyme A 
cholesterol acyl transferase (ACAT); (ii) de novo cholesterol synthesis is reduced by the 
inhibition of 3-hydroxy-3-methyl-glutaryl Co A (HMGCoA) reductase, the rate-limiting 
enzyme in cholesterol biosynthesis; (iii) synthesis of the B/E receptor is inhibited which 
therefore limits further uptake of LDL cholesterol. Although the numbers and activity of 
LDL receptors are major factors in determining plasma LDL cholesterol levels, the initial 
rates of entry of VLDL into plasma and the efficiency with which VLDL are converted to 
LDL play crucial roles in determining steady-state LDL concentrations in the plasma.
The scavenger pathway is an alternative mechanism for the removal of LDL from 
the circulation. This mechanism is not mediated by the B/E receptor but by the scavenger 
receptor on tissue macrophages as well as by non-specific endocytotic uptake. These 
processes become increasingly important when either defects in the LDL receptor or 
abnormalities in VLDL and LDL composition are present.
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1.4.2.3. High density lipoprotein metabolism
HDL is thought to play a critical role in preventing tissue accumulation of 
cholesterol. Nascent HDL are secreted by the liver as cholesterol-poor, protein-rich 
particles containing apo C, E and A, although some HDL is produced by the intestine. 
HDL particles can contain apo AI and All or just AI alone and because of the varying 
amounts of cholesterol per HDL particle, measurements of apo AI in plasma provide a 
better indication of HDL particle number than measurements of HDL cholesterol. Surface 
components of chylomicrons and VLDL are transferred to HDL during lipolysis. 
Cholesterol is transferred from peripheral cell membranes to HDL and is subsequently 
esterified by LCAT, which circulates in association with HDL. In this way, the small dense 
HDL precursor, known as HDL3, increases in size during the lipolytic process and 
cholesterol transfer process producing larger particles known as HDL2. The esterified 
cholesterol can either be stored within the non-polar core of the particle or transferred to 
triglyceride-rich lipoproteins by CETP in exchange for triglyceride. HDL2 as well as 
triglyceride-rich lipoproteins are cleared by the liver and therefore assist the pathway for 
reverse cholesterol transport by which cholesterol from the peripheral tissues can be 
removed and transported to the liver for excretion in the bile. Triglyceride-rich HDL2 is 
hydrolysed by hepatic lipase producing HDL3. In addition, hepatic lipase may hydrolyse 
HDL phospholipids, which in turn may promote the transfer of cholesterol from the HDL 
surface to the liver. Finally, there may be specific HDL receptors on peripheral cells that 
may be involved in the specific uptake and degradation of the HDL particles (Graham et al, 
1987).
I.4.2.4. Lipoprotein (al metabolism
Lp (a) is synthesised in the liver. Little is known about its clearance, but it is 
believed to be cleared by the B/E receptor. Increased plasma Lp(a) concentrations are 
associated within increased risk of cardiovascular disease (Hoefler et al, 1988), but the 
precise physiological function of Lp (a) is unknown (Kostner et al, 1992).
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1.5. LIPOPROTEINS AND HEART DISEASE
Total plasma or serum cholesterol levels have been shown to correlate with CHD in 
both case-control and prospective studies (Nichamen et al.,1975; Keys, 1980; Martin et 
al.,1986; Stamler et al.,1986; Shaper et al., 1986). Initially it was believed that a threshold 
level existed below which the risk of CHD reached a plateau, but a more recent study 
suggests that the risk is continuous over the whole range of serum cholesterol (Martin et 
al.,1986). This study showed that risk of CHD rises appreciably when cholesterol levels 
exceed 6.5 mmol/1 and even more so when levels exceed 7.8 mmol/1. Lowest rates of CHD 
occurred in individuals with serum cholesterol levels of below 5.2 mmol/1. Although 
hypercholesterolaemia alone is certainly a major factor for CHD risk, there are a variety of 
processes in lipoprotein metabolism which also play an important role in atherogenesis.
1.5.1. Chylomicrons
Abnormalities in transport and metabolism may lead to the involvement of 
chylomicrons in the atherogenic process (Zilversmit, 1979). Situations where prolonged 
residence times of chylomicrons might occur would include states where there is reduced 
LPL activity (eg. diabetes) or where there is an imbalance of apo CII and CIII. Excess 
VLDL could also compete with chylomicrons for LPL resulting in elevated chylomicrons 
(Brunzell et al, 1973). Several studies have associated abnormalities of chylomicrons or 
chylomicron remnant metabolism with the presence of CHD (Groot et al., 1991; Simons et 
al., 1987). In these studies men with CHD have higher postprandial levels of chylomicron 
triglycerides than men without the disease.
1.5.2. Very low density lipoproteins
Fasting triglyceride levels are among the most potent risk factors for CHD. In fact, 
hypertriglyceridaemia is one of a number of CHD risk factors in a constellation known as 
Syndrome X. This syndrome comprises of insulin resistance, glucose intolerance or 
diabetes, obesity, hypertriglyceridaemia, low HDL cholesterol, and hypertension. However, 
in multivariate analyses including other lipid parameters, the association between fasting
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triglyceride and CHD is often not maintained, primarily because HDL cholesterol, by virtue 
of its inverse association with triglycerides, eliminates triglyceride as a risk factor for CHD 
(Austin, 1991). Elimination through statistical analysis constitutes a paradox because in 
reality, the concentration of HDL is dependent on the metabolism of triglyceride-rich 
lipoproteins (Tall, 1990), and multivariate analysis requires an independent variable. The 
heterogenous nature of VLDL reduces the likelihood that simply measuring triglyceride 
levels will predict risk. VLDL consist of a large range of particle sizes, depending on the 
triglyceride content of the particle, however, contrary to measuring serum and VLDL 
triglyceride, there is not a quick and simple method for measuring concentrations of VLDL 
subfractions.
Large triglyceride-rich VLDL particles, not abundant in normal subjects, can 
undergo cholesterol ester transfer thus becoming cholesterol ester-enriched. These VLDL 
remnants, as well as chylomicron remnants, are also known as p-VLDL and can be 
removed by the scavenger pathway, taken up by receptors on macrophages (Goldstein et 
al., 1980) resulting in foam cell formation. A P-VLDL receptor has been identified in 
macrophages which is specific for chylomicrons, large VLDL particles from 
hypertriglyceridaemic subjects and the P-migrating VLDL of patients with 
hypertriglyceridaemia (Mahley et al., 1984). More recently, it has been shown that the 
uptake of hypertriglyceridaemic, large VLDL by macrophages was higher than for normal 
VLDL and that these hypertriglyceridaemic VLDL populations were enriched with 
cholesteryl ester and apo E (Sehayek et al., 1990). Some evidence suggests that 
chylomicrons and hypertriglyceridaemic VLDL may have a unique receptor on macrophages 
which does not require apo E for uptake. (Gianturco et al., 1989, Gianturco et al., 1990).
Hypertriglyceridaemia has major effects on the composition and function of LDL 
and HDL (Eisenberg et al., 1984), which accordingly could influence their metabolism. 
Predominance of small dense LDL and reduced levels of HDL are commonly found in 
individuals with increased levels of VLDL (Austin and Krauss, 1986; Austin et al., 1988). 
Furthermore, low HDL cholesterol have been shown to be associated with CHD risk 
(Hulley et al.,1980) and predominance of small dense LDL appears to be a strong marker 
for the risk of premature CHD (Austin et al, 1988). Triglyceride transfers to HDL and LDL 
via CETP in exchange for cholesterol ester (Tall, 1986). LDL enriched with triglyceride is 
substrate for hydrolysis by lipases which results in a continuous particle size reduction to 
produce small, dense cholesterol and triglyceride depleted LDL (LDL-3) (Auwerx et al., 
1988; Levy et al., 1990). Recent evidence suggests that hepatic lipase is responsible for this 
hydrolysis (Zambon et al., 1993). Kinetic studies of LDL metabolism suggest that small
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dense LDL are derived from large triglyceride-rich VLDL in the hypertriglyceridaemic state, 
whereas in the normotriglyceridaemic state, the liver produces smaller VLDL particles 
which give rise to larger, more buoyant LDL (LDL-1 and -2) (Caslake et al., 1992). The 
transfer of cholesterol ester from HDL partly accounts for the reduced HDL cholesterol 
levels found in individuals with elevated levels of triglyceride and small, dense LDL.
Most of life is spent in the postprandial state in the western world, and although 
most studies have measured triglycerides in the fasting state only, it has recently been shown 
that postprandial triglyceride levels exhibited an association with CAD that was statistically 
independent and stronger than that of HDL cholesterol (Patsch et al., 1992). In the 
postprandial state and in hypertriglyceridaemia, the atherogenic potential of triglyceride-rich 
lipoproteins, including production of cholesterol ester-rich VLDL remnants, low HDL 
cholesterol and a preponderance of small, dense LDL, is exacerbated.
1.5.3. Low density lipoproteins
LDL is the main cholesterol-bearing lipoprotein in plasma and has been the one most 
consistently related to CHD (Grundy, 1986). Cholesterol is provided from endogenous 
synthesis in the liver and from the diet. In man, the levels of endogenous LDL secreted 
exceed that required by the peripheral tissues, to suppress cell HMGCoA reductase and 
therefore to regulate cholesterol synthesis. However, failure of this feedback mechanism 
can result in elevated LDL cholesterol levels, resulting in atherogenesis. For example, the 
number of functional LDL receptors plays an important role in the condition of familial 
hypercholesterolaemia (Goldstein and Brown, 1983). This condition is the result of single 
gene defects affecting the production and function of the LDL receptor. Heterozygotes 
have only half the normal number of functional receptors resulting in approximate doubling 
of plasma cholesterol; homozygotes have virtually no functional receptors and have 3-4 
times the normal plasma cholesterol levels. The latter often die from CHD before the age of 
twenty. Familial hypercholesterolaemia occurs in 0.2% of the population and therefore 
deficient regulation of LDL metabolism by the LDL receptor cannot be responsible for 
atherosclerosis in the general population. This has led investigators to search for qualitative 
alterations in LDL that might play an important role in atherosclerosis.
Monocytes not only possess LDL receptors but also receptors for various forms of 
modified LDL. Unlike LDL receptors, these receptors (known as acetyl LDL receptors or 
scavenger receptors) are not down-regulated by accumulation of cholesterol within the
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macrophage. One modification of LDL is peroxidation of phospholipids and partial 
degradation of apo B producing oxidised LDL which alters and reduces its interaction with 
the LDL receptor, and instead is avidly taken up by the modified LDL receptor (Steinberg 
et al., 1987). Oxidised LDL is more atherogenic than normal LDL in that it is chemotactic 
for monocytes (Quin et al., 1987), it inhibits mobility of tissue macrophages (Quin et al.,
1985), and it is cytotoxic causing damage to endothelial cells (Henrikson et al., 1979). The 
accumulation of oxidatively modified LDL in macrophages results in the formation of foam 
cells which promote the progression of a fibrous plaque. Other modifications of LDL that 
lead to increased uptake by macrophages include acetylation (Goldstein et al., 1979) and 
glycation (Lyons et al., 1987).
There is also increasing evidence that subpopulations of LDL exist that differ in lipid 
composition, density and size and which may have differing atherogenic potentials. Small, 
dense LDL appear to be a strong marker for the risk of developing premature CHD (Austin 
et al., 1988). The LDL profile is commonly classified into two LDL phenotypes based on 
separation by gel electrophoresis: Phenotype A, (predominance of large light LDL), and 
Phenotype B (predominance of small dense LDL). Thirty to thirty-five percent of the adult 
male population have type B phenotype, however, the LDL phenotype B is less frequent in 
young males (<20 yrs) and premenopausal females (Austin et al., 1990; Campos et al., 
1992a), with a slightly higher prevalence in postmenopausal women (Campos et al., 1992a; 
Selby et al., 1993). Complex segregation analysis has indicated heritability of these 
phenotype patterns with evidence for a single major gene and an autosomal dominant 
pattern of inheritance of the LDL phenotype B (Austin et al., 1986). Recently, the LDL 
phenotype B has been genetically linked to a locus on chromosome 19 near the LDL 
receptor gene locus (Nishina et al., 1992). Due to the complex interrelationship between 
VLDL, HDL and small dense LDL (Me Namara et al., 1992), the increased risk of CHD 
associated with this subclass of LDL is not independent of its association with HDL and 
VLDL (Campos et al., 1992b). It has recently been demonstrated that small, dense LDL 
are more readily oxidised under various in vitro conditions (Tribble et al., 1992), probably 
because they carry less lipid-soluble antioxidants such as vitamin E. There is also evidence 
to suggest that small, dense LDL does not bind as well to LDL receptors as their larger 
counterparts (Kleinman et al., 1987a; Kleinman et al., 1987b). If this is also the case in 
vivo, generation of small, dense LDL will increase atherogenic potential.
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1.5.4. High density lipoproteins
It has long been established that there is an inverse relationship between HDL and 
CHD (Miller and Miller, 1975). Subjects lacking Apo Al have been shown to lack HDL 
and some of these subjects have developed severe early atherosclerosis (Norum et al., 
1982). Low HDL cholesterol levels are commonly associated with high concentrations of 
triglyceride-rich lipoproteins (Hulley et al., 1980). HDL is derived in part from surface 
components of VLDL, and therefore decreased HDL is consistent with accumulation of 
VLDL. Furthermore, elevated triglyceride levels can stimulate HDL cholesterol ester 
transfer, resulting in cholesterol ester depletion of HDL. It is believed that cholesterol ester 
transferred from HDL may then be delivered into the vessel wall as VLDL remnants or via 
their conversion to LDL, rather than being transported to the liver in HDL. This would 
explain the relationship between hypertriglyceridaemia, low HDL cholesterol levels and 
atherosclerosis.
Triglyceride-enrichment of HDL is also a consequence of cholesterol ester transfer 
with triglyceride-rich lipoproteins which can lead to alterations in the HDL particle size 
distribution. Patsch and co-workers (1984), proposed that excessive postprandial 
triglyceridaemia leads to cholesterol ester depletion of HDL2. The triglycerides that replace 
the cholesterol ester are rapidly hydrolysed by HL producing smaller HDL3 particles, a 
similar process to the production of small, dense LDL. A low HDL2/HDL3 cholesterol ratio 
is associated with atherosclerosis (Miller et al., 1981).
1.6. DIABETES MELLITUS
Diabetes Mellitus is a group of metabolic disorders characterised by chronic 
hyperglycaemia due to relative insulin deficiency and/or insulin resistance. Diabetes is 
present when, during a 75g oral glucose tolerance test, the fasting venous plasma glucose is 
more than 7.8mM or when the 2-hour value is more than ll.lm M . Two main types of 
diabetes exist:
1. Insulin-dependent diabetes mellitus (EDDM).
Patients with IDDM have absolute insulin lack. p-Islet cells of the pancreas fail to 
either synthesise or secrete insulin. EDDM is far less common than NIDDM, affecting only
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10-20% of the diabetic population. P-cell deficiency is caused by destruction of the cell, 
and is probably due to genetic susceptibility, viral infection, and attack on the p-cells by 
autoantibodies. Because of their insulin deficiency, untreated IDDM always have elevated 
glucose levels, both because glucose fails to enter cells and is continually released by the 
liver. Lack of insulin stimulates glycogenolysis and proteolysis and elevates plasma levels of 
fatty acids and ketones due to increased lipolysis. Large amounts of glucose and ketones 
are often present in the urine. Patients with IDDM require insulin treatment to control 
symptoms and prevent ketoacidosis and death.
2. Non-insulin-dependent diabetes mellitus.
This type is the result of insulin resistance and relative insulin lack. Many patients 
with diabetes suffering from NIDDM can have near normal plasma glucose concentrations 
when fasting, and consequently have near normal insulin levels. In addition, NIDDM 
patients have enough insulin to suppress excess lipolysis, and to ensure adequate ketone 
entry into Kreb’s cycle, thus avoiding ketoacidosis. They can often be adequately treated 
without insulin administration. However insulin’s target cells do not respond normally due 
to alterations either in the insulin receptors or in the insulin receptor coupling mechanism.
Where hypocaloric dietary regulation and exercise are inadequate for reducing 
fasting hyperglycaemia, drugs such as sulphonylureas and metformin can be implemented. 
Sulphonylureas enhance the release of insulin from pancreatic P-cells. This restores acute 
insulin release in response to meals, which avoids the prolonged postprandial blood glucose 
elevation and subsequent hyperinsulinaemia. Metformin acts on insulin target cells resulting 
in enhanced insulin action. This reduction in insulin resistance results in an increase in 
peripheral glucose uptake and a decrease in hepatic glucose output.
Diabetic patients develop a variety of acute and chronic abnormalities which may be 
accompanied by lipid disorders and changes in lipid metabolism. Although most acute 
symptoms are linked to glucose metabolism, lipid handling is often deranged, with high 
levels of fatty acids, ketones and hypertriglyceridaemia. Chronic complications of diabetes 
may be specific to diabetes (microvascular disease; e.g. retinopathy, neuropathy and 
nephropathy) or reflect an increased risk of problems seen in the non-diabetic population 
(macrovascular disease; e.g. CHD). The two can be related because, for example, CHD is 
greatly increased in diabetic renal disease with proteinuria. Macrovascular disease is not 
only increased in diabetes, but also in normal individuals in whose blood glucose levels are 
in the top 5% of population values (Fuller et al., 1980). Furthermore, higher levels of blood
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glucose and glycosylated haemoglobin (HbAlc) (as evidence of inadequate control), in non­
diabetic subjects are associated with increased cardiovascular risk (Singer et al., 1992; 
Wilson et al., 1992). Other factors, in addition to glycaemic control, may also influence 
macrovascular disease. Hypertension, dyslipidaemia and hyperfibrinogenaemia are more 
likely to be present over many years, before and after diabetes diagnosis.
Diabetes is associated with a three- to four-fold increase in risk for CHD and 
vascular disease is the cause of three quarters of deaths (Garcia et al., 1974). Lipid and 
lipoprotein concentration abnormalities are common in diabetes but together with other risk 
factors does not account for the excess risk of CHD (Kannel and McGee, 1979). It is 
postulated that a range of quantitative changes in lipoprotein subtraction composition, not 
shown in basic lipid and lipoprotein levels, are present in diabetes and contribute to the 
excess risk of CHD.
1.6.1. Lipoprotein abnormalities in diabetes mellitus
Epidemiological studies have shown that hypertriglyceridaemia, but not 
hypercholesterolaemia, is the most common lipid abnormality in diabetic patients, the 
majority of whom have NIDDM (Barret-Connor et al., 1982; West et al., 1983; Wilson et 
al., 1985). In NIDDM patients the prevalence of hypertriglyceridaemia is 2-3 times higher 
than in the non-diabetic population (Barret-Connor et al., 1982).
1.6.1.1. Insulin-dependent diabetes mellitus
Triglycerides are elevated in poorly controlled IDDM (Bierman et al., 1966; 
Glasgow et al., 1981; James and Pometta, 1990) which may be due to increased rates of 
VLDL production in the liver (Nikkila et al., 1973). However, these levels are restored to 
normal in optimally-controlled patients (Nikkila et al., 1973). If poorly-controlled, HDL 
levels are low due to reduced LPL activity (Nikkila et al., 1977), but since insulin increases 
LPL activity, these levels are normalised in optimally controlled patients. Low LPL activity 
also results in diminished clearance of VLDL (Nikkila et al., 1977) resulting in accumulation 
of VLDL and chylomicrons, but this is reversed with insulin therapy. LDL is usually within 
normal limits, however, LDL production rates have been reported to be elevated in IDDM 
but return to normal after insulin infusion (Rosenstock et al., 1985). This may reflect the
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increased synthesis of the precursor VLDL or the impaired removal of VLDL remnants, 
which are often measured as a component of LDL. In IDDM, LDL apoB has been shown 
to be glycosylated which may reduce receptor-mediated clearance of LDL (Kesaniemi et al., 
1983; Uusitupa et al., 1986). Atherogenic VLDL and LDL subfraction profiles have been 
reported in IDDM (James and Pometta, 1990). Elevated plasma concentrations of the 
VLDL subfractions were observed, as well as a preponderance of small dense LDL 
compared to non-diabetic controls. Insulin treatment modified VLDL and LDL subfraction 
profiles so that they more closely resembled that of the controls.
I.6.I.2. Non-insulin-dependent diabetes mellitus 
Triglyceride-rich lipoproteins
In NIDDM, elevated triglyceride is common (Howard, 1987) secondary to 
decreased removal and increased production (Kissebah et al., 1982), the latter of which is 
probably due to insulin resistance causing an increased flux of glucose and free fatty acids to 
the liver (Sniderman et al., 1993). The reduction in VLDL clearance may be due to insulin 
resistance impairing LPL activity (Pfeifer et al., 1983).
In obese Pima Indians with NIDDM, VLDL-triglyceride production tends to 
increase without an increase in VLDL-apo B suggesting an increase in particle size, while 
fractional catabolic rates of both VLDL-triglyceride and apo B are significantly lower than 
in those without diabetes (Taskinen et al., 1986). Sulphonylurea therapy can improve these 
abnormalities: LPL activity increased and hepatic lipase activity decreased with treatment 
and the VLDL particle size (triglyceride : apo B ratio) returned to normal (Taskinen et al.,
1986).
Large, triglyceride-rich VLDL may, like chylomicron remnants, be removed by apo 
E recognition. In NIDDM, this clearance is normal or impaired in the case of 
hypertriglyceridaemia (Nikkila et al., 1977; Kissebah et al., 1982) resulting in accumulation 
of VLDL remnants, which are known to be atherogenic (Goldstein et al., 1980, Mahley et 
al., 1984). In NIDDM, VLDL apolipoprotein composition is abnormal with a decreased 
proportion of apo C to apo E which may influence metabolism by macrophages (Klein et al., 
1990) . In addition, VLDL apo E may be glycosylated and an increase in the more acidic 
and sialated forms of apo E have been found in diabetes (Black et al., 1990) which may 
affect binding to the B/E receptor.
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Considerable heterogeneity of triglyceride-rich lipoproteins with structural and 
functional diversity has been demonstrated in the non-diabetic population (Packard et al., 
1979; Packard et al., 1984). More recently (Taskinen et al., 1990), it was reported that 
patients with NIDDM had an abnormal VLDL apo B metabolism. It was demonstrated that 
patients with NIDDM preferentially produce larger VLDL particles, which, upon insulin 
treatment, were reduced in favour of an increase in smaller VLDL particles. This change 
led to a normalisation of apo B kinetics, since small VLDL was more readily converted to 
LDL than large VLDL. The fractional catabolic rate of LDL increased and LDL production 
in the liver was reduced. In NIDDM with poor control and mild hypertriglyceridaemia, 
both VLDL and LDL subfraction profiles were grossly abnormal and potentially 
atherogenic (James and Pometta, 1991). Larger cholesterol ester-rich VLDL was more 
prevalent than the small triglyceride-rich VLDL. Substantial but incomplete improvement 
occurred with better glycaemic control. Similarly, in patients with NIDDM, improved 
diabetic control achieved with insulin infusions from a programmed implanted pump, 
corrected triglyceride-rich lipoprotein subfraction profiles towards that of non-diabetics 
(Georgopoulos et al., 1992). In another study however, Patti and co-workers (1991) 
reported an increase in the smallest cholesterol-enriched VLDL subtraction in 
normotriglyceridaemic patients with NIDDM compared to non-diabetic controls.
Until recently, most of the investigations into lipaemia in NIDDM have been 
performed in the fasting state. However, triglyceride-rich lipoprotein abnormalities and 
clearance defects may be more evident when examined in the postprandial state. A recent 
comparison of postprandial lipemia in NIDDM with hypertriglyceridaemia compared to 
NIDDM with normotriglyceridaemia, showed lipaemia was due to high levels of 
chylomicron remnants. These subjects had higher concentrations of small dense LDL which 
correlated with fasting triglyceride and extent of postprandial lipemia (Tan et al., 1992). 
Also it has been demonstrated that normotriglyceridaemic patients with NIDDM have an 
excess of chylomicron remnants after an oral fat load (Chen et al., 1993), suggesting that 
the degree of postprandial lipaemia is greater in patients with NIDDM. Diabetics with 
fasting chylomicronaemia develop monocyte-macrophage derived foam cells in eruptive 
xanthomas that are filled with triglyceride and cholesteryl ester (Parker et al.,1970). Insulin 
normalises this leaving only cholesterol ester in the foam cells. The cause of delayed 
clearance of chylomicron remnants remains to be determined, however low LPL activity, 
commonly found in NIDDM, may play a role.
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Low density lipoproteins
The plasma concentrations of LDL cholesterol are usually found to be within normal 
limits in NIDDM patients (Barrett-Connor et al., 1982). However, recently levels of LDL 
have been found to be raised in patients with NIDDM (Harris, 1991). This may be due to 
down-regulation of LDL receptors on hepatocytes caused by insulin resistance (Chait et al., 
1979). In patients with marked hypertriglyceridaemia, LDL removal is impaired (Kissebah 
et al., 1983). Triglyceride-enriched LDL has decreased ability to bind to fibroblasts and 
internalise cholesterol and therefore cannot downregulate cholesterol synthesis (Hiramatsu 
et al., 1985). On the other hand, large VLDL, common in diabetes (particularly with 
hypertriglyceridaemia), is less readily converted to LDL (Stalenhoef et al., 1984, Packard et 
al., 1984) which may balance out the aforementioned reasons for LDL accumulation.
Cumulative flotation ultracentrifugation has been used to show that small dense 
LDL (LDL-3) is particularly common in poorly-controlled, hypertriglyceridaemic patients 
with NIDDM (James and Pometta, 1991). Concentrations of LDL-3 were reduced after 
insulin therapy. Feingold and co-workers (1992) reported that phenotype B was more 
common in normolipidaemic NIDDM than in normolipidaemic controls. Phenotype B was 
associated with an increase in plasma triglyceride and low HDL-cholesterol. This 
association was not seen in NIDDM patients with type A phenotype. Although small dense 
LDL has been associated with CHD in the general population (Austin et al., 1988), no 
studies of this association have been reported in diabetics. Tilley-Kiesi (1992) investigated 
the LDL profile in normolipidaemic NIDDM (+\- CHD) and in controls (+\- CHD). It was 
reported that NIDDM and controls with CHD had larger LDL than NIDDM and controls 
without CHD due to a higher triglyceride content. However, in the non-diabetic 
population, small LDL is more prevalent in men with CHD than in men without CHD 
(Campos et al., 1992b), and small LDL was associated with high plasma triglyceride and 
low HDL-cholesterol (Campos et al., 1992b; Me Namara et al., 1992). These authors 
concluded that LDL size is not an independent discriminator for CHD after conventional 
risk factors such as LDL-cholesterol and HDL-cholesterol have been taken into account.
It would appear that small dense LDL found in patients with NIDDM might be the 
consequence of high levels of VLDL, particularly large, triglyceride-rich VLDL in these 
patients. Small, dense LDL are derived from large triglyceride-rich VLDL in the 
hypertriglyceridaemic state, whereas in the normotriglyceridaemic state, the liver produces 
small VLDL particles which give rise to larger, more buoyant LDL (Caslake et al., 1992). 
In addition, patients with NIDDM have been shown to have increased CETP (Bagdade et
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al., 1993) and HL activities (Hamo et al., 1980). Furthermore, LDL size and peak density 
have been shown to be related to insulin resistance in NIDDM (Stewart et al., 1993), and 
nondiabetic subjects with LDL subclass phenotype B are more insulin-resistant than those 
with subclass phenotype A (Reaven et al., 1993; Selby et al., 1993). The mechanism(s) 
explaining the link between insulin resistance and LDL subfractions remain to be 
determined, but it is also known that insulin resistance is associated with increased 
production of large triglyceride-rich VLDL (Taskinen et al., 1990) which may give rise to 
small, dense LDL.
An additional abnormality of LDL in NIDDM is glycation (Kim et al., 1982). The 
extent of glycation of LDL in patients with NIDDM with moderate hypertriglyceridaemia is 
2-5% and has been shown to decrease LDL metabolism by 5-25% (Steinbrecher et al., 
1984). Glycation may not only promote foam cell formation, but may also confer increased 
susceptibility of the LDL in individuals with diabetes to oxidation (Hunt et al., 1990). In 
addition, small, dense LDL, commonly found in NIDDM, is more prone to oxidation thus 
further increasing the atherogenic potential of diabetic LDL.
High density lipoproteins
HDL cholesterol levels are frequently found to be reduced in patients with NIDDM 
(Lopes-Virella et al., 1977; Barrett-Connor et al., 1983; Howard, 1987;). This is consistent 
with impaired LPL activity (Pfeifer et al., 1983), increased HL activity (Harno et al., 1980) 
and decreased VLDL clearance (Howard, 1987) in these patients. Insulin resistance is 
associated with low HDL levels (Laakso et al., 1990). Intensive insulin therapy in NIDDM 
patients is associated with an increase in HDL2 which is positively correlated with LPL 
activity during insulin therapy (Taskinen et al., 1988). Triglyceride-enrichment of HDL is 
common and may occur as the result of cholesterol ester transfer with triglyceride-rich 
lipoproteins (Tall, 1986).
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1.6.2. Treatment of lipid disorders and relevance to diabetes
Lipid-lowering therapy has been shown to reduce progression of coronary lesions 
(Levy et al., 1984) and increase regression in coronary lesions (Blankenhom et al, 1987). 
Prognosis for individuals with pre-existing CHD can be improved by lipid-lowering therapy 
(Carlson et al., 1988; Blankenhom et al., 1987; Brown et al., 1990; Kane et al., 1990). 
Recently, metanalysis has demonstrated from cohort studies of half a million men that a 
long term reduction in serum cholesterol of 10% lowers the risk of CHD by 50% at age 40 
and by 20% at age 70 (Law et al., 1994). Although there are no comparable studies in 
diabetes, there is no reason to believe that similar therapy would be less beneficial in 
diabetic compared to non-diabetic subjects.
Hypertriglyceridaemia has been shown to be a significant predictor of subsequent 
cardiovascular mortality in diabetes (Fontbonne et al., 1989) and the Stockholm study 
(Carlson et al, 1988) demonstrated that a reduction in triglyceride levels can be an 
important factor in decreasing cardiovascular mortality. Where diabetic dyslipidaemia does 
not respond to diet, exercise, lifestyle and glycaemic control, lipid-lowering drugs should be 
considered. Fibrate drugs are often first choice, but other drug groups such as HMGCoA 
reductase inhibitors, may be needed. The fibric acid group of drugs have been associated 
with significant reductions in coronary events in the Helsinki Heart Study, especially in 
patients with combined hyperlipidaemia (Manninen et al., 1987).
1.6.2.1. Fibric acid derivatives
Fibric acid derivatives (eg. gemfibrozil, ciprofibrate, fenofibrate and bezafibrate) 
have the ability to lower plasma and VLDL triglyceride by increasing LPL activity, reducing 
fatty acid release from adipose tissue and inhibiting hepatic triglyceride synthesis, and are 
therefore beneficial for treating dyslipidaemia in NIDDM. Several investigations have 
shown that fibrates affect VLDL composition and heterogeneity (Eisenberg et al., 1984; 
Paucillo et al., 1990; Winocour et al., 1992). Paucillo et al. (1990) reported that in 
hypertriglyceridaemic patients, gemfibrozil reduced the levels of the larger VLDL 
subffactions, while the levels of the smallest fractions remained the same. Fibrates may 
increase LDL cholesterol levels in hypertriglyceridaemic subjects (Carlson et al., 1977), 
because normalising triglyceride-rich lipoprotein metabolism allows conversion of VLDL to 
LDL, rather than conversion to IDL which is removed by the liver. In addition, normalising
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triglyceride-rich lipoprotein metabolism results in restoration of cholesterol ester-rich LDL 
which previously was triglyceride enriched due to cholesterol ester transfer. This increase 
in LDL cholesterol is not seen in hypercholesterolaemic subjects after fibrate therapy. 
Increased receptor mediated catabolism of LDL (Series et al., 1989, Stewart et al., 1982) 
has been demonstrated in vivo after bezafibrate therapy. This may be caused by increased 
receptor expression mediated by enhanced secretion of cholesterol into the bile, known to 
occur after fibrate therapy. Alternatively, changes in LDL composition may provoke more 
avid binding to the receptors.
Fibrates also affect LDL density. It appears that fibrate therapy can reduce levels of 
small dense LDL (Eisenberg et al., 1986). Small dense LDL subspecies have been changed 
to larger less atherogenic LDL by gemfibrozil in type II hyperlipidaemic patients (Tsai et al., 
1992). A reduction in small dense LDL after fibrate therapy is in agreement with a 
reduction in plasma triglyceride.
Fibrates increase HDL cholesterol levels (Roufty et al., 1985; Sorisky et al., 1987) 
and this is likely to be due to increased VLDL catabolism. In addition, HDL cholesterol 
will increase as the amount of triglyceride-rich lipoproteins available for cholesterol ester 
transfer is reduced.
Postprandial lipemia in hypertriglyceridaemic subjects is reduced by fibrates which is 
probably due to the increase in catabolism of chylomicrons and VLDL (Oster et al., 1985; 
Weintraub et al., 1987; Simpson et al., 1990). Fibrates such as gemfibrozil have been 
shown to increase HDL2 and HDL3 in the postprandial state in hypertriglyceridaemic 
subjects (Ditschuneit et al., 1992).
Bezafibrate, has similar effects on lipoprotein metabolism as previously described for 
gemfibrozil and other fibrates. Bezafibrate has been reported in NIDDM to reduce serum 
triglyceride and cholesterol as well as increase HDL (Seviour et al., 1988; Rovellini et al., 
1992). In patients with IDDM and hypercholesterolaemia, bezafibrate can reduce 
cholesterol and triglyceride of large VLDL and reduce free cholesterol and esterified 
cholesterol in IDL (Winocour et al.,1992). In the same study, in patients with IDDM and 
hyperlipidaemia, bezafibrate again reduced large VLDL cholesterol and triglyceride, but 
reduced free and esterified cholesterol in small VLDL. In both cases LDL composition was 
unchanged. Small, dense LDL subspecies have been changed to larger less atherogenic 
LDL by bezafibrate in patients with hyperlipoproteinaemia (Homma et al., 1994).
Reductions in fasting blood glucose after bezafibrate therapy have been reported in 
patients with NIDDM (Seviour et al., 1988; Jones and Alberti., 1988; Mikhailidis et al.,
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1990; Rovellini et al., 1992), although Riccardi and co-workers (1989) found no change in 
glucose levels. In addition, bezafibrate therapy has been reported to reduce non-esterified 
fatty acids (NEFA) concentrations in NIDDM (Alberti et al., 1990; Jones et al., 1990).
1.6.2.2. HMG-CoA reductase inhibitors
Lovastatin, simvastatin, fluvastatin and pravastatin are competitive inhibitors of 
HMGCoA reductase, the rate-limiting enzyme of cholesterol synthesis. These drugs are 
the most potent available for reducing plasma concentrations of LDL cholesterol. Their 
inhibition of HMGCoA reductase, and thus cholesterol synthesis, results in the up- 
regulation of LDL receptor expression on the cell surface enhancing uptake of LDL and 
VLDL remnants from the plasma. Concurrently, hepatic synthesis of VLDL and LDL may 
be reduced. They also produce moderate increases in HDL.
Recently, the effect of these drugs in patients with NIDDM have been investigated. 
Lovastatin has been shown to reduce LDL and VLDL cholesterol levels and increase HDL 
cholesterol levels in NIDDM patients with primary hypercholesterolaemia (Golberg et al., 
1990). Studies have shown statins to be better at reducing LDL cholesterol levels and 
fibrates better at reducing triglyceride levels and increasing HDL levels (Crepaldi et al., 
1990; Ojala et al., 1990). Fibrates have also been shown to be better than statins at 
reducing postprandial lipaemia (Simo et al., 1993). In hypertriglyceridaemic subjects 
gemfibrozil reduced chylomicron triglyceride and there was a close correlation between 
change in fasting triglyceride and change in postprandial response in subjects taking 
gemfibrozil but not in those taking lovastatin. Also LPL and HL activities were increased 
by gemfibrozil but not by lovastatin.
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1.7. SYSTEMIC LUPUS ERYTHEMATOSUS AND PSORIATIC ARTHRITIS
Systemic lupus erythematosus (SLE) is an autoimmune disease caused by circulating 
immune complexes and is characterised by anti-nuclear factor and other auto-antibodies. 
The incidence of SLE is highest in people of 20-40 years and is more common in females 
than in males. Active SLE symptoms such as inflammation of joints usually occur at the 
onset of the disease and therapy is required, whereas inactive SLE is asymptomatic and 
does not usually require therapy. SLE has a bimodal pattern of morbidity and mortality 
(Urowitz et al., 1976). A major contribution to this pattern is made early in the disease by 
renal and cerebral involvement. It is now recognised that the late morbidity and mortality is 
related to accelerated atherosclerosis. Many factors contribute to hyperlipidaemia in 
patients with SLE, such as a persistent nephrotic state (Appel et al., 1985) and use of 
corticosteroids (Ettinger et al., 1987) the latter of which causes elevated plasma levels of 
triglyceride, LDL cholesterol and apo B100 (Ettinger and Hazzard, 1988). However active 
SLE itself contributes to a distinct pattern of dyslipidaemia (Ilowite et al., 1988) with raised 
serum and VLDL triglyceride, and reduced HDL cholesterol. On the other hand, one study 
(Leong et al., 1994) found no such activity related differences.
Certain cytokines expressed by macrophages (interleukin-1 and tumour necrosis 
factor-a) are known to suppress LPL activity (Beutler et al., 1985; Fried and Zechner, 
1989; Ogawa et al., 1989) and to increase oxidative metabolism, having atherogenic 
implications. These cytokines are upregulated in SLE.
Hydroxychloroquine is used for treating SLE patients with a milder form of the 
disease. It has potential lipid-lowering properties and has been shown to reverse deleterious 
effects of steroids on lipids separate to its steroid-sparing activity in patients with rheumatic 
disease (Wallace et al., 1990). Recently, hydroxychloroquine has been associated with 
reduced plasma levels of triglyceride, VLDL triglyceride, LDL triglyceride, HDL 
triglyceride and VLDL cholesterol in SLE (Hodis et al., 1993), and therefore may be useful 
in ameliorating the effects of the active disease as well as effects of steroid therapy on 
triglyceride-rich lipoprotein metabolism.
Psoriasis is a skin disease characterised by the appearance of scaly patches on the 
surface of the skin. The onset of the disease usually occurs between the ages of 20 and 50 
years, and is as common in males as it is in females. Ten percent of patients develop 
psoriatic arthritis affecting many joints, particularly small joints of the hand. Recently, 
dyslipoproteinaemia has been reported in subjects with rheumatoid arthritis (RA) and
38
psoriatic arthritis (PA) (Lazarevic et al., 1992). Both patient groups showed a reduction in 
serum cholesterol, LDL cholesterol and HDL cholesterol compared to normal healthy 
controls. There were no differences in plasma triglycerides. These changes were 
ameliorated in severe cases of the disease, with the additional lowering of serum 
triglycerides in PA patients, which is in agreement with the findings of Jones et al. (1993). 
As disease activity decreased with treatment, RA patients showed normalisation of almost 
all serum lipid concentrations. Similar findings were reported in RA patients from two 
parallel studies (Svenson et al., 1987a; Svenson et al., 1987b). Because the severity of the 
disease is parallel to the degree of dyslipidaemia, the level of inflammation activity may play 
a role in the development of dyslipidaemia in RA and PA.
1.8. XANTHINE OXIDASE
1.8.1. PROPERTIES OF XANTHINE OXIDASE
Xanthine oxidase is an enzyme which has the unusual property that it can exist in a 
dehydrogenase form (D-type) which uses NAD+ as an electron acceptor and an oxidase 
form (O-type), which uses oxygen as an electron acceptor. The enzyme was one of the first 
flavoproteins to be purified (Ball, 1939) and it was later found to contain molybdenum (De 
Renzo et al., 1956) and iron (Rithert and Westerfeld, 1954). The flavin molecule together 
with these metals plays an important role in the enzyme’s catalysing capacity. Xanthine 
oxidase is a dimer containing two subunits of 150KD; each subunit contains as cofactors 
involved in catalysis one molybdenum molecule, two iron-sulphur centres and one FAD 
group. The reducing substrate (e.g. purines, aldehydes, pteridines) is oxidised at the 
molybdenum site and electrons that become available are channelled via the iron-sulphur 
centre to FAD where the oxidising substrate (e.g. NAD+, 0 2, methylene blue) is reduced.
Xanthine oxidase (D-type) has the physiological function in purine catabolism of 
oxidising hypoxanthine to xanthine and then to uric acid (urate), using NAD+ as an electron 
acceptor.
Hypoxanthine + H20  + NAD+ —> Xanthine + NADH + H
Xanthine + H20  + NAD —> Uric acid + NADH + H
39
The enzyme also has the unusual property that when molecular oxygen serves as the 
electron acceptor for that reaction, oxygen is reduced to superoxide anion (0 2') and 
hydrogen peroxide (H20 2).
Hypoxanthine + 2H20  + 2 0 2 -> Xanthine + 0 2 + H20 2
Xanthine + 2H20  + 0 2 -> Urate + 0 2 + H20 2
Hydrogen peroxide, itself is a moderately strong oxidant, can react with a superoxide 
radical and through the Haber-Weiss reaction produce the very toxic hydroxyl radical 
(Haber and Weiss, 1935; McCord et al., 1978). Therefore the enzyme has the capacity to 
produce essentially toxic, reactive oxygen species (ROS). Xanthine oxidase and ROS 
produced by the enzyme have been proposed to play a role in a number of pathological 
conditions, some of which include cerebral ischaemia (Kontos et al., 1981), irradiation 
damage (Petkav et al.,1978), intestinal ischaemia (Granger et al., 1981), pulmonary 
disorders (Johnson et al., 1981), autoimmune rheumatic diseases (Miesel et al., 1993), 
atherosclerosis (Ohara et al.,1993), and gout (Kelley et al.,1989).
Xanthine oxidase exists in vivo predominantly in the dehydrogenase form, which can 
be converted to the oxidase form by a number of processes including proteolysis, heating, 
storage at -20°C, anaerobiosis, certain organic solvents, incubation with subcellular 
fractions and sulphydryl (SH) reagents (Stirpe and Della Corte, 1969).
Dithiothreitol, a SH-reductant, can prevent conversion of the D-type to the O-type 
and even reverse the conversion induced by different treatments (Della Corte and Stirpe, 
1972), except for proteolysis, which is irreversible. Therefore the conversion from the D- 
type to the O-type could occur reversibly by oxidation of sulphydryl groups or irreversibly 
by proteolytic cleavage. Exceptionally, the conversion of the O-type to the D-type by SH- 
reductants was not possible in the intestine (Battelli et al., 1972), probably because of the 
high proteolytic activity derived from the pancreatic enzymes. On the whole, protease 
inhibitors are adequate in preventing proteolytic conversion. Isolation of the two distinct 
forms has permitted characterisation of these enzyme forms.
The D-type and O-type differ in their protein environment around the flavin group, 
which is possibly responsible for the different reactivities toward NAD+ and 0 2 (Massey et 
al., 1989; Saito et al., 1989). Recently, it has been suggested that the molybdenum centre 
of the two enzyme types is different (Hunt et al., 1993). NADH and NAD+ are used as 
reducing and oxidising agents respectively at a high rate by the D-type (Rajagopalan and
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Handler, 1967; Schopfer et al., 1988) whereas they only react slowly or not at all with the 
O-type (Massey et al., 1969). On the other hand, the D-type but not the O-type reacts only 
slowly with atmospheric oxygen in the presence of NAD+. Despite the classical role of the 
D-type in using NAD+ as an electron acceptor and the O-type in using 0 2 as an electron 
acceptor, the D-type, in the absence of NAD+ has been reported to produce 9-15% of urate 
compared with the O-type in aerobic conditions, with concomitant production of ROS 
(Saito and Nishino, 1989; Hunt and Massey, 1992). Clearly the rate of 0 2 consumption by 
the D-type is lower than the O-type in the absence of NAD+, but it is not negligible.
The presence of inactive demolybdo- and desulpho-enzyme molecules have been 
known for a long time (Massey and Edmonson, 1970; Johnson et al., 1974; Bray, 1975; 
Harrison et al., 1991). In bovine milk, 20-40% desulpho-enzyme molecules were found 
(Massey et al., 1969; Bray, 1975). Abadeh and co-workers (1992a) found that in human 
milk, more than 98% of total xanthine oxidase was in an inactive form with approximately 
26% in the demolybdo-form and the remainder in the desulpho-form. It has been suggested 
that interconversion of inactive to active form was regulated posttranslationally by 
incorporation or subtraction of an essential sulphur atom at the molybdenum centre 
(Coughlan et al., 1981).
1.8.2. Distribution of xanthine oxidase
Xanthine oxidase is widely distributed in the tissues of many species, including 
bacteria (Bray, 1988) and plants (Perez-Vicente et al., 1992). A variety of biochemical 
methods have been used to detect xanthine oxidase in mammalian tissues (Parks and 
Granger, 1986), including most tissues in rat (Hashimoto, 1974; Parks and Granger, 1986).
In humans, high activity has only been detected in the liver and small intestine 
(Watts et al., 1965; Brunschede and Krooth, 1973), whereas low activity was found in other 
organs, particularly heart (Eddy et al., 1987; Muxfelt et al., 1987; Grum et al., 1989; De 
Jong et al., 1990; Kooij et al., 1992a; Abadeh et al., 1992b; Abadeh et al 1993). However, 
two studies (Krenitsky et al., 1974; Wajner and Harkness, 1989) found high activity in many 
human tissues. These contradictions could be explained by assumption that tissues were 
sampled from patients with intestinal and liver disease and therefore may have high xanthine 
oxidase activity in the blood (De Jong et al., 1990; Kooij et al., 1992a).
Biochemical methods do not discriminate, however, between the activity of the 
enzyme in different cell types within one tissue, and accordingly histological methods have
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been developed. These techniques permit localisation of xanthine oxidase enzyme activity 
by the reduction of nitro-blue tetrazolium to insoluble formazan in the presence of 
hypoxanthine. Enzyme activity has been localised in cell epithelium of rat duodenum 
(Pricket et al.,1970), in the cytoplasm of rat (Auscher et al.,1977) and hamster hepatocytes 
(Ibrahim and Stoward, 1978), and in the renal collecting tubule cells of hamsters (Ibrahim 
and Stoward, 1978). Recently, xanthine oxidase activity has been demonstrated in 
epithelium, endothelial cells and fibroblasts of all organs of rat except brain (Kooij et 
al., 1992b), and only in the small intestine and liver in humans (Kooij et al., 1992a).
Immunohistochemical techniques have been used antibodies to detect xanthine 
oxidase (Jarasch et al.,1981) in the cytoplasm of capillary endothelial cells of bovine 
mammary glands, liver, heart and intestine, but not in larger blood vessels. Later, in 
humans, activity was detected in the endothelial cells of capillaries of heart, liver, placenta 
and kidney (Jarasch et al.,1986; Bruder et al.,1984).
This discovery of xanthine oxidase protein in the endothelial cells of heart and 
tissues other than liver and intestine is in contrast to many biochemical and histochemical 
findings. However, the former results have recently been supported by a number of studies 
(Abadeh et al., 1993; Hellsten-Westing, 1993; Moriwaki et al.,1993). Abadeh and co- 
workers (1993) found similar amounts of enzyme molecule in human and rat heart by 
immunoprecipitation, but activity was 100-fold higher in rat. It was suggested that this lack 
of activity was due to the human enzyme being in the desulpho- and demolybdo-form. 
Therefore it would seem that enzyme is present in these tissues, but its activity is below the 
detection limits of most methods. However it is possible that enzyme from human intestine 
and liver is released into the blood after injury, and sticks to the endothelium of capillaries 
of other tissues, since capillaries of small vessels, but not of large can endocytose 
macromolecules (Jarasch et al., 1981). This is consistent with the presence of antibodies to 
xanthine oxidase in human blood (Bruder et al., 1984; Harrison et al., 1990; Ng et al., 1990) 
and that the presence of xanthine oxidase but not activity has been detected in endothelial 
cells of human capillaries other than liver and intestine.
1.8.3. Function of xanthine oxidase
Xanthine oxidase, in humans is involved in purine catabolism by catabolising 
hypoxanthine to xanthine and then to uric acid. However the contribution of xanthine 
oxidase in purine catabolism is only minor because of the well-developed salvage pathway.
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In bacteria, its main function is oxidation of purines to provide carbon, nitrogen and energy 
(Wagner et al., 1984). Xanthine oxidase is found exclusively as the non-convertible D-type 
in all organisms except mammals, and therfore xanthine oxidase might have functions in 
mammals specific to ROS. It has been proposed (Kooij et al., 1992b), because enzyme 
activity was found only in the small intestine and liver in humans, that in the intestine ROS 
from the O-type enzyme are involved in proliferation and/or differentiation of epithelial cells 
when they migrate to the apical villus.
With respect to a possible antioxidant function in humans, it is possible that the 
enzyme participates in the antioxidant defence system against radicals produced in the liver 
and/or blood, since urate, the product of the enzyme, has been found in high concentrations 
in blood and is a strong scavenger of free radicals (Ames et al., 1981). These authors 
suggested that this may contribute to the larger life span of humans compared to other 
mammals. On the other hand, Koster and Slee (1983) did not find any free radical 
scavenging properties of urate. More recently, urate has been suggested to play a role in 
preventing generation of lipid peroxidation produced during mastication and digestion of 
ingested foods (Terao and Nagao, 1991) and as an antioxidant in human nasal mucosa 
(Peden et al., 1990).
Since H20 2 and 0 2 ' are produced in virtually all reactions catalysed by O-type 
xanthine oxidase, the enzyme also serves as a ubiquitous source of oxidising agents. 
Indeed, xanthine oxidase has been proposed as a source of oxygen radicals in 
polymorphonuclear leukocytes (Tubaro et al., 1980), and in this way the enzyme may have 
a protective role against bacteria.
1.8.4. Ischaemia-reperfusion with special reference to the heart
Involvement of xanthine oxidase in the induction of tissue damage during 
reperfusion after ischaemia was first indicated when it was found that allopurinol, an 
inhibitor of xanthine oxidase, prevented the rise of urate levels in the blood and increased 
survival rate of dogs after haemorrhagic shock (Crowell et al.1967; Jones et al.,1968). 
Saugstadt and Aasen (1980), showed that hypoxanthine levels in the blood during hypoxia 
were inversely related to survival rate of pigs. They suggested that superoxide anion 
radicals are produced during reperfusion of xanthine oxidase using the increased amounts of 
hypoxanthine that becomes available during ischaemia.
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Granger and co-workers (1981), demonstrated oxygen free radicals could be 
involved in ischemia reperfiision injury because a marked decrease in injury was observed in 
intestinal tissue upon administration of superoxide dismutase or catalase, scavengers of 
oxygen-derived radicals and hydrogen peroxide respectively. They proposed that the 
dehydrogenase form of xanthine oxidase is converted to the oxidase form during ischaemia 
and ATP is broken down into hypoxanthine. Upon reperfusion, oxygen is introduced and 
xanthine oxidase consumes hypoxanthine with the production of ROS which causes tissue 
injury. Over the past decade, XO involvement in tissue injury due to ischaemia reperfusion 
process has been postulated in a number of tissues, some of which are shown below in 
Table 1.2.
Table 1.2. Tissues in which the involvement of XO in injury due to ischaemia reperfusion 











McCord et al., 1985; Brown et al., 1988; Teradaetal., 1991
Schneider et al., 1991; Suematsu et al., 1992
Ishietal., 1992; Repine et al., 1992; Ward, 1991
Granger et al., 1981; Granger et al., 1988; Rangan and Buckley, 1993
Suzuki and Ford, 1991; Punch et al., 1992
Peachey et al., 1993
Im etal., 1989; Pokomyetal., 1989
Lin and Phillis, 1991; Thom, 1992
Schiller et al., 1991
The conversion of D-type xanthine oxidase to O-type has been demonstrated in 
regional myocardial ischaemia (McCord, 1985; Chambers et al.,1985). McCord (1985) 
postulated that ROS generated by xanthine oxidase could cause cellular damage of 
myocardial tissue during reperfusion leading to myocardial infarction. However the effects 
of xanthine oxidase inhibitors on experimental myocardial infarction have been variable.
Treatment with allopurinol one day before coronary artery occlusion followed by 
reperfusion limited the extent of canine myocardial infarction (Werns et al.,1986; Charlat et 
al.,1987). However, when treatment was administered only 30 mins before coronary artery 
occlusion allopurinol did not reduce extent of myocardial injury (Reimer et al.,1985).
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This failure of acute treatment to reduce myocardial injury suggests that allopurinol 
requires longer treatment time to allow conversion of allopurinol to oxypurinol, its active 
metabolite, which is a non-competitive inhibitor with a longer half-life (Spector et al.,1988). 
Also short term administration of the drug may merely delay tissue injury, while substantial 
therapy may be required to prevent infarction. Low doses may actually increase reperfiision 
injury because a reduction in urate concentrations may lead to a reduction in free radical 
scavenging. Zhong and co-workers (1989) reported that, in liver tissue, cell injury was 
increased with low doses of allopurinol while high doses prevented cell death.
Furthermore, it is possible that myocardial protection due to allopurinol is not due to 
its inhibition of xanthine oxidase. Allopurinol was reported to limit infarct size in rabbit and 
pig although xanthine oxidase activity was not detected in myocardium of either species 
(Godin and Bhimji, 1987; Das et al., 1987). Also amflutizole, another potent inhibitor of 
xanthine oxidase, did not reduce infarct size in the dog (Werns et al., 1989). In vitro data 
has demonstrated that oxypurinol acts as a scavenger for hydroxyl radicals (Hoey et al., 
1988), and perhaps it is via free radical scavenging that allopurinol reduces infarct size.
The conversion of D-type xanthine oxidase to O-type in ischaemia regarding the 
production of ROS during reperfusion is still a controversial issue (Brass et al.,1991; 
Battelli et al.,1992). Furthermore, it has been demonstrated that xanthine oxidase in the 
dehydrogenase form is capable of producing ROS in the presence of oxygen and absence of 
NAD+ (Saito and Nishino, 1989; Hunt and Massey, 1992) suggesting that conversion from 
the D-type to the O-type is not a requirement for ischemia-reperfiision injury.
Most biochemical assays could not detect xanthine oxidase activity in human tissues, 
except liver and intestine (Eddy et al., 1987; Muxfelt et al., 1987; Grum et al., 1989; De 
Jong et al., 1990, Kooij et al., 1992b; Abadeh et al., 1992b; Abadeh et al., 1993), which 
argues against a major role for xanthine oxidase in most organs. On the other hand, these 
studies cannot exclude the possibility that the enzyme is present in an inactive form. 
Immunohistochemical studies have detected xanthine oxidase in human heart (Bruder et al., 
1984; Jarasch et al., 1986; Abadeh et al., 1993), and Abadeh et al., (1992a) reported that 
xanthine oxidase from human milk was 98% inactive, 26% of which was in the demolybdo- 
form and the remainder was in the desulpho-form. It was reported that activity was 100 
fold less in human heart than in rat heart (Abadeh et al., 1992b; Abadeh et al., 1993). This 
would suggest that the presence of xanthine oxidase in human heart occurs predominantly in 
the inactive form as shown for the enzyme in human milk (Abadeh et al., 1992a). This 
would account for the low or zero activity of xanthine oxidase often reported in human 
heart, and for the ability of Jarasch and co-workers (1986) to locate the enzyme in human
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heart. It is interesting that the inactive form of human milk enzyme, while incapable of 
oxidising most human substrates, can, nevertheless, oxidise NADH generating free radicals 
(Nakamuru, 1991; Abadeh et al., 1992a). The presence of a similar enzyme in human heart 
may well contribute to ischaemia-reperfusion injury in this tissue.
1.8.5. Anti-xanthine oxidase antibodies and heart disease
Studies by Davies and colleagues (Davies et al., 1969; Davies et al., 1974) reported 
that antibodies to cows’ milk, which are present in most subjects, were higher in patients 
who had suffered a myocardial infarction than in controls, findings that were confirmed by 
one study (Oster et al., 1974), but not supported in others (Toivanen, 1975; Scott, 1976). 
These studies measured antibodies to dried milk powder, clearly a complex antigenic 
mixture. However, Davies (1980) found that the antibodies to dried whole milk, as 
detected by haemagglutination assay, were largely directed toward the washed cream 
fraction, and later reported (Davies et al., 1982) that the antibodies were directed to bovine 
milk fat globule membrane.
Harrison et al. (1990) pursued this and showed that human antibodies against bovine 
milk fat globule membrane themselves interact primarily with the enzyme xanthine oxidase. 
They went on to develop an enzyme linked immunosorbent assay (ELISA) for anti­
xanthine oxidase antibodies and compared their levels in the serum of 107 patients who had 
suffered a myocardial infarction with those in 86 controls Levels of IgM anti-XO antibodies 
were significantly higher in the patients with myocardial infarction. There were no 
differences found for IgA and IgG anti-XO antibodies, and total levels of IgM did not differ 
between patients and controls. Serial assays following myocardial infarction showed no 
evidence that raised levels of IgM anti-XO antibodies resulted from the infarction itself.
While all human sera tested, whether from normal or diseased donors, have been 
shown to contain anti-XO antibodies (Harrison et al., 1990), their origin and role are far 
from established. They could arise in response to dietary cow’s milk. Uptake of 
macromolecules into the bloodstream from the intestine has been reported in humans 
(Walker et al., 1974) and moreover, it has been claimed that human anti-XO antibody levels 
depend on dairy food consumption (Rzucildo et al., 1979; Deeth, 1983). Alternatively these 
antibodies could arise in response endogenous enzyme which is known to be present in the 
capillary endothelium of many tissues (Jarasch et al., 1981; Jarasch et al., 1986).
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If the antibodies are in fact autoantibodies, it is tempting to cast them in a protective 
role in the elimination from the circulation, of xanthine oxidase, with its potential for 
generation of destructive ROS.
1.9. AIMS OF THE THESIS
1. Lipid and lipoprotein abnormalities, together with other risk factors, do not account for 
the excess risk of CHD associated with NIDDM. It is postulated that changes in fasting and 
postprandial lipoprotein quantity and quality, not shown by basic lipid and lipoprotein 
levels, are present in NIDDM and contribute to the excess risk of CHD. In view of this, 
fasting and postprandial lipoprotein subtraction distribution and composition were studied in 
patients with NIDDM, firstly in comparison with non-diabetic controls (Chapter 3) and 
secondly as part of fribrate intervention trial (Chapter 4).
Dyslipoproteinaemia has been reported in patients with SLE and psoriatic arthritis. 
To investigate the lipoprotein profile of these patients in more detail, lipoprotein subfraction 
distribution and composition were examined (Chapter 5).
2. Studies have indicated that xanthine oxidase could play an important role in myocardial 
ischemia reperfusion injury. More recently, it has been reported that antibodies to xanthine 
oxidase, present in the serum of all human subjects, were raised in patients with myocardial 
infarction. It is clearly important to study the occurrence and pathological significance of 
anti-XO antibodies in human serum. To this end, levels of antibodies were compared in 
serum from normal healthy donors of varying age and gender (Chapter 6), in patients with 






Apo Al and apo B kits were supplied by Sigma (St. Louis, Missouri, USA).
Cholesterol, triglyceride, phospholipid and free cholesterol kits were supplied by Boehringer 
Mannheim (Lewes, East Sussex, U.K.).
Insulin kits were supplied by Incstar Corporation (Stillwater, Minnesota, USA).
Glucose kits were supplied by Randox Laboratories Ltd (Crumlin, Co Antrim, UK).
NEFA kits were supplied by Wako chemicals GmbH (Nissanstr. 2, W-4040 NEUSS 1, 
Germany).
Bovine xanthine oxidase was supplied by Biozyme (Gwent, South Wales, U.K.).
All other chemicals and reagents were supplied by Sigma (St. Louis, Missouri, USA).
2.2. PREPARATIVE TECHNIQUES
Lipoprotein fractions VLDL, HDL and HDL3 were isolated by standard 
precipitation techniques. Chylomicrons, VLDL subfractions and LDL subfractions were 
isolated by cumulative flotation ultracentrifugation.
2.2.1. Preparation of lipoprotein fractions
Serum was used for VLDL isolation because plasma contains high levels of 
fibrinogen which may interfere with the pelleting of VLDL. Plasma was preferred for HDL 
isolation because of the preservative properties of EDTA.
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2.2.1.1. Very Low Density Lipoprotein
VLDL can be precipitated by SDS to yield results which correlate well with those 
obtained by ultracentrifugation (Ononogbu and Lewis, 1976).
Reagents
1. 10% SDS w/v in 0.15 MNaCl.
2. 1% SDS w/v in 0.15 M NaCl.
Procedure
75 pi of 10% SDS was added to 1ml serum, mixed and incubated at 37°C for 2 
hours. The mixture was centrifuged at 10,000 g for 30mins at 10°C. The pellet was 
redissolved in 1 ml of 1% SDS at 37°C and stored at -20°C prior to assay.
2.2.1.2. High Density Lipoprotein
Chylomicrons, VLDL and LDL were precipitated and the remaining HDL in the 
supernatant was isolated. HDL2 was precipitated in a second step and HDL3 was isolated in 
the supernatant. HDL2 cholesterol and triglyceride were estimated by subtracting HDL3 
levels from total HDL levels (Gidez et al., 1983).
Reagents
1. Manganese Chloride, 1.06 M.
2 Heparin (from porcine intestinal mucosa)(Sigma).
3 Add 1 and 2 to form heparin -MnCl2 (25,000 units heparin /ml of MnCl2).
4 Dextran Sulphate: 1.43% w/v in 0.15 M NaCl.
Procedure
1 ml of 0.15 M NaCl and 0.2 ml of Heparin-MnCl2 were added to 1 ml plasma, 
mixed and incubated at room temperature for 10 mins. The mixture was centrifuged at 
lOOOg at 4°C for 1 hour. 1.0 ml of supernatant (HDL) was added to 0.1 ml dextran 
sulphate, mixed and incubated for 20 mins at room temperature and spun as before for 30 
mins. The supernatant (HDL3) was removed and stored at -20°C prior to assay.
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2.2.1.3. Low Density Lipoprotein
LDL triglyceride and cholesterol were calculated by subtraction of the sum of HDL 
and VLDL cholesterol and triglyceride from total plasma cholesterol and triglyceride 
respectively.
2.2.2. Cumulative flotation ultracentrifugation: preparation of chylomicrons. VLDL 
subfractions and LDL subfractions
Principle
This method is a modification of the density gradient ultracentrifugation procedure 
used to isolate LDL subtractions described by Lindgren et al. (1972). Modifications to this 
LDL subfractionation procedure have been made to permit isolation of chylomicrons, three 
VLDL subfractions and three LDL subtractions. The flotation rates of these lipoproteins 
are shown in Table 2.1.
Table 2.1. Flotation rates for chylomicrons, VLDL and LDL subtractions.
LIPOPROTEIN SVEDBERG








For each lipoprotein subtraction, the angular velocity (w2t) is calculated for transit 
of each lipoprotein from maximum radius to minimum radius for each density solution as it 
floats to the top of the tube, and added to give a total angular velocity (Zw2t), from which 
the run speed and run time is calculated.
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Total angular velocity is calculated as follows:
I hj=i w2tj = £ hj=i ( lnrj+i - lnrj) / h« f Sj - o) Sf
hj (Ss - a)
where,
Sf Svedberg flotation rate of the lipoprotein
Ss Standard density (= 1.063)
Si density of solution in intervals
hs standard viscosity (= 1.158)
hi viscosity of each solution in intervals
a hydrated density of lipoprotein
ri+i maximum radius from the centre of the rotor to the solution intervals
ri minimum radius from the centre of the rotor to the solution intervals
From the formula below, the rotor speed (rpm) and spin time can be calculated.
Angular velocity, w2t = (radian/seconds)2 x seconds
= ( rpm/60 x 2%f x seconds
Method
Blood was collected in vacutainers containing EDTA, and plasma was separated by 
centrifugation at 1800 rpm for 20 mins at room temperature. Plasma was adjusted to 1.118 
g/ml by adding NaCl (0.171g per ml of plasma). Density gradients were prepared from two 
stock solutions: 1.006g/ml NaCl and 1.182 g/ml NaCl/NaBr and checked using a density 
meter. 2ml of the density adjusted plasma was layered on 0.5ml of 1.182g/ml solution. On 
top of the plasma was layered 1ml of 1.0988g/ml, followed by 1ml of 1.086g/ml, 2ml of 
1.079g/ml, 2ml of 1.0722g/ml, 1.5ml of 1.0641g/ml and finally 1.5 ml of 1.0588g/ml
density solution. The layering of the density solutions is depicted in Figure 2.1.
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Fig. 2.1. Formation of the density gradient in the ultracentrifuge tubes.

















Centrifuge tubes were coated with polyvinyl alcohol prior to use to enable the 
density solutions to gravity feed down the tubes (Holmquist, 1982). The tubes were 
centrifuged in a SW41 rotor in an L8-70 ultracentrifuge at 23°C.
The angular velocity, rotor speed, and run times are tabulated below in Table 2.2. 
Times are given from switch on to switch off drive power and corrected for previous runs 
and acceleration and deceleration times. Maximum acceleration was used but the brake was 
not used. For lower expected values of triglyceride-rich lipoproteins 0.5ml of chylomicrons, 
VLDL-1, -2 and -3 were taken. Where higher values of triglyceride-rich lipoproteins were 
expected (in view of postprandial concentrations), run times for chylomicrons, VLDL-1, -2 
and -3 were adjusted slightly to allow a 1.0ml (more dilute) sample volume and 
subsequently the run time for LDL-1 would also differ. Each fraction , 0.5ml or 1.0ml for 
chylomicrons VLDL-1, -2 and -3, and 1ml for LDL-1, -2 and -3 was carefully aspirated 
from the top of the tube and density 1.0588g/ml salt solution was used to refill the tube 
before the next run.
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Table 2.2. The angular velocity, rotor speed, and run times required to isolate chylomicrons, 










Chylomicrons 1.46(1.35) 15K (15K) 1:33 (1:26) 0.5 (1.0)
VLDL-1 4.34 (4.01) 28K (28K) 1:19(1.13) 0.5 (1.0)
VLDL-2 3.82 (3.52) 28K (28K) 1:09(1.03) 0.5 (1.0)
VLDL-3 17.4(15.9) 17K (17K) 15:16(13:56) 0.5 (1.0)
LDL-1 13.1 (15.4) 39K (39K) 2:06 (2:28) 1.0
LDL-2 29.8 37K 5:26 1.0
LDL-3 41.7 28K 13:28 1.0
Values are for 0.5ml collection volumes for chylomicrons, VLDL-1, -2 and -3 and 1.0ml 
collection volumes for LDL-1, -2 and -3. In brackets are values for when 1.0ml collection 
volumes for chylomicrons, VLDL-1, -2 and -3 were taken.
2.3. ANALYSIS OF SERUM AND LIPOPROTEIN FRACTIONS
Cholesterol, triglyceride, phospholipid, free cholesterol, glucose and NEFA were 
measured by colourimetric assay using commercial kits on an Abbott VP supersystem 
autoanalyser. Apo AI and Apo B in whole serum were measured by immunoturbidometric 
assay using commercial kits on the Abbott VP supersystem autoanalyser. Insulin was 
assayed by radioimmunoassay. Lipoprotein protein was measured using a Lowry procedure 
or a more sensitive modified Lowry procedure. Apo B was measured in VLDL and LDL 
subfractions by precipitation of Apo B by addition of isopropanol, followed by protein 
measurement in the supernatant and the apo B protein concentration was calculated by 
subtracting the supernatant protein content from the total protein content. Data for apo B 
(in serum), apo AI, glucose, insulin, and NEFA were provided from other laboratory 
researchers using the kits specified in the ‘reagents’ section, and therefore detailed 
methodology has been omitted. The inter-assay coefficient of variability for these kits was 
5%, except for insulin which was 10%.
Abbott vp supersvstem autoanalvser 
(Abbott Diagnostic Division, Maidenhead, UK)
50pl of blank (salt solution), sample, standards and controls were placed into 
sample cups. Samples were mixed with reagent in the multi-cuvette according to a pre­
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programmed dilution ratio. For cholesterol, triglyceride, free cholesterol and phospholipid 
assays, the samples, standards and controls were incubated for 12 mins at 37°C and 
absorbances were read at 500nm. Quality controls were sera of known lipid concentration.
2.3.1. Triglyceride
The triglycerides were determined after enzymatic hydrolysis with lipases. The 
indicator was a quinoneimine formed by 4-aminophenazone and 4-chlorophenol under 
catalytic influence of H202. The standard used was glycerol (50mg/ml). The inter-assay 
coefficient of variability was 5%.
Triglyceride + 3H20  -» (lipases) -> glycerol + 3RCOOH
Glycerol + ATP —> (glycerol kinase) -»  glycerol-3-phosphate (G-3-P)+ ADP
G-3-P + 0 2 -» (glycerol-3-phosphate oxidase) -> dihydroxyacetone phosphate + H20 2
2 H20 2 + 4-aminophenazone + 4 chlorophenol —» (peroxidase) —> 2H20  + HCL + 4-(p-
benzoquinone-mono-imino)-phenazone.
2.3.2. Cholesterol
Cholesterol was determined after enzymatic hydrolysis and oxidation. The indicator 
quinoneimine was formed from hydrogen peroxide and 4-aminophenazone in the presence 
of phenol and peroxidase. The standard used was cholesterol (50mg/dl). The inter-assay 
coefficient of variability was 5%.
Cholesterol ester —» (cholesterol esterase) -»  Cholesterol + RCOOH
Cholesterol + 0 2 —> (cholesterol oxidase) —> Cholestene-3-one + H20 2
Phenol + 2H20 2 + 4-aminophenazone -» (peroxidase)—» 4-(p-benzoquinone-mono imino)
phenazone + 4 H20.
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2.3.3. Free cholesterol
Free cholesterol was determined after enzymatic oxidation. The indicator was 4-(P- 
benzoquinone-mono-imino) Phenazone, formed from H2O2 and 4-aminophenozone in the 
presence of phenol and peroxidase. The standard used was cholesterol (50mg/dl). The 
inter-assay coefficient of variability was 5%.
Cholesterol + 0 2 -> (cholesterol oxidase) —» 4,-cholestenone +H20 2
2 H2O2 + 4-amino phenazone + phenol —» (peroxidase) —> 4-(p-benzoquinone-mono-imino)
phenozone +4H20.
2.3.4. Cholesterol ester
Cholesterol ester (mmolM) was calculated as (total cholesterol - free cholesterol). 
Cholesterol ester (mg/dl) was calculated as (total cholesterol-free cholesterol) x 1 .6 8  to 
account for the mass of the ester.
2.3.5. Phosholipid
Phospholipid was determined by enzymatic hydrolysis and oxidation . The indicator 
was 4- (P-benzoquinone-mono-imino) phenazone formed from H2 O2  and 4- amino 
phenazone in the presence of phenol and peroxidase. The standard used was choline 
chloride (75 mg/dl). The inter-assay coefficient of variability was 5%.
Phospholipid + H20  -» (phospholipase D) —» choline + phosphatidic acids.
Choline +202 +H20  —» (choline oxidase) —» betaine + 2 H2C>2





Lowry method was used for lipoprotein subtractions, which were diluted if 
necessary prior to assay (Lowry et al., 1951). The inter-assay coefficient of variability was 
< 10%.
Working Reagents
A. 2% w/v Na2C 0 3 in 0.1M NaOH containing 0.02 % NaK tartrate w/v and 0.01 % w/v 
CuS04. 5% SDS w/v was added to prevent turbidity.
B. Folin reagent (1:1 with water).
C. Working standard curve : 0-0.4 mg/ml BSA made up in salt solution .
Method
100 pi of lipoprotein sample was added to 500 pi reagent A and incubated for 10 
minutes at room temperature. 50 fil of reagent B was added, mixed and incubated for 1 
hour at 37°C. Absorbances were read at 690 nm.
Sensitive Lowry method
This is a more sensitive Lowry procedure often used for lipoprotein subfractions 
such as fasting chylomicrons, VLDL-1 and VLDL-2. It was also used for measuring apo B 
concentrations in lipoprotein subfractions (Markwell et al., 1979). The inter-assay 
coefficient of variability was <1 0 %.
Working Reagents
A. 2% NaC03 w/v, 0.4% NaOH w/v, 0.16 % Natartrate w/v, 5% SDS w/v, 0.04% 
Q 1SO4.5H2O w/v.
B. Folin (1:1 with water).
C. Working standard curve: 0-0.1 mg/ml BSA made up in salt solution.
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Method
100 pi of lipoprotein sample was added to 300 pi of reagent A, mixed and incubated 
for ten minutes at room temperature. 30 pi of reagent B was added and incubated for 1 
hour 37°C. Absorbances were read at 690nm.
2.3.7. Isopropanol precipitation for determination of apolipoprotein B in lipoprotein 
subfractions
Apo B was separated from the other apolipoproteins in the lipoprotein subtractions 
by precipitation in isopropanol and its concentration was measured as the difference 
between total protein and the proteins assayed in the supernatant (soluble protein) (Egusa et 
al., 1983). The total protein and supernatant protein were measured either by a standard 
Lowry procedure or by the modified senstive Lowry procedure. Apo B was measured in 
VLDL-1, -2, -3 and LDL-1 from fasting plasma. Concentrations of apo B in chylomicrons 
and non-apo B protein in LDL-2 and -3 were very small and therefore concentrations of apo 
B were not determined in these fractions. The inter-assay coefficient of variability was 
< 10%.
Method
2 0 0 pl of lipoprotein sample was added to 2 0 0 pl of isopropanol, mixed vigorously 
for one minute and incubated overnight at 4°C. The supernatant was removed for protein 
determination using the Lowry or Markwell procedure.
2.4. INSULIN RESISTANCE AND B-CELL FUNCTION
Insulin resistance and p-cell function were calculated from fasting glucose and 
insulin concentrations using the computer-solved homeostasis model assessment (HOMA) 
method as described by Matthews et al. (1985). The estimate of insulin resistance has been 
shown to correlate with those obtained using the euglycaemic and hyperglycaemic clamp 
and the estimate of p-cell function has been shown to correlate with those obtained using 
the hyperglycaemic clamp.
Insulin resistance = fasting insulin / 22.5 e-lnfastmgg,ucose 
P-cell function (%) = 2 0  x insulin / (glucose - 3.5)
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2.5. MEASUREMENT OF HUMAN ANTI-(BOVINE XANTHINE OXIDASE) IgM
AND IgG CLASS ANTIBODIES
2.5.1. Preparation of pure bovine xanthine oxidase
Bovine xanthine oxidase was either supplied commercially (Biozyme), or freshly 
prepared by J.Khan (Bath University) according to the method of Nakamura and Yamazaki 
(1982). Xanthine oxidase was dialysed in 50mM sodium carbonate to remove aluminium 
sulphate present in the crude enzyme, and protein concentration was estimated (Lowry 
method).
2.5.2. Enzyme Linked Immuno-sorbent Assay (ELISA)
Principle
1. Sensitisation of the plate. Antigen coating buffer is incubated at 4°C over night or for 4 
hours at 37°C Some of the antigen is absorbed onto the plastic surface of the plate and the 
rest remains free.
2. Washing. PBSYTween buffer is used in order to wash away any free antigen which is not 
bound to the plate.
3. Addition of the test antibody. The test antibody once added will bind to the antigen.
4. Washing. Unbound proteins are washed away.
5. Addition of a ligand. A ligand is added which is a molecule that can bind to the test 
antibody and is covalently coupled to an enzyme such as peroxidase.
6 . Washing. Free ligands is washed away.
7. Addition of chromogen. The bound ligand is visualised by the addition of a chromagen, a 
colourless substrate which is acted upon by the enzyme portion of the ligand to produce a 
coloured end product.
8 . Stopping the reaction. The reaction is stopped by the addition of 1M H2S0 4 and the 
amount of test antibody is measured by assessing the amount of coloured end-product by 
scanning the optical density of the plate.
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Method
Xanthine oxidase (0.02mg/ml) in 50mM sodium carbonate, pH 9.6, was added to 
each well of a 96-well microtitre plate (Flow Labs. Irvine, Scotland) and incubated 
overnight at 4°C. The wells were washed by incubation at room temperature (60 minutes) 
with 3 successive portions (250fil/well) of phosphate buffered saline containing 0.1% 
Tween 20 and then incubated with serum samples (IOOjliI, diluted 400-fold in the same 
buffer) for 90 minutes at 37°C. The plates were washed as above and lOOpl of goat anti- 
(human IgM or IgG) IgG Horse Radish Peroxidase conjugate (diluted 1000 fold in 
phosphate buffered saline containing 0.1% Tween 20) was added to each well.
The wells were incubated for 2 hours at room temperature, washed three times as 
above and incubated with staining buffer (lOOpl/well) for 20-30 minutes until a blue colour 
developed. The reaction was stopped by the addition of 50fil of 1M sulphuric acid, and 
absorbance was recorded at 450nm. The staining buffer contained 1% 3,3’,5,5’ 
tetramethylbenzidine in dimethylsulphoxide, diluted 100 fold in 0.1 M sodium acetate /citric 
acid pH 6.0 and 30% hydogen peroxide (0.1% til/ml) which was added immediately before 
use.
Titres are quoted as percentage absorbance shown by standard high titre pooled 
human serum, assayed on the same plate. These have been converted to concentration of 
antibody (|ig/ml) in Chapter 6 . All values are means of triplicate determinations and in 
comparative studies, patient and control samples were assayed on the same plate. The inter­
assay coefficient of variability was < 1 0 %.
2.6. STATISTICS
Results in this thesis are expressed as mean and standard error of the mean (SEM). 
Levels of significance for statistical analyses was p^0.05.
Anti-(XO) antibody levels were compared in populations using the Kolmogorov- 
Smirnov two-tailed non-parametric test. The test is sensitive to any kind of difference in the 
distributions from which the two samples were drawn-differences in location (central 
tendency), in dispersion and in skewness. This procedure calculates the maximum distance 
between the cumulative distribution functions (Dmax) of the two samples. If this distance is 
large enough, the hypothesis that the distributions are the same is rejected.
For lipid, lipoprotein and metabolite measurements, normally distributed data and
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data normally distributed after log-transformation were analysed using Student’s t-tests for 
unpaired or paired data. Non-parametric data were analysed using the Mann-Whitney test 
for unpaired data or the Wilcoxon test for paired data.
Correlations were made using Pearson’s correlation test for normally distributed and 
data normally distributed after log-transformation, and the Spearman rank correlation test 
for non-parametric data. Multiple linear regression analysis was also used in Chapter 3.
Oxstat V (Holman, Oxford) was the statistical software used for all analyses.
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CHAPTER 3
FASTING AND POSTPRANDIAL LIPAEMIA IN NIDDM
3.1. INTRODUCTION
It can be postulated that a range of quantitative and qualitative changes in fasting 
and postprandial lipoprotein subfraction composition, not shown in basic lipoprotein levels, 
may be present in diabetes and contribute to excess risk of CHD. Until recently, the 
majority of investigations have focused on fasting dyslipidaemia in NIDDM. However, 
since the majority of life is spent in the postprandial state, investigations into postprandial 
lipaemia would seem worthwhile. Furthermore, if fasting triglycerides are raised in patients 
with NIDDM, then more of life may be in the postprandial state in these patients. In past 
studies, triglyceride has been excluded as a risk factor for CHD because in multivariate 
analysis triglyceride is eliminated by its relationship to multiple other risk factors including 
HDL cholesterol. However it has recently been shown that maximum triglyceride increase 
and magnitude of postprandial lipaemia was a better predictor of CHD than HDL 
cholesterol (Patsch et al.,1992).
The aim of this chapter is to investigate postprandial lipaemia in hyperlipidaemic 




a) Ten patients with moderate dyslipidaemia but satisfactory glycaemic control (Table 3.1 
and 3.2), and treated with diet and glibenclamide (5-15 mg) daily were studied.
b) Ten age- and gender-matched non-diabetic normolipidaemic control subjects were 
obtained from the same geographical area (Tables 3.1 and 3.2).
Ethical approval was obtained from the institutional review committee (Bath District 
Research Ethics Committee).
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Table 3.1. Inclusion and exclusion criteria for diabetic patients and controls.
INCLUSION EXCLUSION
NIDDM Fructosamine <340 pmol/L 
Cholesterol: 5.2 -8.5 mM 
Triglyceride: 1.8-4.5mM
Metformin, Cyclical HRT, 
Renal and Hepatic disease, 
Other significant disease
CONTROL Triglyceride: < 2.0 mM
Table 3.2. Demographic data for patients and controls.
NIDDM CONTROL
NUMBER 1 0 1 0
AGE (yrs)± SEM 53.6 ±2.91 53.2 ±3.42
GENDER 8  male, 2  female 8 male, 2  female
BM3 (kg.m'2) ± SEM 27.8 ±0.89 24.9 ± 0.79 a
a: p<0.05
3.2.2. Protocol
1. Fulfill entry criteria.
2. Written informed consent.
3. 8  weeks run-in on placebo (single-blind) with stable glycaemic control and lipid
parameters.
4. 0800 hours: Fasting blood sample
5. 0815 hours: Standard low fat breakfast followed by normal daily activity.
6 . 1 2 0 0  hours: Standard low fat lunch provided.
7. 1800 hours: Admitted for overnight study.
8 . 1845 and 1855 hours: Blood samples taken to check that lipid levels were similar to
fasting levels.
9. 1900 hours: Test meal: mixed meal, high fat (50g fat, 1000 calories).
10. Blood samples were taken at hourly intervals for 12 hours after the test meal.
3.2.3. Measurements
Cholesterol and triglyceride in serum and serum lipoproteins (VLDL, HDL, HDL2 
and HDL3), serum apolipoproteins (AI and B), glucose, insulin and NEFA were measured 
at every time interval (data supplied by C.Stirling and co-workers). Lipoprotein
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subfractions were isolated from plasma sampled at fasting, and at 3 and 8  hours after the 
test meal. Measurements for each subfraction included total cholesterol, triglyceride, 
phospholipid, free cholesterol, esterified cholesterol and total protein. The mass of each 
fraction was calculated as the sum of the latter five components. Composition of these 
fractions was expressed as a percentage of total mass. Fasting apo B concentrations were 
determined in VLDL-1, -2 and -3 and LDL-1 fractions only (see Methods 2.3.7). 
Cholesterol and triglyceride values for VLDL and LDL were calculated as the sum of these 
lipid components in VLDL and LDL subfractions respectively. Areas under curves (AUCs) 
were calculated using the trapezoid rule. Incremental areas under curves (IAUCs) were 
calculated by subtracting the baseline value, extrapolated over time, from the AUC value. 
Insulin resistance and p-cell function were assessed using the HOMA method (see Methods 
section).
3.2.4. Statistics
Comparisons between groups (diabetic patients vs controls) were made using an 
unpaired t-test. Comparisons within subject groups (fasting vs postprandial) were made 
using a paired t-test. Measurements for triglyceride, glucose, insulin, p-cell function % and 
insulin resistance were log-transformed prior to analysis. Correlations were made using 
Pearson’s correlation test and multiple linear regression analysis. Non-parametric data 
which could not be log-transformed (IAUC for triglyceride, glucose, and insulin) were 
compared by Mann-U-Whitney test (unpaired), Wilcoxon test (paired). Data are presented 
as mean ± SEM.
3.3. RESULTS
3.3.1. Fasting lipids, lipoproteins and metabolites in diabetic patients and controls
Fasting lipids, lipoproteins, insulin, NEFA and glucose results are shown in Table
3.3. Serum, LDL and VLDL triglyceride, VLDL cholesterol and apo B were significantly 
elevated in diabetic patients compared to controls. Since serum and LDL cholesterol were 
similar in both subject groups, much of the difference in apo B levels is likely to be 
accounted for by the raised levels of VLDL in diabetic patients. However, elevated apo B
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levels could also be accounted for in part by an increase in small, dense LDL. Additionally 
an increase in VLDL triglyceride and cholesterol may occur without an increase in VLDL 
apo B when bigger VLDL molecules are synthesised. HDL and HDL2 cholesterol were 
significantly lower in diabetic patients compared to controls which were reflected by 
significantly reduced levels of apo AI. HDL3 cholesterol was also reduced in diabetic 
patients, although not significantly so. In addition, diabetic patients had raised levels of 
HDL triglyceride which were reflected in an increase in HDL3 triglyceride (p=0.07).
Diabetic patients had significantly higher levels of glucose and NEFA compared to 
controls. Levels of insulin were also raised in diabetic patients, but the results did not reach 
statistical significance.
Table 3.3. Lipids, lipoproteins, apolipoproteins and other clinical data in diabetic patients
and controls.
NIDDM Controls
Cholesterol (mM) 6.56±0.32 6.00+0.44
Triglyceride (mM) 3.48±0.27 1.44+0.14 c
VLDL cholesterol (mM) 1.17±0.20 0.46+0.08 b
VLDL triglyceride (mM) 2.08±0.23 0.61+0.13 c
LDL cholesterol (mM) 3.25±0.34 2.79+0.29
LDL triglyceride (mM) 0.33±0.03 0.23+0.03 a
HDL cholesterol (mM) 0.94±0.05 1.75+0.18 c
HDL triglyceride (mM) 0.25+0.02 0.19+0.02 b
HDL2 cholesterol (mM) 0.34+0.03 0.82+0.16 b
HDL2 triglyceride (mM) 0.07+0.01 0.06+0.02
HDL3 cholesterol (mM) 0.61+0.05 0.93+0.10 b
HDL3 triglyceride (mM) 0.21+0.03 0.13+0.02
Apo B (mg/dl) 162+8.0 75.0+7.2 c
Apo AI (mg/dl) 150+4.1 182+8.0 b
Glucose (mM) 10.1+0.67 5.49+0.10 c
Total insulin (mU/1) 11.9+3.35 9.21+1.44
NEFA (mM) 0.81+0.06 0.57+0.07 a
All values are mean ± SEM.
a: p<0.05; b: p<0.01; c: p<0.001
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3.3.2. Fasting chylomicrons, VLDL subfractions and LDL subfractions in diabetic
patients and controls
Concentrations of mass for chylomicrons, VLDL-1, -2 and -3, LDL-1, -2 and -3 are 
shown in Fig. 3.1, and lipid and protein components of these lipoproteins are shown in 
Table 3.4. Chylomicrons, VLDL-1, -2 and -3 were significantly elevated in diabetic patients 
compared to controls as were the triglyceride components of chylomicrons and all the lipid 
and protein components of the VLDL subfractions. Raised levels of apo B in VLDL 
sublf actions indicate that the number of particles of these subtractions was higher in diabetic 
patients than in controls. Diabetic patients had a more polydisperse LDL subffaction profile 
than control subjects. LDL-3 mass and all its lipid and protein components were 
significantly higher in diabetic patients compared to controls. There were no significant 
differences in LDL-1 and -2 mass, although LDL-1 mass tended to be higher and LDL-2 
mass tended to be lower in diabetic patients. LDL-2 was free cholesterol significantly 
higher in controls.
Results from analyses of lipid and protein composition of chylomicrons and VLDL 
subffactions and LDL subtractions (expressed as a percentage of total mass) are shown in 
Table 3 .5. Percentage esterified cholesterol in VLDL-1 and free cholesterol in VLDL-2, -3, 
LDL-1, -2 and -3 were significantly reduced in diabetic patients compared to controls. This 
was reflected by an increase in % triglyceride in VLDL-1, -2 and -3, LDL-1 and -2, 
although only reaching statistical significance for LDL-2. Diabetic patients also had 
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Chylomicrons, VLDL subtractions and LDL subtractions
Fig. 3.1. Concentration of chylomicrons (chylo). VLDL subfractions (V-l, V-2 and V-3) 
and LDL subtractions (L-l, L-2 and L-3) in NIDDM patients and controls, 
a: p<0.05; b: p<0.01; c: p<0.001
 ^ NIDDM b
Control
Chylo V-1 V-2 V-3 L-1 L-2 L-3
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Table 3.4. Fasting concentrations of lipid and protein components of chylomicrons, VLDL subfractions and LDL subfractions in diabetic patients and controls.
Chylomicrons VLDL-1 VLDL-2 VLDL-3 LDL-l LD L-2 LD L-3
NIDD Contr NIDD Contr NIDD Contr NIDD Contr NIDD Contr NIDD Contr NIDD Contr
CH 0.64±







1 1 .3± 
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All concentrations are mean ± SEM (mg/dl).
NIDD: NIDDM; Contr: Controls; CH: cholesterol; TG: triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
a: p<0.05; b: p<0.01; c: pcO.OOl
Table 3.5. Fasting composition of chylomicrons, VLDL subtractions and LDL subfractions in diabetic patients and controls.
Chylomicrons VLDL-1 VLDL-2 VLDL-3 LDL-1 LDL-2 LDL-3
NIDD Contr NIDD Contr NIDD Contr NIDD Contr NIDD Contr NIDD Contr NIDD Contr
CH 9.04±
1.56
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All values are mean % of total mass ± SEM.
NIDD: NIDDM; Contr: Controls; CH: cholesterol; TG: triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
a: p<0.05; b: p<0.01; c: p<0.001
A measurement of qualitative changes in lipoproteins, lipoprotein subfractions and 
metabolites is shown in Table 3.6. The ratio of LDL/HDL cholesterol was significantly 
increased in diabetic patients. HDL2/HDL3 ratio was substantially reduced (by 39%) in 
diabetic patients, although the results did not reach statistical significance. Furthermore, 
HDL, HDL2 and HDL3 were triglyceride-enriched in diabetic patients compared to controls 
as shown by their significantly higher triglyceride/cholesterol ratio.
Percent VLDL-3 in total VLDL (%VLDL-3/EVLDL) was significantly reduced in 
diabetic patients compared to controls, mirrored by a substantial increase in %VLDL- 
1/ZVLDL (38%). These findings suggest that diabetic patients had a smaller proportion of 
small VLDL and consequently a greater proportion of large VLDL. Percent LDL-3 in total 
LDL (%LDL-3/ELDL), was significantly elevated in diabetic patients, suggesting that 
diabetics had a greater proportion of small, dense LDL compared to controls.
The ratio of non-apo B protein to apo B protein was significantly elevated in VLDL 
subfractions in diabetic patients compared to controls which was reflected by an increase in 
triglyceride/apo B ratio in these subfractions in diabetic patients, albeit only significantly so 
for VLDL-2. These ratios are indicative of lipoprotein particle size and therefore the 
differences suggest that diabetic patients have larger particle size within each of the VLDL 
subfractions than controls.
p-cell function was reduced and insulin resistance was elevated in diabetic patients 
compared to controls, although the latter difference was not significance.
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Table 3.6. Qualitative lipoprotein, lipoprotein subtraction and metabolite parameters in
diabetic patients and controls.
NIDDM Controls
%VLDL-1/ EVLDL 31.0±3.37 22.5+2.58
% VLDL-2/ ZVLDL 28.0±0.81 24.8+1.96
% VLDL-3/ ZVLDL 41.0±3.54 52.7+2.83 a
%LDL-3/ZLDL 45.1+2.20 23.7+3.60 c
LDL chol/ HDL chol 3.52+0.37 1.89+0.34 b
HDL2/ HDL3 chol 0.60+0.09 0.99+0.26
HDL trig/chol 0.28+0.03 0 .1 2 +0 . 0 2 b
HDL2 trig/chol 0.21+0.03 0.10+0.03 b
HDL3 trig/chol 0.38+0.08 0.15+0.02 a
Insulin resistance 5.23+1.40 2.23+0.34
p-cell function % 40.2+12.3 96.5+16.7 b
VLDL-1 trig/apo B 19.4+4.63 13.4+2.92
VLDL-2 trig/apo B 11.9+1.45 8.01+2.03 a
VLDL-3 trig/apo B 4.17+0.45 3.26+0.61
VLDL-1 non-apoB/apo B 1.74+0.37 0.82+0.14 a
VLDL-2 non-apoB/apo B 1.63+0.32 0.87+0.10 b
VLDL-3 non-apoB/apo B 0.63+0.07 0.39+0.05 a
All values are mean ± SEM.
EVLDL. sum of VLDL subtraction mass; ELDL: sum of LDL subtraction mass; 
chol: cholesterol; trig: triglyceride; non-apo B: non-apo B protein, 
a: p<0.05; b: p<0.01; c: p<0.001
3.3.3. Postprandial lipid, lipoproteins and metabolites in diabetic patients and 
controls
Postprandial responses for lipids, lipoproteins and metabolites are shown in Fig. 3.2-
3.5, and AUC and IAUC for these data are shown underneath in Tables 3.7, and 3.9-3.11 
respectively. Paired comparisons between fasting levels of these parameters and levels at 
three hours and eight hours after the test meal within each subject group are shown in Table 
3.8.
After the test meal, serum and VLDL triglyceride, VLDL cholesterol and apo B 
increased in both subject groups respectively (Figs. 3.2 and 3.3). AUC for these parameters 
and IAUC for VLDL triglyceride were significantly increased in diabetic patients compared 
to controls (Tables 3.7 and 3.9). Peak triglyceride was delayed in diabetic patients at 5-7 
hours compared to 3-5 hours in controls. Peak serum apoB and VLDL cholesterol and
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triglyceride levels were very delayed in diabetic patients at approximately 8  hours compared 
to 4 hours for controls. Comparisons within each subject group (Table 3.8) show that 
levels of VLDL triglyceride and apo B were significantly higher at 8  hours compared to 
fasting levels in diabetic patients, whereas in controls there were only significant differences 
at 3 hours, suggesting that the return from peak to baseline levels for VLDL triglyceride 
and apo B were slower in diabetic patients compared to controls.
Despite diabetic patients having significantly higher AUC for serum cholesterol 
(Table 3.7), levels decreased after the test meal in both subject groups (Fig. 3.2). This was 
particularly apparent in the control group, in which cholesterol levels were significantly 
reduced at 3 and 8 hours compared to fasting levels (Table 3.8). In addition, reductions in 
LDL cholesterol at 8  hours were larger and more significant in controls compared to 
diabetic patients (Table 3.8).
For diabetic patients and controls, HDL, HDL2 and HDL3 cholesterol and apo AI 
levels decreased after the test meal (Figs 3.3 and 3.4). AUC for these parameters were 
significantly reduced in diabetic patients, but there were no differences in IAUC (Tables 3.9 
and 3.10). In both subject groups there were significant reductions in HDL and HDL3 
cholesterol after 8  hours, but there were only significant reductions in HDL2 cholesterol and 
apo AI after 8 hours in the control group (Table 3.8).
In both subject groups HDL and HDL3 triglyceride levels, after an initial decrease, 
increased, peaked and returned to approximately baseline levels (Figs. 3.3 and 3.4). The 
AUC for HDL and HDL3 triglyceride was higher in diabetic patients than controls (reaching 
significance for HDL3), but there were no differences in IAUC (Tables 3.9 and 3.10). 
Furthermore, peak levels for HDL and HDL3 triglyceride were delayed in diabetic patients. 
HDL2 triglyceride increased after the test meal in both diabetic patients and controls, and 
the AUC, IAUC and peak level for HDL2 triglyceride was similar in both subject groups 
(Fig. 3.4, Table 3.10). There were no significant differences between fasting levels and 
levels at 3 and 8  hours for HDL, HDL2 and HDL3 triglyceride in either of the subject groups 
(Table 3.8).
After the test meal, concentrations of insulin and glucose increased, peaked and 
returned to the baseline within 12 hours in both subject groups. However peak levels for 
these parameters were delayed in diabetic patients (Fig. 3.5). AUC for insulin and glucose 
and IAUC for glucose were significantly higher in diabetic patients compared to controls 
(Table 3.11). Insulin levels were significantly higher after 3 and 8 hours compared to 
fasting levels in diabetic patients but only at 3 hours in controls (Table 3.8), indicative of a 
prolonged insulin response in diabetic patients. Levels of NEFA, after the test meal, initially
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decreased and then increased, peaked and returned to below baseline level in both subject 
groups (Fig. 3.5). Diabetic patients had a significantly raised AUC for NEFA (Table 3.11) 
and a delayed peak compared to controls.
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Fig. 3.2 Fasting and postprandial concentrations for serum triglyceride, serum cholesterol, 
VLDL triglyceride and VLDL cholesterol.









Cholesterol (mM.hrs) 75.5+3.31 63.5±4.02 a -3.16±6.21 -8.41±1.98
Triglyceride (mM.hrs) 55.0±2.73 26.7±2.18 c 13.2±2.77 9.46±1.15
VLDL triglyceride (mM.hrs) 29.43±2.95 15.8±2.34 c 10.8+1.59 6.54±1.10 a
VLDL cholesterol (mM.hrs) 12.1±0.89 8.56±0.89 a 0.75±0.68 -0.01±0.93
All areas were calculated as a product of concentration (units as in table above) and time 
(hours) over 12 hours. AUCs are calculated as areas above zero concentration, while 
IAUCs are calculated as net areas above or below (+ or -) the concentration at basal time in 
this and subsequent calculations. All values are mean ± SEM. 
a: p<0.05; c: p<0.001
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Table 3.8. Comparison of paired data (Ohrs vs 3hrs and Ohrs vs 8 hrs) within each subject 
group.
Diabetic patients
0  hours 3 hours 8 hours
Controls
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All values are mean ± SEM. 
chol: cholesterol; trig: triglyceride.
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Fig. 3.3. Fasting and postprandial concentrations of HDL cholesterol and triglyceride, apo 
AI and apo B.









HDL cholesterol (mM.hrs) 9.93±0.49 18.3+2.18 b -1.3+0.21 -2.73+0.86
HDL Triglyceride (mM.hrs) 3.10±0.39 2.52±0.25 0.12+0.27 0.25+0.18
Apo AI (mg/dl.hrs) 1691+41 1995+82 b -103+44.0 -191+33.3
Apo B (mg/dl.hrs) 1640±57 1009+77 c 124+68.2 105+26.9
All areas were calculated as a product of concentration (units as in table above) and time




i  i i r 
2 4 6 8 10 12
^  0.16 
0 1 4  H 
.g 0.12 
g 0.10 - 
.2> 0.08
CN 0.06 -
Q  0.04 -  
X i 1— i----- 1---1---- r

















0 2 4 6 8 10 12








0 2 4 6 8 10 12
Hours After Test Meal 
■ ■ Control
Fig. 3.4. Fasting and postprandial concentrations of HDL2 cholesterol and triglyceride and 
HDL3 cholesterol and triglyceride.









HDL2 cholesterol (mM.hrs) 4.04±0.53 8.62+1.35 b 0.02+0.36 -1.24+0.92
HDL2 triglyceride (mM.hrs) 0.98+0.14 1.08+0.18 0.13+0.19 0.31+0.13
HDL3 cholesterol (mM.hrs) 5.95+0.51 9.63+1.20 b -1.33+0.42 -1.52+0.32






00 a -0.24+0.27 -0.06+0.20
All areas were calculated as a product of concentration (units as in table above) and time
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Fig. 3.5 Fasting and postprandial concentrations of glucose, total insulin and NEFA.









Glucose (mM.hrs) 139±9.69 69.211.19 c 17.614.12 3.3211.20 b
Total insulin (mU/l.hrs) 555+150 270131.5 a 4121122 160125.3
NEFA (mM.hrs) 9.8910.67 6.9910.51 b 0 .2 0 1 0 . 8 6 0.1410.66
All areas were calculated as a product of concentration (units as in table above) and time
(hours) over 12 hours. All values are mean ± SEM. a: p<0.05; b: p<0.01; c: p<0.001
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3.3.4. Postprandial chylomicrons, VLDL subfractions and LDL subfractions in 
diabetic patients and controls
Postprandial response for concentration (mass) of chylomicrons, VLDL subfractions 
and LDL subfractions are shown in Figs. 3.6 and 3.7 and AUC and IAUC for these data are 
shown underneath in Tables 3.12 and 3.13 respectively. Comparisons between fasting levels 
and levels at 3 and 8  hours for these parameters within each subject group are also shown 
in these figures. Comparisons between diabetic patients and controls of the levels of the 
lipid and protein components of chylomicrons, VLDL subfractions and LDL subfractions at 
3 and at 8  hours are shown in Tables 3.15 and 3.17 respectively.
After the test meal, levels of chylomicrons, VLDL-1 and -2 increased in both subject 
groups (Fig. 3.6), and the AUC for these lipoprotein fractions were significantly elevated in 
diabetic patients compared to controls (Table 3.12). For chylomicrons and VLDL-1, in 
both subject groups, concentrations were significantly higher at 3 and 8  hours compared to 
fasting levels (Fig. 3.6). However, whereas in diabetic patients the concentrations of 
chylomicrons and VLDL-1 continued to increase up to 8  hours, in controls the 
concentrations were less at 8 hours than at 3 hours. This was particularly evident in the 
VLDL-1 fraction, since diabetic patients had significantly raised IAUC compared to 
controls (Table 3.12). VLDL-2 increase was higher in controls as shown by the comparison 
of concentrations at 3 and 8 hours with fasting levels in diabetic patients and controls (Fig.
3.6). Despite diabetic patients having significantly higher AUC for VLDL-3 (Table 3.12), 
their levels of VLDL-3 fell after the test meal, whereas in controls levels increased (Fig.
3.6). This difference is confirmed by the comparison of the IAUC, where controls had 
significantly raised IAUC for VLDL-3 compared to diabetic patients (Table 3.12). In 
addition, there was a significant reduction in VLDL-3 after 8  hours in diabetic patients, 
whereas in controls the levels were clearly elevated after 8  hours, although the difference 
did not reach significance. The AUC and IAUC for triglyceride in chylomicrons and VLDL 
subfractions showed similar trends to that for total mass in diabetic patients and controls 
(Table 3.14).
All LDL subfractions decreased after the test meal in both subject groups (Fig. 3.7), 
and elevated fasting levels of LDL-3 persisted postprandially, as shown by the significantly 
raised AUC for LDL-3 in diabetic patients compared to controls (Table 3.13). Reductions 
in LDL-1 and LDL-2 were similar in patients and controls, since there were no differences 
in IAUC (Table 3.13) or paired comparisons within each subject group for these 
subfractions (Fig. 3.7). As shown by analysis of concentrations of LDL-3 at 3 and 8  hours
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compared to fasting levels, there was a more significant decrease in LDL-3 in diabetic 
patients after the test meal compared to the control group (Fig. 3.7). The AUC and IAUC 
for cholesterol in LDL subtractions showed similar trends to that for total LDL mass in 
diabetic patients and controls (Table 3.14). Similarly to fasting comparisons, there were no 
differences in postprandial total LDL cholesterol, but diabetic patients had significantly 
higher LDL triglyceride (Table 3.14). As shown by the negative IAUC values, total LDL 
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Fig. 3.6. Fasting and postprandial concentrations of chylomicrons, VLDL-1, -2, and -3.
For comparisons of paired data (Ohrs vs 3hrs and Ohrs vs 8 hrs) within each subject group: 
a: p<0.05; b: p<0.01; c: p<0.001.









Chylomicron mass (mg/dl.hrs) 442±47.4 295+45.5 a 384+46.7 261+46.9
VLDL-1 mass (mg/dl.hrs) 1278+158 424+59.5 c 392+56.3 204+27.0 b
VLDL-2 mass (mg/dl.hrs) 905+74.5 372+53.0 c 112+61.6 140+43.2
VLDL-3 mass (mg/dl.hrs) 933+119 538+76.7 b -178+76.0 88.2+47.6 b
All areas were calculated as a product of concentration (units as in table above) and time 
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Fig. 3.7. Fasting and postprandial concentrations of LDL-1, -2 and -3.
For comparisons of paired data (Ohrs vs 3hrs and Ohrs vs 8 hrs) within each subject group: 
a: p<0.05; b: p<0.01; c: p<0.001.









LDL-1 mass (mg/dl.hrs) 523±62.2 443±71.1 -56.9+28.0 -54.0+21.9
LDL-2 mass (mg/dl.hrs) 1134+145 1353+140 -50.7+38.4 -92.0+24.8
LDL-3 mass (mg/dl.hrs) 1311±118 621+130 c -112+35.0 -57.9+35.0
All areas were calculated as a product of concentration (units as in table above) and time
(hours) over 8 hours. All values are mean ± SEM. c: p<0.001
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Chylomicron chol 16.3+2.15 12.4+2.56 11.2+2.54 8.42+1.39
VLDL-1 chol 88.9±11.9 38.5+7.20 b 22.1+5.61 15.0+2.35
VLDL-2 chol 96.8+10.9 42.5+6.02 c 6.50+9.83 14.4+4.20
VLDL-3 chol 161+25.4 99.2+19.6 -45.2+17.8 8.60+9.55 a
LDL-1 chol 153+21.1 132+23.6 -18.9+12.0 -20.1+6.64
LDL-2 chol 362+53.3 456+50.3 -24.1+14.9 -36.8+7.85
LDL-3 chol 417+40.2 198+41.0 b -32.3+9.72 -19.9+11.1
Total LDL chol 932+93.6 785+83.2 -75.3+30.7 -76.8+13.8
Chylomicron trig 363+40.8 233+38.1 a 321+39.3 215+39.2
VLDL-1 trig 857+113 272+40.4 c 267+41.3 133+16.9 b
VLDL-2 trig 513+40.0 204+32.4 c 74.3+33.7 77.6+28.1
VLDL-3 trig 382+42.7 213+25.2 b -59.0+35.4 47.9+24.3 a
LDL-1 trig 81.8+8.37 65.3+8.68 -13.1+4.46 -7.98+5.17
LDL-2 trig 78.0+11.0 61.9+6.99 -3.26+3.50 -1.91+1.47
LDL-3 trig 57.5+5.15 29.6+5.92 b -0.54+2.34 1.72+1.26
Total LDL trig 217+22.0 157+16.3 a -16.9+8.64 -8.17+6.49
All areas were calculated as a product of concentration (mg/dl) and time (hours) over 8  
hours. All values are mean ± SEM.
chol: cholesterol; trig: triglyceride, a: p<0.05; b: p<0.01; c: pcO.OOl
Results from analyses of composition (expressed as percentage of total mass) of 
chylomicrons, VLDL subfractions and LDL subfractions at 3 and 8  hours are shown in 
Tables 3.16 and 3.18 respectively. At 3 hours after the test meal there was a significant 
increase in % triglyceride and decrease in % free cholesterol in chylomicrons and LDL-2 in 
diabetic patients compared to controls. In addition, % esterified cholesterol in VLDL-1 was 
significantly reduced in diabetic patients. At 8  hours after the test meal there was a 
significant increase in % triglyceride and decrease in % free cholesterol in LDL-2 in diabetic 
patients compared to controls.
Paired analyses of composition of chylomicrons, VLDL subfractions and LDL 
subfractions at 3 and 8  hours compared to fasting values are shown in Table 3.8. There was 
a significant reduction in postprandial % free cholesterol in VLDL-2, VLDL-3, LDL-1, 
LDL-2 and LDL-3 in controls, and in VLDL-1 and LDL-3 in diabetics patients compared to 
fasting levels. In controls only, postprandial % triglyceride in VLDL-3 and LDL-2 was 
significantly elevated. A significant increase in postprandial % triglyceride occured in LDL- 
3 for both subject groups. In addition, postprandial % esterified cholesterol in LDL-3 was 
significantly elevated in diabetic patients compared to fasting levels.
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Table 3.15. Concentrations of lipid and protein components of chylomicrons, VLDL and LDL subfractions 3 hours after test meal.
Chylomicrons VLDL-1 VLDL-2 VLDL-3 LDL-1 LDL-2 LDL-3









1 1 .7± 
1.33
5.52+ 










6 . 6 6
57.1+
















































2 . 1 0  a
13.8± 
1.53



























0 . 6 6
5.54±
1.08






















1 1 .0 ± 
2.23






































2 1 .8 + 
4.69 b




























All concentrations are mean ± SEM (mg/dl).
NIDD: NIDDM; Contr: Controls; CH: cholesterol; TG: triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
a: p<0.05; b: p<0.01; c: p<0.001
Table 3.16. Composition of chylomicrons, VLDL and LDL subfractions 3 hours after test meal.
Chylomicrons VLDL-1 VLDL-2 VLDL-3 LDL-1 LDL-2 LDL-3
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All values are mean % of total mass ± SEM.
NIDD: NIDDM; Contr: Controls; CH: cholesterol; TG: triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
a: p<0.05; b: p<0.01; c: p<0.001
Table 3.17. Concentrations of lipid and protein components of chylomicrons, VLDL and LDL subfractions 8 hours after test meal.
Chylomicrons VLDL-1 VLDL-2 VLDL-3 LD L-l LD L-2 LDL-3
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All concentrations are mean ± SEM (mg/dl).
NIDD: NIDDM; Contr: Controls; CH: cholesterol; TG: triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
a: p<0.05; b: p<0.01; c: p<0.001
Table 3.18. Composition of chylomicrons, VLDL and LDL subfractions 8 hours after test meal.
Chylomicrons VLDL-1 VLDL-2 VLDL-3 LDL-1 LDL-2 LDL-3
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All values are mean % of total mass ± SEM.
NIDD: NIDDM; Contr: Controls; CH: cholesterol; TG: triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
a: p<0.05; b: p<0.01; c: p<0.001
Comparisons of qualitative parameters at 3 and 8  hours are shown in Table 3.19. In 
general, differences in these qualitative parameters between diabetic patients and controls 
are similar at 3 and 8 hours to those in the fasting state. Percent VLDL-1 /X VLDL was 
significantly higher at 3 and 8  hours in diabetic patients than in controls, and %VLDL- 
3/XVLDL was significantly reduced at 8  hours in diabetic patients. There were no 
differences in % VLDL-2/XVLDL between diabetic patients and controls. Diabetic patients 
had significantly elevated % LDL-3/XLDL and LDL/HDL cholesterol ratio at 3 and 8  hours 
compared to controls. HDL2/HDL3 cholesterol ratio was reduced at 3 and 8  hours by 14% 
and 15% respectively in diabetic patients compared to controls, although results did not 
reach significance. HDL, HDL2 and HDL3 was triglyceride enriched at 3 and 8  hours in 
diabetic patients (not significant for HDL3 at 3 hours), as shown by triglyceride/cholesterol 
ratios for these lipoproteins.
Paired analyses between qualitative parameters at 3 and 8  hours compared to fasting 
values for both subject groups is shown in Table 3.8. After the test meal, %VLDL- 
1/XVLDL significantly increased, % VLDL-3 /XVLDL significantly decreased and % 
VLDL-2/XVLDL, %LDL-3/XLDL and HDL2/HDL3 cholesterol ratio remained the same for 
both diabetic patients and controls. LDL/HDL cholesterol ratio was significantly elevated 
at 8  hours in the control group only. Triglyceride/cholesterol ratio for HDL, HDL2 and 
HDL3 was elevated postprandially in both subject groups, but only reaching significance for 
HDL and HDL2 in controls.
Table 3.19. Qualitative parameters in diabetic patients and controls 3 and 8  hours after test 
meal.
3 hours 8  hours
NIDDM Control NIDDM Control
% VLDL-1 / Z  VLDL 41.7±2.62 34.1+1.79 a 42.9+3.68 29.8+2.61 a
% VLDL-2/ ZVLDL 28.7±0.50 27.6+1.87 30.0+0.79 27.5+1.79
% VLDL-3/ EVLDL 29.6±2.65 38.4+3.16 27.1+3.56 42.8+3.89 b
%LDL-3/ILDL 45.1+2.17 23.7+3.60 c 44.1+2.54 24.2+3.22 c
LDL chol/ HDL chol 3.45+0.34 1.96+0.35 b 3.87+0.43 1.98+0.36 b
HDL2/HDL3 chol 0.67+0.10 0.88+0.17 0.70+0.15 0.93+0.18
HDL trig/chol 0.30+0.05 0.16+0.03 a 0.39+0.06 0.17+0.02 b
HDL2 trig/chol 0.28+0.06 0.15+0.03 a 0.31+0.04 0.14+0.02 c
HDL3 trig/chol 0.34+0.05 0.18+0.03 0.45+0.05 0.19+0.04 b
All values are mean ± SEM. 
chol: cholesterol; trig: triglyceride 
a: p<0.05; b: p<0.01; c: p<0.001
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3.3.5. Lipids, lipoproteins, lipoprotein subfractions and metabolites: their
relationship with postprandial triglyceride and small dense LDL
Correlations of BMI, fasting values of lipids, lipoproteins, lipoprotein subtractions 
and metabolites with postprandial triglyceride response (AUC for serum triglyceride) are 
shown in Table 3.20. Correlations were made in three subject groups: i) 1 0  diabetic 
patients; ii) 10 non-diabetic controls; iii) in 18 diabetic patients (studied in chapter 4, which 
include the 1 0  diabetic patients in this chapter, and which have similar entry criteria).
The parameters which had the strongest association with postprandial triglyceride 
were serum triglyceride and triglyceride-rich lipoproteins. BMI and fasting values of 
triglyceride for serum and triglyceride-rich lipoproteins were positively associated with 
postprandial triglyceride in all groups. More of these correlations were significant in the 
control group than in the 10 diabetic patients. However, highly significant correlations in 
the 18 diabetic patients (probably due to larger patient number) suggest that these 
associations in the 10 diabetic patients are reliable. There were neither significant 
correlations with HDL, HDL2 and HDL3 cholesterol nor with any of the metabolites. 
However there were non-significant positive associations with insulin resistance in all 
groups.
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(n=1 0 ) (n=1 0 ) (n=18)
BMI 0.38 0.74 a 0.34
Triglyceride 0.62 0 . 8 6  b 0.89 c
VLDL trig 0.67 a 0 . 6 6  a 0.90 c
Chylomicron trig 0.51 0.64 a 0.71 c
VLDL-1 trig 0.74 a 0.87 b 0.84 c
VLDL-2 trig 0.56 0.51 0.89 c
VLDL-3 trig 0.26 0.53 0.76 c
HDL chol -0.05 -0.19 -0.28
HDL2 chol -0.42 -0.30 0.06
HDL3 chol 0.04 0.03 -0.40
NEFA 0.40 -0 . 1 2 -0.05
Total Insulin 0.38 0.16 0.24
Glucose -0 . 0 2 0.57 -0.37
Insulin resistance 0.37 0.23 0.37
3 -cell function % 0.36 -0.44 -0.08
Values are Pearson’s correlation coefficients for the 10 diabetic and 10 control subjects 
used in this chapter, and additionally the 18 diabetics studied in chapter 4. These 18 
diabetics include the 1 0  subjects from this chapter, and have the same entry criteria, 
a: p<0.05; b: p<0.01; c: p<0.001
Correlations of BMI, and fasting and AUC values lipids, lipoproteins, lipoprotein 
subffactions and metabolites with the proportion of small, dense LDL (%LDL-3/ZLDL) are 
shown in Table 3.21. Correlations were made in three subject groups: i) 10 diabetic 
patients; ii) 10 non-diabetic controls; iii) in 18 diabetic patients (studied in chapter 4, which 
include the 1 0  diabetic patients in this chapter, and which have similar entry criteria).
The strongest correlations with %LDL-3/ELDL involved triglyceride-rich 
lipoproteins and HDL cholesterol. BMI, serum triglyceride and triglyceride-rich 
lipoproteins were positively associated with %LDL-3/ELDL in diabetic patients, the 
majority of these correlations reaching significance for the 18 diabetic patients. Similar 
trends can be seen for controls, with the exception of negative associations with 
chylomicrons and proportion of large VLDL (VLDL-1/E VLDL). In the 18 diabetic 
patients and controls correlations of %LDL-3/ELDL with triglyceride-rich lipoproteins 
were weaker with AUC values than with fasting values. %LDL-3/ELDL correlated 
negatively with fasting and AUC values for HDL and HDL2 cholesterol in all groups, 
reaching significance for controls and the 18 diabetic patients. There were no significant
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correlations with HDL3 cholesterol. Fasting and postprandial NEFA correlated positively 
and significantly with %LDL-3/ELDL in diabetic patients, and there was also a significant 
positive correlation with fasting glucose in the 18 diabetic patients. However, since fasting 
NEFA did not correlate significantly with %LDL-3/ELDL in the 18 diabetic patients this 
result may not be reliable. Insulin resistance was positively associated with %LDL-3/ELDL 
in diabetic patients (p=0.06 for the 18 diabetic patients).
Table 3.21. Correlation coefficients (r) of %LDL-3/ELDL mass with fasting and 







BMI 0.13 0.17 0.54 a
Triglyceride 0.54 0.30 0.74 c
Triglyceride AUC 0.37 0 . 1 2 0.52 a
VLDL trig 0.55 0.54 0.75 c
VLDL trig AUC 0.62 0.39 0.61 b
Chylo trig 0.39 -0.32 0.56 a
Chylo trig AUC 0.62 -0.16 0.25
VLDL-1 trig 0.58 0.38 0.69 b
VLDL-1 trig AUC 0.32 0.37 0.64 b
VLDL-2 trig 0.51 0.61 0.74 c
VLDL-2 trig AUC 0 . 1 1 0.52 0 . 6 8 b
VLDL-3 trig 0.25 0.56 0.69 b
VLDL-3 trig AUC -0.23 0.35 0.35
% VLDL-1 /E VLDL 0.48 -0.06 0.56 a
HDL chol -0.41 -0.89 c -0.64 b
HDL chol AUC -0.38 -0.72 a -0.57 a
HDL2 chol -0.60 -0.82 b -0.55 a
HDL2 chol AUC -0.73 a -0.79 b -0.60 b
HDL3 chol -0.37 -0.32 -0 . 2 2
HDL3 chol AUC 0.47 -0.43 -0 . 1 2
NEFA 0.84 b 0 . 0 1 0 . 2 1
NEFA AUC 0.33 0.49 0.61 b
Insulin 0.45 -0 .1 1 0.28
Insulin AUC 0.06 0.46 0.19
Glucose 0 . 1 0 0.32 0.52 a
Glucose AUC 0 . 0 2 0.13 0.35
Insulin resistance 0.50 -0.08 0.45
P-cell function % 0.39 -0.18 -0 . 1 2
Values are Pearson’s correlation coefficients for the 10 diabetic and 10 control subjects 
used in this chapter, and additionally the 18 diabetics studied in chapter 4. These 18 
diabetics include the 1 0  subjects from this chapter, and have the same entry criteria, 
a: p<0.05; b: p<0.01; c: p<0.001
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To assess the combined influence of serum triglyceride, HDL cholesterol and insulin 
resistance on %LDL-3/ELDL in patients with NIDDM, multivariate analysis was performed 
with the 18 diabetic patients with %LDL-3/ELDL as the dependent variable. Two models 
were constructed, one with fasting lipid values (Table 3 .22) and the other with postprandial 
(AUC) values (Table 3.23).
Fasting triglyceride was significantly associated with %LDL-3/ELDL, whereas 
association with HDL cholesterol did not quite reach statistical significance. Insulin 
resistance was less strongly associated with %LDL-3/ELDL than the lipid values indicating 
that the lipid values, particularly triglyceride, had more influence on the variability of 
%LDL-3/ELDL. In this way, the outcome of multivariate analysis agrees with that of 
univariate analysis in which the strength of association for insulin resistance was also less 
than that for these lipid values.
Postprandial lipid values were less strongly associated with %LDL-3/ZLDL. This is 
consistent with univariate analysis findings which show that these postprandial lipid values 
have weaker associations with %LDL-3/XLDL than the fasting values.
Table 3.22. Multiple regression analysis for the determinants of %LDL-3/ZLDL mass ratio 
in the fasting state in 18 diabetics
Association p value
Triglyceride positive 0.019
HDL cholesterol negative 0.069
Insulin resistance positive 0.330
For the model R2 = 0.69. These 18 diabetics (studied in chapter 4) include the 10 subjects 
from this chapter, and have the same entry criteria.
Table 3.23. Multiple regression analysis for the determinants of %LDL-3/ZLDL mass ratio 
in the postprandial state in 18 diabetics
Association p value
Triglyceride AUC positive 0.346
HDL cholesterol AUC negative 0.154
Insulin resistance positive 0 . 2 1 0
For the model R2 = 0.46. These 18 diabetics (studied in chapter 4) include the 10 subjects 
from this chapter, and have the same entry criteria.
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3.4. DISCUSSION
Hypertriglyceridaemia in diabetes, and especially in NIDDM, is likely to worsen in 
the postprandial state which may have adverse effects on quantity and quality of lipoprotein 
subfractions, not obvious from basic lipid and lipoprotein measurements. Therefore, the 
primary aim of this study was to examine the fasting and postprandial chylomicron, VLDL 
subffaction and LDL subfraction distribution and composition in NIDDM patients with 
hypertriglyceridaemia. In this study, modifications to the fasting VLDL subfraction profile 
in diabetic patients were exaggerated postprandially. The abnormal fasting LDL subfraction 
distribution, not apparent from total and LDL cholesterol measurements, persisted 
postprandially in diabetic patients.
James and Pometta (1991) showed that hypertriglyceridaemic NIDDM patients had 
elevated fasting levels of VLDL subfractions, reduced HDL cholesterol, a polydisperse LDL 
profile, and raised levels of small dense LDL (LDL-3), compared to normolipidaemic non­
diabetic controls. These observations are confirmed in the present study. Elevated fasting 
levels of serum and VLDL triglyceride in diabetic patients could be due to increased VLDL 
production. Raised levels of glucose and NEFA were found in the diabetic patients, 
indicating insulin resistance and/or relative insulin lack. The increased NEFA flux from 
inadequately controlled adipose tissue lipolysis can increase hepatic triglyceride synthesis 
and VLDL production (Sniderman et al., 1993). It is likely that impaired clearance of 
VLDL also plays a role because reduced levels of HDL cholesterol present in diabetic 
patients is indicative of low LPL activity also due to insulin resistance and/or relative insulin 
lack. In the present study, P-cell function, but not insulin levels, was significantly reduced 
in diabetic patients, indicative of relative insulin lack. Insulin resistance was found to be 
substantially higher in diabetic patients compared to controls, as expected, although this 
difference did not reach significance. Using the HOMA method to estimate insulin 
resistance is less accurate than measurements obtained by the use of euglycaemic or 
hyperglycaemic clamp, possibly accounting for this lack of significance.
Diabetic patients had a higher proportion of the large triglyceride-rich VLDL-1 
which is less readily converted to LDL (Stalenhoef et al., 1984; Packard, et al., 1984), thus 
providing less surface component for HDL generation. Increase in VLDL subfraction 
particle size was present in diabetic patients, as indicated by greater proportion of VLDL-1 
at the expense of VLDL-3 and increased ratios of triglyceride/apo B and non-apo B/ apo B 
in each of the VLDL subfractions. Increased ratios of triglyceride/apo B and non-apo B/ 
apo B suggest an increase in triglyceride in the core of the lipoprotein and an increase in the
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surface component of the lipoprotein respectively, both of which may be the result of an 
increase in triglyceride synthesis compared to apo B synthesis. Triglyceride enrichment of 
VLDL and increase in particle size have previously been reported in NIDDM (Taskinen et 
al., 1986). Large triglyceride-rich lipoproteins provide more substrate for CETP than their 
smaller counterparts, and consequently have greater potential for producing cholesterol 
ester-rich VLDL remnants. These remnants can be removed by scavenger pathways 
(Goldstein, 1980), resulting in foam cell formation. Although % cholesterol ester in 
VLDL-1 and % free cholesterol in VLDL-2 and -3 were reduced in diabetic patients, this 
was probably a reflection of triglyceride enrichment as confirmed by higher triglyceride/apo 
B ratios. Indeed, cholesterol ester/apo B ratios (data not shown) for these fractions tended 
to be higher in diabetic patients.
There was little difference in fasting levels of LDL cholesterol between diabetic 
patients and control subjects which may be due to two metabolic processes with opposing 
effect. Large triglyceride-rich VLDL is less readily converted to LDL, but on the other 
hand insulin resistance down-regulates LDL receptors on hepatocytes (Chait et al., 1979), 
thus reducing LDL clearance. In addition, elevated glucose levels in diabetics increases the 
likelihood of LDL glycation which has previously been demonstrated in moderately 
hypertriglyceridaemic patients with NIDDM, and has been shown to reduce LDL 
metabolism, thus promoting clearance via the scavenger pathway (Steinbrecher et al., 
1984). Glycation may not only promote foam cell formation, but also confer increased 
susceptibility of LDL to oxidation (Hunt et al., 1990).
In the present study, postprandial serum and VLDL triglyceride levels and 
incremental increases in VLDL triglyceride were higher in diabetic patients than in controls. 
In addition, the postprandial VLDL triglyceride and cholesterol peaks were delayed in 
diabetic patients suggesting impaired clearance of triglyceride-rich lipoproteins. 
Incremental increases in chylomicrons and VLDL-1 were higher and peak levels delayed in 
diabetic patients suggesting that clearance of chylomicrons and VLDL-1 was impaired, and 
that this impaired clearance is reflected in postprandial serum and VLDL triglyceride levels. 
The VLDL-1 fraction includes chylomicron remnants as well as endogenously synthesised 
large VLDL. Tan and co-workers (1992) showed that chylomicron remnants were elevated 
in hypertriglyceridaemic subjects with NIDDM compared to normolipidaemic NIDDM 
patients. Even normotriglyceridaemic NIDDM patients have an excess of chylomicron 
remnants after an oral fat load (Chen et al., 1993). Decreased chylomicrons apo B 
clearance has been previously described in hypertriglyceridaemic NIDDM patients and this 
was concluded to be due to decrease in LPL activity (Haffner et al., 1984). Catabolism of
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chylomicrons may be influenced by substrate competition with VLDL for the same saturable 
lipolytic pathway (Brunzel et al., 1973), the larger pool of VLDL in NIDDM reducing 
chylomicron metabolism. This might explain the positive association between fasting VLDL 
triglyceride and the magnitude of postprandial lipemia (triglyceride AUC) in diabetic 
patients and controls. Reduction in fasting triglyceride in NIDDM by intensive insulin 
therapy can improve clearance time of chylomicrons (Abrams et al., 1982). The rise in 
VLDL-2 levels after the test meal was higher in controls than diabetic patients, and whereas 
VLDL-3 levels increased in controls, they decreased in diabetic patients. It would therefore 
appear that in diabetic patients the production by the liver of small VLDL-3 and to a lesser 
extent VLDL-2 has been reduced in favour of production of larger triglyceride-rich VLDL. 
This would occur when the triglyceride accumulation compared to apo B synthesis is very 
high and in this way more triglyceride can be packaged into each VLDL particle. In 
controls, the accumulation of triglyceride is less allowing a greater proportion of small 
VLDL to be synthesised. In addition, reduced levels of small VLDL would also arise from 
slower degradation of the excess large VLDL and chylomicron remnants. In line with this, 
Karpe et al. (1993 a) demonstrated a postprandial increase in large VLDL in 
normotriglyceridaemic and hypertriglyceridaemic patients with CHD, but a decrease in small 
VLDL in the hypertriglyceridaemic patients only.
Postprandial responses in insulin, glucose and NEFA were elevated and delayed in 
diabetic patients indicating insulin resistance and/or relative insulin lack in diabetic patients. 
Because NIDDM patients have relative insulin lack their insulin response to glucose is 
inadequate resulting in prolonged glycemia, which in turn stimulates further insulin 
production resulting in prolonged insulin response. Postprandial insulin responses in 
NIDDM have previously been reported to be delayed (Polonsky et al., 1988). The increase 
in insulin levels after the test meal leads to the initial fall in NEFA concentrations, due to 
inhibition of lipolysis in adipose tissues (Swislocki et al., 1987). In this way, hepatic VLDL 
production is reduced in the postprandial state to avoid competition with chylomicrons and 
their remnants. NEFA concentrations rise again due to the decline in insulin levels allowing 
lipolysis to resume. However, in diabetic patients, levels of NEFA were elevated, despite 
higher insulin levels  ^ suggesting that insulin resistance and not just insulin deficiency is 
responsible. Insulin resistance results in impaired inhibition of lipolysis in adipose tissue, 
elevating plasma NEFA concentration (Frayn and Coppack, 1992) which can stimulate 
further VLDL synthesis, and compete for clearance with postprandial triglyceride-rich 
lipoproteins. Reduced suppression of lipolysis by insulin has been demonstrated in NIDDM 
(Fraze et al., 1985; Skowronski et al., 1991) and shown to be associated with raised levels
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of triglyceride and apo B (McKeigue et al., 1993). Insulin resistance can therefore lead to 
elevated postprandial lipemia by stimulating VLDL production as well as by reducing 
chylomicron and VLDL metabolism, which might explain the positive association (albeit not 
significant) between insulin resistance and postprandial triglyceride response in controls and 
diabetics.
In both subject groups, HDL and LDL cholesterol decreased after the test meal. 
This may occur because the proportion of large triglyceride-rich VLDL, less readily 
catabolised to give rise to LDL and HDL, was higher in both subject groups after the test 
meal. In addition cholesterol ester transfer from HDL and LDL by CETP may have been 
stimulated by elevated triglyceride-rich lipoproteins as has been reported in NIDDM 
compared to non-diabetic subjects (Bagdade et al., 1993). Despite significant reductions in 
HDL cholesterol, HDL triglyceride/cholesterol ratio increased after the test meal in both 
subject groups (significant only in controls), indicating triglyceride enrichment of HDL. 
HDL may have acquired triglyceride from triglyceride-rich lipoproteins by the actions of 
CETP. In this way, elevated levels of large triglyceride-rich lipoproteins in diabetics may 
account for increased triglyceride enrichment of HDL in the fasting and postprandial state, 
despite lower HDL cholesterol and apo AI levels. Patsch and co-workers (1984), proposed 
that excessive postprandial triglyceridaemia leads to cholesterol ester depletion of HDL2. 
The triglycerides that replace the cholesterol ester are rapidly hydrolysed by HL producing 
smaller HDL3 particles. This might explain the lower (although not significant) 
HDL2/HDL3 cholesterol ratio in diabetic patients compared to controls.
Elevated levels of LDL-3 and %LDL-3/ELDL ratio persisted after the test meal in 
diabetic patients. Small dense LDL has been described in patients with CHD (Austin et al., 
1988; Campos et al., 1992b). Contributing to their atherogenic potential, small, dense LDL 
have been shown to bind less well to LDL receptors compared to larger LDL (Kleinman et 
al., 1987a; Kleinman et al., 1987b), and are more readily oxidised than larger LDL (Tribble 
et al., 1992), perhaps because they carry less lipid soluble antioxidants such as vitamin E. 
As mentioned in Chapter one, the most probable mechanism by which small dense LDL 
arise is that triglyceride transfers to HDL and LDL via CETP in exchange for cholesteryl 
ester (Tall, 1986). LDL enriched with triglyceride becomes a substrate for lipases, which 
results in the formation of small, dense LDL (LDL-3) (Auwerx et al., 1988; Levy et al., 
1990; Zambon et al., 1993). Kinetic studies of LDL metabolism suggest that small dense 
LDL are derived from large triglyceride-rich VLDL in the hypertriglyceridaemic state, 
whereas in the normotriglyceridaemic state, the liver produces small VLDL particles which 
give rise to larger, more buoyant LDL (LDL-1 and -2) (Caslake et al., 1992).
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Data from the present study are consistent with, and support this hypothesis. 
Diabetic patients had elevated levels of small dense LDL and raised VLDL, particularly 
large triglyceride-rich VLDL-1. Furthermore, they had larger particle size within each 
VLDL subfraction, as indicated by increased non apo B protein/apo B and triglyceride/apo 
B ratios. Diabetic patients also had higher LDL triglyceride, and % triglyceride in LDL-2, 
and reduced % cholesterol in LDL-2 possibly resulting from transfer of triglyceride from 
elevated triglyceride-rich lipoproteins or from lipase action on triglyceride-rich lipoproteins 
resulting in triglyceride-rich LDL.
In the present study, in NIDDM patients, % LDL-3 /ILDL correlated positively 
with BMI, glucose, insulin resistance (p=0.06) and fasting and postprandial levels of 
triglyceride-rich lipoproteins, and correlated negatively with fasting and postprandial levels 
of HDL cholesterol. Correlations were stronger with fasting lipid values compared to 
fasting values, possibly because postprandial values are subject to more variation. The 
positive relationship between postprandial triglyceride-rich lipoproteins and LDL density 
has previously been reported in subjects with CHD (Karpe et al., 1993b). The relationship 
of hypertriglyceridaemia and HDL cholesterol with LDL size is well established in NIDDM 
(Feingold et al., 1992; Stewart et al., 1993). The negative association between HDL 
cholesterol and preponderance of small, dense LDL reflects the efficiency of catabolism of 
triglyceride-rich lipoproteins. A low HDL cholesterol would indicate a slow clearance of 
triglyceride-rich lipoproteins which as previously discussed, could influence LDL size 
distribution. The positive association between glucose and insulin resistance and 
preponderance of small, dense LDL confirms the findings of previous studies (Feingold et 
al., 1992; Selby et al., 1993; Reaven et al., 1993). Insulin resistance is associated with high 
serum and VLDL triglycerides in subjects with normal and impaired glucose intolerance and 
in NIDDM (Abbott et al., 1987; Laakso et al., 1990), which, as previously discussed, can 
lead to the production of small, dense LDL.
There are conflicting reports on whether small dense LDL in NIDDM arise from 
hypertriglyceridaemia or from factors specifically associated with diabetes. It was reported 
by Feingold et al., (1992) that phenotype B (predominance of small, dense LDL) was more 
common in normolipidaemic NIDDM patients than normolipidaemic controls, suggesting 
that diabetes itself plays a role in the production of small, dense LDL. In addition, two 
studies in non-diabetic subjects showed a strong positive relationship between insulin 
resistance and the appearance of small dense LDL (Reaven et al., 1993; Selby et al., 1993). 
The latter were associated with higher triglyceride levels, higher BMI and lower HDL 
cholesterol. In one study (Reaven et al., 1993), when subjected to multiple linear regression
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analysis, with the inclusion of triglycerides, the relationship between insulin resistance and 
LDL size and was no longer significant. More recently however, it has been reported 
(James et al., 1994) that LDL-2/LDL-3 mass ratio was negatively associated with fasting 
levels of glucose and HbAlc both remaining significantly correlated with LDL-2/LDL-3 
mass ratio when corrected for triglycerides. Also, multiple linear regression analysis, 
including triglycerides and HDL cholesterol, showed that LDL-2/LDL-3 mass ratio 
correlated with HbAlc. In the present study, multivariate analysis confirmed the findings of 
univariate analysis, by showing that the strength of the correlations were weaker with 
insulin resistance compared to serum triglyceride and HDL cholesterol, suggesting that 
hypertriglyceridaemia has greater influence than NIDDM on the prevalence of small, dense 
LDL.
In summary, this study has demonstrated abnormalities in the fasting and 
postprandial composition and distribution of lipoprotein subfractions in 
hypertriglyceridaemic patients with NIDDM. Elevated fasting levels of large triglyceride- 
rich lipoproteins partly due to insulin resistance and/or relative insulin lack in NIDDM 
patients were exacerbated postprandially. Triglyceride enrichment of LDL and HDL, raised 
levels of small, dense LDL, and lower HDL cholesterol concentrations persisted 
postprandially. These abnormalities contribute significantly to the increased risk of 
atherogenesis in hypertriglyceridaemic patients with NIDDM.
96
CHAPTER 4
EFFECTS OF BEZAFIBRATE 
ON FASTING AND POSTPRANDIAL LIPAEMIA IN NEDDM
4.1. INTRODUCTION
The fibric acid group of hypolipidaemic drugs have been associated with significant 
reductions in coronary events in the Helsinki Heart study, especially in patients with 
combined hyperlipidaemia (Manninen et al., 1987). Fibric acid derivatives have been 
recommended for the treatment of diabetic hyperlipidaemia (Durrington and Winocour 
1989; Winocour and Laker 1990). These agents have the ability to lower triglyceride levels 
and increase HDL by increasing LPL activity, which would be clearly beneficial for 
treatment of dyslipidaemia in NIDDM.
In chapter three, patients with NIDDM were shown to have many quantitative and 
qualitative lipoprotein abnormalities including elevated fasting levels of triglyceride-rich 
lipoproteins which were exacerbated postprandially, as well as increased levels of small 
dense LDL and reduced levels of HDL cholesterol in both the fasting and postprandial state. 
Diabetic patients had an increased proportion of large VLDL, and particle size was greater 
within each VLDL subtraction compared to controls. Furthermore, HDL and LDL was 
triglyceride-enriched in diabetic patients. These findings clearly emphasise the potential 
importance of lowering triglyceride levels in patients with NIDDM. Bezafibrate has been 
used widely in the treatment of hyperlipidaemia including patients with NIDDM (Seviour et 
al., 1988; Rovellini et al., 1992; Niort et al., 1992). However, these study and earlier 
studies of bezafibrate in NIDDM have only investigated basic fasting lipid and lipoprotein 
measurements.
The aim of this double-blind placebo-controlled study was to investigate the effects 
of bezafibrate on the quantity and quality of fasting and postprandial lipids, lipoproteins, and 




18 patients with moderate dyslipidaemia but satisfactory glycaemic control (Table 
4.1 and 4.2), and treated with diet and glibenclamide (5-15 mg) daily were studied. These 
18 patients include the 10 patients described in chapter 3. All patients received (single 
blind) placebo run-in for 8  weeks before the first visit, and then received either (double­
blind) placebo or bezafibrate (400mg daily of Bezalip Mono Slow Release) for 8  weeks 
before the second visit. Ethical approval was obtained from the institutional review 
committee (Bath District Research Ethics Committee).
Table 4.1. Inclusion and exclusion criteria for patients.
INCLUSION EXCLUSION
NIDDM Fructosamine < 340 pmol/L 
Cholesterol: 5.2 -8.5 mM 
Triglyceride: 1.8-4.5 mM
Metformin, Cyclical HRT, 
Renal and Hepatic diseases, 
Other significant disease
HRT: Hormone Replacement Therapy.
Table 4.2. Demographic data for patients.
PLACEBO GROUP BEZAFIBRATE GROUP
NUMBER 9 9
AGE ± SEM (yrs) 59.3± 2.92 54.2±2.23
GENDER 8  male, 1 female 7 male, 2 female
BMI ± SEM (kg.m"2) 27.3± 0.59 28.1±1.50
4.2.2. Protocol
1. Fulfil entry criteria.
2. Written informed consent.
3. A) First visit: 8  weeks run-in on placebo (single-blind) with stable glycaemic control and 
lipid parameters.
Or:-
B) Second visit: 8  weeks on placebo or bezafibrate (double-blind) with stable glycaemic 
control and lipid parameters.
4. 0800 hours: Fasting blood sample.
5. 0815 hours: Standard low fat breakfast followed by normal daily activity.
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6 . 1200 hours: Standard low fat lunch provided.
7. 1800 hours: Admitted for overnight study.
8 . 1845 and 1855 hours: Blood samples taken to check that lipid levels were similar to
fasting levels.
9. 1900 hours: Test meal: mixed meal, high fat (50g fat, 1000 calories).
1 0 . Blood samples were taken at hourly intervals for 12 hours after the test meal.
4.2.3. Measurements
Cholesterol and triglyceride in serum and serum lipoproteins (VLDL, HDL, HDL2 
and HDL3), serum apolipoproteins (AI and B), glucose, insulin, NEFA were measured at
every time interval (data supplied by C.Stirling and co-workers). Chylomicrons, LDL
subfractions (LDL-1, LDL-2 and LDL-3) and VLDL subfractions (VLDL-1, VLDL-2 and 
VLDL-3) were isolated from plasma sampled at fasting, 3 and 8 hours after the test meal. 
Measurements for each subfraction included total cholesterol, triglyceride, phospholipid, 
free cholesterol, esterified cholesterol and total protein. The mass of each fraction was 
calculated as the sum of the latter five components. Composition of these fractions was 
expressed as a percentage of total mass. Fasting apo B concentrations were determined in 
VLDL-1, -2 and -3 and LDL-1 fractions only (see Methods 2.3.7). Cholesterol and 
triglyceride values for VLDL and LDL were calculated as the sum of these lipid 
components in VLDL and LDL subfractions respectively. Areas under curves (AUCs) were 
calculated using the trapezoid rule. Incremental areas under curves (IAUCs) were 
calculated by subtracting the baseline value, extrapolated over time, from the AUC value. 




Comparisons between treatment groups were made using an unpaired t-test and
comparisons within treatment groups before and after therapy were made using a paired t-
test. Measurements for triglyceride, glucose, insulin, insulin resistance, and p-cell function 
were log-transformed prior to analysis. Non-parametric data, which could not be log- 
transformed (IAUC for triglyceride, glucose, and insulin) were compared by Mann-U- 
Whitney test (unpaired), Wilcoxon test (paired). Data are presented as mean ± SEM. The 
following convention is used to indicate levels of statistical significance: 
a: p<0.05; b: p<0.01; c: p<0.001 compared with start, 
d: p<0.05; e: p<0.01; f: p<0.001 compared with bezafibrate group.
4.3. RESULTS
4.3.1. Fasting lipids, lipoproteins and metabolites in bezafibrate- and placebo-treated 
groups
Fasting lipids, lipoproteins and metabolites results are shown in Table 3. There were 
no significant differences in any of these parameters before treatment between the 
bezafibrate-treated group and the placebo group. Following bezafibrate therapy, there were 
significant reductions in serum apo B (-21%) and VLDL cholesterol (-51%) and triglyceride 
(-45%), and a 27% reduction in serum triglyceride (p=0.06). There were no significant 
differences in cholesterol and triglyceride in LDL, HDL, HDL2 and HDL3, or apo AI after 
bezafibrate treatment. There were, however, trends to improve serum (4%) and LDL 
cholesterol (10%) . Bezafibrate had no significant effects on insulin, glucose or NEFA 
levels, although insulin levels approximately doubled in both patient groups, reaching 
statistical significance in the placebo group.
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Table 4.3. Lipids, lipoproteins, apolipoproteins and metabolites in the bezafibrate and
placebo groups.
Bezafibrate Placebo
Start end Start End
Cholesterol (mM) 6.63±0.44 6.38+0.31 7.14+0.39 7.23+0.45
Triglyceride (mM) 3.31±0.46 2.40+0.39 2.80+0.35 2.66+0.45
VLDL cholesterol (mM) 1.19+0.25 0.58+0.11 a 0.90+0.12 0.80+0.12
VLDL triglyceride (mM) 2 . 1 1  =b0 .3 8 1.17+0.25 a 1.57+0.26 1.67+0.22
LDL cholesterol (mM) 3.13±0.39 2.82+0.18 3.80+0.36 3.70+0.42
LDL triglyceride (mM) 0.31±0.03 0.30+0.02 0.28+0.04 0.31+0.02
HDL cholesterol (mM) 0.97+0.07 0.97+0.10 1.00+0.08 1.08+0.09
HDL2 cholesterol (mM) 0.35±0.08 0.27+0.03 0.32+0.04 0.33+0.04
HDL3 cholesterol (mM) 0.61±0.04 0.71+0.09 0.69+0.08 0.75+0.07
HDL triglyceride (mM) 0.29+0.03 0.27+0.03 0.21+0.08 0 .2 0 +0 . 0 2
HDL2 triglyceride (mM) 0.07±0.02 0.07+0.02 0.05+0.01 0.05+0.01
HDL3 triglyceride (mM) 0 .2 2 ±0 . 0 2 0.20+0.03 0.18+0.02 0.21+0.04
Apo B (mg/dl) 121+8.7 96.0+9.90 a 118+7.4 118+9.06
Apo AI (mg/dl) 144+4.7 154+8.9 151+6.6 158+7.03
Glucose (mM) 8.44+0.84 7.88+0.69 10.0+0.64 9.61+0.84
Insulin (mU/1) 14.1+4.31 28.6+6.98 10.5+1.80 20.2+2.81 b
NEFA (mM) 0.73+0.08 0.68+0.09 0.75+0.05 0.64+0.11
All values are mean ± SEM. a: p<0.05; b: p<0.01 compared with start.
4.3.2. Fasting chylomicrons, VLDL subfractions and LDL subfractions in bezafibrate 
and placebo groups
Concentrations (mass) of chylomicrons, VLDL-1, -2 and -3, LDL-1, -2 and -3 are 
shown in Fig. 4.1a and 4.1b, and lipid and protein components of these lipoproteins in 
Tables 4.4 and 4.5. Bezafibrate treatment resulted in significant reductions in VLDL-1 (- 
51%) and VLDL-2 mass (-49%) (Fig. la) which were reflected in reductions of total 
protein and all lipid components of these subtractions (Table 4.4). In addition, there was a 
significant reduction in VLDL-3 triglyceride (-40%) following bezafibrate therapy (Table 
4.4). There was a significant decrease in LDL-1 esterified cholesterol and increase in LDL- 
2 free cholesterol following bezafibrate therapy, and it is interesting to note that the LDL 
profile was less polydisperse, which could not be said of the placebo group (Table 4.5). 
The placebo group had significantly higher levels of LDL-3 compared to the bezafibrate- 
treated group before and after treatment, which was reflected by higher total LDL 
cholesterol in the placebo group.
Composition (expressed as a percentage of total mass) for chylomicrons, VLDL
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subfractions and LDL subfractions are shown in Tables 4.6 and 4.7. Percent protein in 
chylomicrons was significantly increased following bezafibrate therapy, which was reflected 
in a reduction in % triglyceride (Table 4.6). Percent esterified cholesterol in VLDL-1, -2 
and -3 fell significantly in the bezafibrate-treated group which was reflected in a significant 
increase in triglyceride in VLDL-1 and -2 (Table 4.6). There was little in the way of 
compositional differences in LDL subfractions (Table 4.7).
160
100 -
Chylo VLDL-1 VLDL-2 VLDL-3
Chylomicrons and VLDL subtractions 
Bezafibrate start Bezafibrate end
Placebo start mm & Placebo end
Fig. 4.1a Concentrations of chylomicrons (Chylo), and VLDL subfractions in bezafibrate 





1 J Bezafibrate Start watm  Bezafibrate End 
Placebo Start placebo End
Fig. 4.1b: Concentrations of LDL subfractions in bezafibrate and placebo groups. 
All values are mean ± SEM. d: p<0.05 compared with bezafibrate group.
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Table 4.4. Fasting concentrations of lipid and protein components of chylomicrons and VLDL subfractions in bezafibrate and placebo groups.
Chylomicrons VLDL-1 VLDL-2 VLDL-3
Bezafibrate Placebo Bezafibrate Placebo Beza: ibrate Placebo Beza:ibrate Placebo
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All values are mean ± SEM (mg/dl).
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein, 
a: p<0.05; b: p<0.01 compared with start, 
d: p<0.05 compared with bezafibrate group.
Table 4.5. Fasting concentrations of lipid and protein components of LDL subfractions in bezafibrate and placebo groups.
LDL-1 LD L-2 LD L-3
Beza ibrate Placebo Beza: ibrate Placebo Beza ibrate Placebo
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All values are mean ± SEM (mg/dl).
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein.
a: p<0.05 compared with start.
d: p<0.05; e: p<0.01 compared with bezafibrate group.
Table 4.6. Fasting composition of chylomicrons and VLDL subfractions in bezafibrate and placebo groups.
Chylomicrons VLDL-1 VLDL-2 VLDL-3
Bezafibrate Placebo Bezafibrate Placebo Bezafibrate Placebo Bezafibrate Placebo
Start End Start End Start End Start End Start End Start End Start End Start End
CH 10.6 ± 8.05± 6.99± 1 0 .8 + 8.28± 6.92± 8.57+ 6 .8 8 + 11.7± 9.45+ 9.96± 9.83+ 17.9+ 16.8+ 19.0+ 17.6+
2.35 2.89 0.71 3.47 0.47 0 .2 1  a 1.43 0.82 0.44 0.40 b 0.83 0.74 0.81 1.42 0.89 0.89
TG 73.3+ 55.8+ 6 8 .0 ± 53.1± 6 8 .2 + 71.1± 61.7± 6 8 .3± 57.0± 61.4± 56.6+ 58.3+ 40.8+ 38.2+ 39.3+ 39.6+
2.63 7.81 6.07 8.09 1.41 1.15 b 4.21 2.16 1.81 1.37 b 0.98 2 . 2 0 1.50 2.30 1.72 1.84
PL 5.55± 9.79± 9.71+ 13.0+ 1 0 .8 + 1 0 .1+ 1 2 .0 ± 1 2 .3± 14.1± 11.5+ 15.5+ 15.1+ 17.2+ 16.9+ 18.0+ 18.4+
1.05 2.72 3.29 3.27 1.35 0.95 1.36 1.05 1.33 1.29 0.79 0.97 1 . 2 0 1.35 0.52 0.90
FC 2.95± 3.38± 1.45± 1.63+ 3.82± 3.67± 5.61± 4.07± 4.64± 4.48+ 4.97+ 5.77+ 6.78+ 7.33+ 7.81+ 8.04+
0.91 1.94 0.58 0 . 6 8 0.29 0.43 1 .2 0 0.62 0.34 0.56 0.56 0.54 0.39 0.74 0 . 2 2 0.41
EC 1 2 .8 ± 7.85± 9.31± 15.4+ 7.48± 5.47± 4.97± 4.72± 11.9± 8.35± 8.38+ 6.83+ 18.7+ 15.8+ 18.9+ 16.0+
3.77 2.33 1.14 6 . 1 0 0.76 0 . 8 8  a 0.64 d 0.37 1.17 0.65 a 0.87 d 0.89 1.31 1.27 a 1.41 1.30 a
Prot 5.38± 23.2± 1 1 .8 + 16.9± 9.67± 9.75± 15.7± 1 0 .6 ± 1 2 .4± 14.2± 14.5+ 14.0+ 16.5+ 2 1 .8 + 16.1+ 18.0+
1.08 6.48 a 4.21 4.87 0.73 0.67 3.88 0.42 0.92 1.25 1.43 0.83 1.46 4.27 1.36 1.93
All values are mean % of total mass ± SEM.
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein, 
a: p<0.05; b: p<0.01 compared with start, 
d: p<0.05 compared with bezafibrate group.
Table 4.7. Fasting composition of LDL subfractions in bezafibrate and placebo groups.
LD L-l LD L-2 LDL-3
Bezafibrate Placebo Beza ibrate Placebo Beza ibrate Placebo
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All values are mean % of total mass ± SEM.
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein.
a: p<0.05 compared with start.
d: p<0.05 compared with bezafibrate group.
A qualitative comparison of lipoproteins and lipoprotein subtractions and 
metabolites is shown in Table 4.8. Percentage LDL-3 in total LDL (%LDL-3/ZLDL), 
indicative of the proportion of small dense LDL, fell significantly after bezafibrate therapy 
and was significantly lower than the placebo group. Percentage VLDL-3 in total VLDL 
(%VLDL-3/ ZVLDL) significantly increased in the bezafibrate-treated group which was 
reflected in non-significant reductions in the larger triglyceride-rich VLDL subfractions. 
There were no significant differences in triglyceride enrichment of HDL, in ratios of 
HDL2/HDL3 and LDL/HDL cholesterol, or in VLDL subfraction particle size (indicated by 
triglyceride/apo B and non-apo B/apo B ratios) following bezafibrate treatment. Insulin 
resistance and p-cell function were not significantly altered after bezafibrate therapy, 
however, it is interesting to note that these parameters increased in both treatment groups, 
reaching significance for insulin resistance in the placebo group.
Table 4.8. Fasting qualitative parameters in bezafibrate and placebo groups.
Beza: ibrate Placebo
Start end Start end
%VLDL-1/ ZVLDL 32.0±4.23 27.7+3.18 26.1+3.44 29.0+2.50
% VLDL-2/ ZVLDL 28.7+1.07 25.9+1.66 27.3+1.89 27.9+1.18
% VLDL-3/ ZVLDL 39.4±4.70 46.3+4.23 a 46.6+4.86 43.1+2.96
%LDL-3/ZLDL 37.7+4.36 31.0+4.31 b 44.4+3.21 45.6+3.36 d
LDL chol/HDL chol 3.23±0.34 3.05+0.22 3.89+0.36 3.40+0.26 b
HDL2/ HDL3 chol 0.63+0.19 0.44+0.09 0.53+0.11 0.48+0.08
HDL trig/chol 0.32+0.05 0.34+0.08 0.23+0.03 0 .2 1 +0 . 0 1
HDL2 trig/chol 0.25+0.06 0.25+0.07 0.16+0.03 0.17+0.03
HDL3 trig/chol 0.38+0.03 0.38+0.09 0.28+0.04 0.29+0.05
Insulin resistance 5.11+1.60 10.9+2.98 4.64+0.84 8.95+1.69 a
p-cell function % 105+45.7 137+29.3 35.2+7.49 73.4+10.7
VLDL-1 trig/apo B 22.2+4.68 23.0+6.16 14.9+5.00 14.6+1.52
VLDL-2 trig/apo B 11.8+1.42 9.62+0.77 11.2+1.40 9.88+1.64
VLDL-3 trig/apo B 4.15+0.51 2.98+0.40 5.18+1.10 3.70+0.42
VLDL-1 
Non-apoB/apo B
1.91+0.49 1.83+0.58 1.49+0.35 1.25+0.18
VLDL-2 
Non-apoB/apo B
1.42+0.16 1.16+0.19 1.86+0.49 1.23+0.27
VLDL-3 
Non-apoB/apo B
0.56+0.07 0.38+0.05 0.84+0.15 0.54+0.05 d
All values are mean ± SEM.
Choi: Cholesterol; Trig: Triglyceride; Non-apo B: Non-apo B protein.
a: p<0.05; b: p<0.01 compared with start; d: p<0.05 compared with bezafibrate group.
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4.3.3. Postprandial lipids, lipoproteins and metabolites in bezafibrate and placebo
groups
Postprandial responses for lipids, lipoproteins and metabolites are shown in Figs. 
4.2-4.9 and the calculated areas under the postprandial curves (AUC) together with the 
incremental areas under the curves (IAUC) are shown below each Figure in Tables 4.9-4.16 
respectively.
While there were no differences in the time to reach peak triglyceride levels (Fig. 2) 
following bezafibrate therapy, AUC for serum triglyceride fell significantly (-35%) (Table 
4.9), with an accompanying (non-significant) reduction in AUC for cholesterol (-12%) 
(Table 4.9).
AUCs for VLDL cholesterol and triglyceride and serum apo B fell significantly by 
38%, 63% and 27% respectively in the bezafibrate-treated group and were significantly 
lower than the placebo group (Table 4.10 and 4.14). IAUC for VLDL triglyceride 
significantly decreased (-74%) after bezafibrate therapy (Table 4.10) reflected by a 
reduction in peak VLDL triglyceride time from 6-9 hours to 3-8 hours (Fig. 4.3). There 
were no significant postprandial differences in HDL, HDL2 and HDL3 cholesterol and 
triglyceride or apo AI in response to bezafibrate therapy (Fig. 4.4-4.7, Tables 4.11-4.14).
Following bezafibrate therapy, AUC for NEFA was significantly reduced (20%) 
(Table 4.15). There was no significant difference in AUC for glucose in response to 
bezafibrate therapy (Table 4.15), and although IAUC for glucose was significantly raised 
(Table 4.15), the difference was extremely small (Fig. 4.8). AUC and IAUC for insulin 
were not significantly altered after bezafibrate treatment although these parameters 
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Fig. 4.2. Fasting and postprandial concentrations of cholesterol and triglyceride in 
bezafibrate and placebo groups.
Beza Start Beza End Placebo Start Placebo End
Cholesterol (mM.hrs) 
AUC
71.5±4.32 63.1±2.90 74.9+4.01 71.1+3.97
Cholesterol (mM.hrs) 
IAUC
-8.12+2.51 -13.4+1.49 -10.8+1.64 -15.6+1.99 a
Triglyceride (mM.hrs) 
AUC
59.6±5.83 38.6±4.94 a 43.8+3.97 46.5+6.63
Triglyceride (mM.hrs) 
IAUC
19.8±3.77 9.77+1.55 10.2+2.13 d 14.6+2.00
Table 4.9. AUC and [AUC for cholesterol and triglyceride in bezafibrate and placebo
groups. All values are mean ± SEM and were calculated as a product of concentration and 
time over 12 hours. AUCs were calculated as areas above zero concentration, while IAUCs 
were calculated as net areas above or below (+ or -) the concentration at basal time for this 
Table and subsequent Tables.
Beza: bezafibrate
a: p<0.05 compared with start.
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Fig. 4.3. Fasting and postprandial concentrations of VLDL cholesterol and triglyceride in 
bezafibrate and placebo groups.
Beza Start Beza End Placebo Start Placebo End
VLDL chol (mM.hrs) 
AUC
12.7+1.14 7.86+0.73 c 11.2+0.67 13.2+0.95 f
VLDL chol (mM.hrs) 
IAUC
2.11±0.59 0.92+0.60 0.40+0.86 2.17+1.38
VLDL trig (mM.hrs) 
AUC
32.7±5.65 12.0+1.42 a 23.8+2.79 27.9+4.47 e
VLDL trig (mM.hrs) 
IAUC
16.8+3.83 4.52+1.49 a 8.36+0.98 10.4+3.63 d
Table 4.10. AUC and IAUC for VLDL cholesterol and triglyceride in bezafibrate and 
placebo groups. All values are mean ± SEM and were calculated as a product of 
concentration and time over 12 hours.
Beza: bezafibrate
a: p<0.05; c: p<0.001 compared with start.
d: p<0.05; e: p<0.01; f: p<0.001 compared with bezafibrate group.
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Fig. 4.4. Fasting and postprandial concentrations of HDL cholesterol and triglyceride in 
bezafibrate and placebo groups.
Beza Start Beza End Placebo Start Placebo End
HDL chol (mM.hrs) 
AUC
9.91±0.71 10.8+1.00 10.8+0.85 10.8+0.85
HDL chol (mM.hrs) 
IAUC
-1.67±0.59 -0.92+0.55 -1.17+0.24 -2.14+0.37
HDL trig (mM.hrs) 
AUC
3.92±0.28 3.28±0.30 2.59+0.31 d 2.97+0.22
HDL trig (mM.hrs) 
IAUC
0.41+0.28 -0.02+0.31 0.05+0.21 0.29+0.31
Table 4.11. AUC and IAUC for HDL cholesterol and trig yceride in bezafibrate and placebo
groups. All values are mean ± SEM and were calculated as a product of concentration and 
time over 12 hours.
Beza: bezafibrate
d: p<0.05 compared with bezafibrate group.
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Fig. 4.5. Fasting and postprandial concentrations of HDL2 cholesterol and triglyceride in 
bezafibrate and placebo groups.
Beza Start Beza End Placebo Start Placebo End
HDL2 chol (mM.hrs) 
AUC
4.14±0.72 3.95±0.45 4.1710.52 3.6410.47
HDL2 chol (mM.hrs) 
IAUC
-0.10±0.55 0.75±0.44 0.3810.40 -0.3610.30
HDL2 trig (mM.hrs) 
AUC
1.70±0.35 1.3810.19 0.9110.14 1.1210.16
HDL2 trig (mM.hrs) 
IAUC
0.82±0.28 0.5410.10 0.3710.16 0.4810.17
Table 4.12. AUC for IAUC for HDL2 cholesterol and trig yceride in bezafibrate and placebo
groups. All values are mean ± SEM and were calculated as a product of concentration and 
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Fig. 4.6. Fasting and postprandial concentrations of HDL3 cholesterol and triglyceride in 
bezafibrate and placebo groups.
Beza Start Beza End Placebo Start Placebo End
HDL3 chol (mM.hrs) 
AUC
5.75±0.58 6.82±1.02 6.67+0.60 7.21+0.67
HDL3 chol (mM.hrs) 
IAUC
-1.59+0.36 -1.68+0.25 -1.55+0.49 -1.78+0.33
HDL3 trig (mM.hrs) 
AUC
2.64+0.21 2.24+0.24 2.05+0.22 2.16+0.19
HDL3 trig (mM.hrs) 
IAUC
-0.01±0.16 -0.21+0.29 -0.06+0.14 -0.37+0.55
Table 4.13. AUC and IAUC for HDL3 cholesterol and triglyceride in bezafibrate and 
placebo groups. All values are mean ± SEM and were calculated as a product of 
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Fig. 4.7. Fasting and postprandial concentrations of Apo B and Apo AI in bezafibrate and 
placebo groups.
Beza Start Beza End Placebo Start Placebo End
Apo B (mg/dl.hrs) 
AUC
1703±73.5 1245+120 c 1530±63.5 1690+125 d
Apo B (mg/dl.hrs) 
IAUC
248±107 93.3±38.7 115+31.9 269+71.4 d
Apo AI (mg/dl.hrs) 
AUC
1694±53.4 1767+88.6 1679+67.1 1708+82.5
Apo AI (mg/dl.hrs) 
IAUC
-31.5+34.4 -83.7±42.7 -133+31.8 d -193+41.7
Table 4.14. AUC and IAUC for Apo B and Apo AI in bezafibrate and placebo groups. All 
values are mean ± SEM and were calculated as a product of concentration and time over 12 
hours.
c: p<0.001 compared with start.
d: p<0.05 compared with bezafibrate group.
Beza: bezafibrate
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Fig. 4.8. Fasting and postprandial concentrations of NEFA and Glucose in bezafibrate and 
placebo groups.
Beza Start Beza End Placebo Start Placebo End
NEFA (mM.hrs) 
AUC
9.68+0.89 7.72+0.82 a 8.54+0.56 8.86+0.70
NEFA (mM.hrs) 
IAUC
0.96±1.20 -0.44+1.36 -0.51+0.50 1.13+1.31
Glucose (mM.hrs) 
AUC
111±10.4 112+10.0 129+11.0 133+9.71
Glucose (mM.hrs) 
IAUC
10.1+4.81 17.7+5.57 a 8.86+5.66 17.8+12.6
Table 4.15. AUC and IAUC for NEFA and glucose in bezafibrate and placebo groups. All 
values are mean ± SEM and were calculated as a product of concentration and time over 12 
hours.
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Fig. 4.9. Fasting and postprandial concentrations of insulin in bezafibrate and placebo 
groups.
Beza Start Beza End Placebo Start Placebo End
Insulin (mU/l.hrs) 
AUC
717±163 826+138 343±43.8 d 685±144 b
Insulin (mU/l.hrs) 
IAUC
548±119 483+110 217+36.8 d 443±131 a
Table 4.16. AUC and 
mean ± SEM and were
AUC for insulin in bezafibrate and placebo groups. All values are 
calculated as a product of concentration and time over 12 hours.
a: p<0.05; b: p<0.01 compared with start, 
d: p<0.05 compared with bezafibrate group.
Beza: bezafibrate
4.3.4. Postprandial chylomicrons and VLDL and LDL subfractions in bezafibrate 
and placebo groups
Postprandial responses for chylomicrons, VLDL subfractions and LDL subfractions 
are shown in Figs. 4.10-4.13, and the calculated areas under the postprandial curves (AUC) 
together with the incremental areas under the curves (IAUC) are shown in Tables 4.17-4.20 
respectively. Levels of lipid and protein components for these parameters at 3 and 8 hours 
are shown in Tables 4.22-4.23 and 4.26-4.27 respectively.
AUC for chylomicrons and VLDL-1, -2 and -3, and IAUC for chylomicrons 
decreased significantly in bezafibrate-treated patients by 55%, 49%, 36%, 27% and 56% 
respectively (Tables 4.17 and 4.18). Also, AUC for chylomicrons and IAUC for 
chylomicrons and VLDL-1 were significantly lower compared to the placebo group (Table 
4.17). Levels of VLDL-1 (Fig. 4.10) and VLDL-2 (Fig. 4.11) were lower at 8 hours than
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at 3 hours after bezafibrate therapy, whereas before bezafibrate treatment, levels were 
highest at 8 hours, suggesting that rate of clearance of these fractions was increased. 
Although there was no significant difference in IAUC for VLDL-3 after bezafibrate 
treatment (Table 4.18), it can be seen from Fig. 4.11 that concentration of VLDL-3 
decreased postprandially before bezafibrate treatment whereas levels increased after 
bezafibrate treatment. Concentrations (mass) of chylomicrons, VLDL-1 and -2 were 
significantly reduced at 3 and 8 hours following bezafibrate treatment, whereas levels of 
VLDL-3 were only significantly reduced at 3 hours (Tables 4.22 and 4.26).
Following bezafibrate therapy, there were no differences in postprandial responses 
of LDL subffactions (Fig. 4.12-4.13, Tables 4.19-4.20) or in total LDL cholesterol (Table 
4.21) . However, as with fasting comparisons, cholesterol ester in LDL-1 decreased at 3 
hours and free cholesterol in LDL-2 increased at 3 and 8 hours after bezafibrate treatment 
(Tables 4.23 and 4.27) and the postprandial LDL subfraction profile became less 
polydisperse (Figs. 4.12 and 4.13). AUC and IAUC for cholesterol and triglyceride in 
chylomicrons, VLDL subfractions and LDL subfractions showed similar trends after 
bezafibrate therapy to that for total mass (Table 4.21).
Composition of chylomicrons, VLDL subfractions and LDL subfractions (expressed 
as percentage of total mass) at 3 and 8 hours are shown in Tables 4.24-4.25 and 4.28-4.29 
respectively. At three hours after the test meal, VLDL-1 and -2 % triglyceride was 
significantly higher in bezafibrate treated patients, with accompanying lower % cholesterol 
in these fractions (significant for VLDL-2) (Table 4.24). In addition, % free cholesterol 
was significantly higher and % esterified cholesterol significantly lower in LDL-3 at three 
hours following bezafibrate therapy (Table 4.25). Percent esterified cholesterol in LDL-3 
was significantly lower after bezafibrate therapy 8 hours after the test meal (Table 4.29).
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Fig. 4.10. Fasting and postprandial concentrations of chylomicrons and VLDL-1 in 
bezafibrate and placebo groups.
Beza Start Beza End Placebo Start Placebo End
Chylo (mg/dl.hrs) 
AUC
487+53.0 217133.6 b 372157.0 4921106 e
Chylo (mg/dl.hrs) 
IAUC
432±51.4 190130.8 b 332153.4 4531101 d
VLDL-1 (mg/dl.hrs) 
AUC
1389±247 7021133 b 9441141 12011161 a
VLDL-1 (mg/dl.hrs) 
IAUC
424+62.9 227179.4 317152.0 508186.6 a d
Table 4.17. AUC and IAUC for chylomicrons and VLDL-1 in bezafibrate and placebo 
groups. All values are mean 1 SEM and were calculated as a product of concentration and 
time over 8 hours.
Beza: bezafibrate
a: p<0.05; b: p<0.01 compared with start.

















Hours after test meal 
• —•  Bezafibrate Start 
Bezafibrate End
5  120  -  o> □-------










Hours after test meal 
o—o Placebo Start 
Placebo End
Fig. 4.11. Fasting and postprandial concentrations of VLDL-2 and VLDL-3 in bezafibrate 
and placebo groups.
Beza Start Beza End Placebo Start Placebo End
VLDL-2 (mg/dl.hrs) 
AUC
1053±158 673±96.6 b 862+77.2 1018+119
VLDL-2 (mg/dl.hrs) 
IAUC
231±60.0 253±60.2 256+54.1 392+57.8
VLDL-3 (mg/dl.hrs) 
AUC
916±129 666+75.8 a 826+86.2 893+97.3
VLDL-3 (mg/dl.hrs) 
IAUC
-85.1+91.2 67.2±29.1 -60.9+73.2 -10.1+54.5
Table 4.18. AUC and IAUC for chylomicrons and VLDL-1 in bezafibrate and placebo 
groups. All values are mean ± SEM and were calculated as a product of concentration and 
time over 8 hours.
Beza: bezafibrate
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Fig. 4.12. Fasting and postprandial concentrations of LDL-1 and LDL-2 in bezafibrate and 
placebo groups.
Beza Start Beza End Placebo Start Placebo End
LDL-1 (mg/dl.hrs) 
AUC
548+63.5 456±34.4 533+74.5 490+41.4
LDL-1 (mg/dl.hrs) 
IAUC
-46.8±29.3 -25.5±17.0 -57.2±19.5 -124±49.8
LDL-2 (mg/dl.hrs) 
AUC
1198±262 1266+143 1217±142 1117+162
LDL-2 (mg/dl.hrs) 
IAUC
-158±46.7 -201+47.1 -206±49.8 -182+56.3
Table 4.19. AUC and IAUC for LDL-1 and LDL-2 in bezafibrate and placebo groups. All 
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Fig. 4.13. Fasting and postprandial concentrations of LDL-3 in bezafibrate and placebo 
groups.
Beza Start Beza End Placebo Start Placebo End
LDL-3 (mg/dl.hrs) 
AUC
979+115 794±126 1455±165 d 1403+159 e
LDL-3 (mg/dl.hrs) 
IAUC
-78.7±33.1 -92.8±20.9 -132±28.4 -145+21.9
Table 4.20. AUC and IAUC for LDL-3 in bezafibrate and placebo groups.
All values are mean ± SEM and were calculated as a product of concentration and time over 
8 hours.
Beza: bezafibrate
d: p<0.05; e: p<0.01 compared with bezafibrate group.
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Table 4.21. AUC and IAUC for cholesterol and triglyceride in chylomicrons and VLDL
and LDL subfractions in bezafibrate- and placebo- treated groups.
Bezafibrate Placebo
Start End Start End
Chylo chol AUC 21.2±3.94 7.92+1.53 a 11.7+2.80 16.9+2.76 d
Chylo chol IAUC 16.5±4.42 6.38+1.49 8.72+2.69 13.9+2.59 d
VLDL-1 chol AUC 115+24.4 52.5+10.6 a 66.0+9.43 90.2+12.8 ad
VLDL-1 chol IAUC 33.3+9.02 20.1+7.11 21.7+4.94 35.8+6.55 a
VLDL-2 chol AUC 108+16.5 54.3+9.03 b 75.5+7.03 92.9+12.2 d
VLDL-2 chol IAUC 9.85+9.49 13.1+7.25 10.2+7.78 28.5+4.95
VLDL-3 chol AUC 162+27.5 115+14.7 145+16.8 147+15.7
VLDL-3 chol IAUC -26.9+22.7 8.79+6.68 -22.7+12.1 -13.4+9.95
LDL-1 chol AUC 166+21.3 130+10.1 165+26.5 150+14.9
LDL-1 chol IAUC -17.8+13.3 -11.0+5.97 -17.4+5.99 -46.9+25.6
LDL-2 chol AUC 419+1.2 418+52.0 443+54.4 d 394+63.4
LDL-2 chol IAUC -26.3+15.6 -36.0+10.7 -39.0+15.5 -48.8+26.7
LDL-3 chol AUC 306+37.2 241+41.4 476+54.6 445+52.1 e
LDL-3 chol IAUC -34.5+10.6 -38.2+8.20 -36.9+7.47 -56.8+8.80
Total LDL chol AUC 891+108 789+58.3 1084+101 989+95.2
Total LDL chol IAUC -78.9+33.3 -85.2+15.8 -93.3+24.5 -152+49.8
Chylo trig AUC 383+37.0 176+26.6 b 309+50.3 403+86.6 e
Chylo trig IAUC 343+33.9 158+24.6 b 280+46.4 377+82.8 d
VLDL-1 trig AUC 921+166 482+89.7 b 638+99.8 806+109
VLDL-1 trig IAUC 275+44.1 147+55.1 222+34.9 347+71.9 d
VLDL-2 trig AUC 515+74.0 332+49.8 b 435+43.3 476+56.9
VLDL-2 trig IAUC 58.4+32.4 74.1+28.3 91.5+35.8 118+20.9
VLDL-3 trig AUC 371+44.1 280+31.7 a 344+37.8 383+45.7
VLDL-3 trig IAUC -23.1+32.9 44.6+15.8 -11.6+42.8 19.5+28.7
LDL-1 trig AUC 79.8+8.61 74.9+6.22 73.7+7.84 73.5+7.42
LDL-1 trig IAUC -8.00+4.45 -0.95+4.29 -6.97+5.19 -12.6+5.56
LDL-2 trig AUC 88.4+12.8 94.5+11.4 66.2+7.36 73.2+5.94
LDL-2 trig IAUC 4.24+2.88 -1.97+3.13 -3.73+3.43 -3.80+5.34
LDL-3 trig AUC 53.7+6.92 43.7+6.45 47.8+7.88 58.0+4.50
LDL-3 trig IAUC 3.52+2.95 3.52+2.74 -0.66+2.81 2.75+2.45
Total LDL trig AUC 222+21.6 213+19.0 188+18.2 205+12.3
Total LDL trig IAUC -0.24+7.13 0.59+6.78 -11.4+10.4 -13.6+7.19
All areas were calculated as a product of concentration (mg/dl) and time (hours) over 8 
hours. All values are mean ± SEM mg/dl.hours. 
a: p<0.05; b: p<0.01 compared with start, 
d: p<0.05; e: p<0.01 compared with bezafibrate group.
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Table 4.22. Concentrations of lipid and protein components of chylomicrons and VLDL subfractions in bezafibrate and placebo groups 3 hours after
test meal.
Chylomicrons VLDL-1 VLDL-2 VLDL-3
Beza ibrate Placebo Bezalibrate Placebo Bezafibrate Placebo Bezafibrate Placebo

































































































































































































































All values are mean ± SEM (mg/dl).
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein, 
a: p<0.05; b: p<0.01; c: p<0.001 compared with start, 
d: p<0.05; e: p<0.01; f: p<0.001 compared with bezafibrate group.
Table 4.23. Concentrations of lipid and protein components of LDL subtractions in bezafibrate and placebo groups 3 hours after test meal.
LDL-1 LDL-2 LD L-3
Beza ibrate Placebo Beza ibrate Placebo Bezafibrate Placebo









































































































































































All values are mean ± SEM (mg/dl).
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein.
a: p<0.05 compared with start.
d: p<0.05; e: p<0.01 compared with bezafibrate group.
Table 4.24. Composition of chylomicrons and VLDL subfractions in bezafibrate and placebo groups 3 hours after test meal.
Chylomicrons VLDL-1 VLDL-2 VLDL-3
Bezafibrate Placebo Bezafibrate Placebo Beza ibrate Placebo Beza ibrate Placebo
Start End Start End Start End Start End Start End Start End Start End Start End
CH 3.40± 4.00± 2.54± 2.99± 7.92± 6.66+ 6.60± 7.35± 11.8+ 8.62± 9.83± 10.7+ 17.6± 17.0± 17.4± 16.5±
0.18 0.63 0.54 0.42 0.58 0.73 0.39 0.26 0.43 1.06 a 0.43 e 0.72 0.56 0.48 0.50 0.54
TG 82.4± 81.3+ 84.5± 84.3± 66.1± 70.7± 68.7± 67.4± 54.7+ 61.5± 59.8± 55.6+ 40.7± 43.1± 40.0± 42.9±
1.04 1.97 1.31 1.11 0.97 1.44 b 1.06 1.14 1.27 1.56 b 0.97 e 2.31 1.15 1.41 2.61 1.13
PL 6.00± 5.55± 5.56± 5.63± 11.9± 11.2± 12.0± 12.8± 16.0+ 14.5± 14.6± 17.9± 18.8± 17.8± 19.8± 18.4±
0.35 0.60 0.85 0.75 0.96 0.91 0.75 0.54 0.99 0.79 0.88 1.90 0.59 0.47 2.28 0.50
FC 1.26± 1.19± 1.32± 1.44+ 3.68± 3.22± 3.62± 3.70± 4.95± 3.87± 4.97± 5.09± 6.75± 7.84± 7.60± 7.17±
0.20 0.30 0.32 0.22 0.34 0.52 0.48 0.35 0.68 0.73 0.42 0.50 0.40 0.55 0.79 0.33
EC 3.60± 4.72± 2.04± 2.59± 7.12± 5.78± 5.01± 6.13± 11.5± 7.98± 8.17± 9.46± 18.2± 15.33± 16.4± 15.7±
0.37 0.90 0.43 d 0.50 1.35 0.51 0.60 0.36 1.59 0.79 0.67 0.58 1.21 1.17 1.63 0.85
Prot 6.71+ 7.23± 6.59± 6.00± 11.1± 9.10± 10.6± 10.0± 12.9± 12.2± 12.5± 11.9± 15.5± 15.9± 16.1± 15.8±
0.95 0.97 0.71 0.75 1.81 0.55 0.69 0.59 1.51 0.20 0.59 0.83 1.71 0.60 0.93 0.60
All values are mean % of total mass ± SEM.
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein.
a: p<0.05; b: p<0.01 compared with start.
d: p<0.05; e: p<0.01 compared with bezafibrate group.
Table 4.25. Composition of LDL subfractions in bezafibrate and placebo groups 3 hours after test meal.
LD L-l LDL-2 LDL-3
Bezafibrate Placebo Bezafibrate Placebo Beza: ibrate Placebo
Start End Start End Start End Start End Start End Start End
CH 29.9± 28.3± 30.8± 30.2+ 37. lit 36.1± 40.1± 38.4± 31.0± 29.3+ 32.8+ 31.7±
0.88 0.51 1.02 1.06 1.56 1.71 1.23 1.60 0.53 0.97 0.35 d 0.31 d
TG 14.8± 16.5± 14.7± 15.7± 9.59± 8.07+ 6.60± 7.63± 5.60± 5.98± 3.32± 4.28±
1.31 0.93 1.52 1.35 1.12 0.62 0.81 0.87 0.47 0.54 0.46 e 0.41 d
PL 21.1± 20.9± 20.8+ 20.6± 24.3± 25.5± 25.2± 25.6± 17.8± 19.6± 19.0± 19.0±
0.66 1.11 0.38 0.92 0.75 1.00 0.85 1.11 0.64 0.96 0.35 0.41
FC 8.35± 9.11+ 9.41± 9.21± 9.70+ 11.4± 10.5± 10.8± 5.96± 8.39± 7.64± 7.31±
0.56 0.72 0.40 0.38 0.54 0.63 0.37 0.35 0.37 0.95 a 0.28 e 0.37
EC 36.2+ 32.3± 35.9± 35.3± 25.6+ 23.4± 28.2± 26.1± 42.1± 35.2± 42.2± 41.0±
2.01 1.49 2.01 1.62 1.92 1.68 1.34 1.93 0.65 2.43 a 0.72 0.87 d
Prot 19.5± 21.1± 19.1+ 19.2± 30.8± 31.6± 29.5± 29.9± 28.6± 30.8± 27.9± 28.4±
1.83 1.02 0.73 2.09 1.85 1.30 1.54 0.85 1.09 1.29 0.80 0.44
All values are mean % of total mass ± SEM.
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein.
a: p<0.05 compared with start.
d: p<0.05; e: p<0.01 compared with bezafibrate group.
Table 4.26. Concentrations of lipid and protein components of chylomicrons and VLDL subfractions in bezafibrate and placebo groups 8 hours after
test meal.
Chylomicrons VLDL-1 VLDL-2 VLDL-3
Bezafibrate Placebo Beza ibrate Placebo Beza ibrate Placebo Beza ibrate Placebo

































































































































































































































All values are mean ± SEM (mg/dl).
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein, 
a: p<0.05; b: p<0.01; c: p<0.001 compared with start, 
d: p<0.05 compared with bezafibrate group.
Table 4.27. Concentrations of lipid and protein components of LDL subfractions in bezafibrate and placebo groups 8 hours after test meal.
LD L-l LD L-2 LDL-3
Bezafibrate Placebo Bezafibrate Placebo Beza: ibrate Placebo









































































































































































All values are mean ± SEM (mg/dl).
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein.
a: p<0.05; b: p<0.01 compared with start.
d: p<0.05; e: p<0.01 compared with bezafibrate group.
Table 4.28. Composition of chylomicrons and VLDL subfractions in bezafibrate and placebo groups 8 hours after test meal.
Chylomicrons VLDL-1 VLDL-2 VLDL-3
Beza: ibrate Placebo Beza ibrate Placebo Beza Ibrate Placebo Beza ibrate Placebo

































































































































































































All values are mean % of total mass ± SEM.
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein, 
b: p<0.01 compared with start.
Table 4.29. Composition of LDL subfractions in bezafibrate and placebo groups 8 hours after test meal.
LDL-1 LD L-2 LD L-3
Beza: ibrate Placebo Beza ibrate Placebo Bezafibrate Placebo

















































































































































All values are mean % of total mass ± SEM.
CH: cholesterol; TG: triglyceride; PL: phospholipid; FC: free cholesterol; EC: esterified cholesterol; Prot: protein.
a: p<0.05 compared with start.
d: p<0.05; e: p<0.01 compared with bezafibrate group.
Qualitative lipoprotein subfraction parameters at 3 and 8 hours after the test meal 
are shown in Tables 4.30 and 4.31 respectively. At 3 and 8 hours after the test meal, 
%LDL-3/ZLDL was significantly lower after bezafibrate treatment, and was also 
significantly lower than the placebo group. At 8 hours only, % VLDL-1/Z VLDL was 
significantly lower after bezafibrate treatment, and was also significantly lower than the 
placebo group, and % VLDL-3/Z VLDL was significantly elevated after bezafibrate 
treatment, indicating an improved clearance rate of large VLDL. This is further emphasised 
by comparing paired analyses of fasting versus postprandial percentages within patients 
before and after bezafibrate treatment (Table 4.32): % VLDL-1 /Z VLDL was significantly 
higher at 3 and 8 hours before bezafibrate therapy, whereas after bezafibrate therapy levels 
were only significantly elevated at 3 hours. Also, % VLDL-3/ZVLDL was significantly 
reduced at 3 and 8 hours before bezafibrate therapy, whereas after bezafibrate therapy levels 
were only significantly lower at 3 hours. No such trends were observed in the placebo 
group (Table 4.33).
Similarly to fasting differences, bezafibrate therapy did not significantly alter 
HDL2/HDL3 and LDL/HDL cholesterol ratios at 3 and 8 hours. There was a significant 
reduction in HDL and HDL3 triglyceride enrichment (triglyceride/cholesterol ratio) at 8 
hours in bezafibrate treated patients.
Table 4.30. Qualitative parameters in bezafibrate- and placebo groups 3 hours after the test
meal.
Beza:ibrate Placebo
Start end Start end
%VLDL-1/ EVLDL 39.0±3.60 35.7±2.86 39.0+2.93 41.9+1.86
% VLDL-2/1 VLDL 28.1±0.53 27.9±1.22 28.9+0.57 29.7+0.71
% VLDL-3/ ZVLDL 32.9±3.77 36.4+3.60 32.1+3.19 29.5+2.15
%LDL-3/XLDL 39.9±5.16 31.9+4.47 a 47.2+3.20 49.1+3.40 a e
LDL chol/HDL chol 3.19±0.29 2.99+0.19 3.85+0.39 3.43+0.22
HDL2/HDL3 chol 0.80±0.20 0.96+0.28 0.54+0.09 0.46+0.13
HDL trig/chol 0.36±0.03 0.31+0.04 0.25+0.05 d 0.31+0.05
HDL2 trig/chol 0.32±0.05 0.31+0.09 0.23+0.07 0.32+0.04
HDL3 trig/chol 0.42+0.03 0.36+0.06 0.28+0.05 d 0.33+0.05
All values are mean ± SEM .
Choi: Cholesterol; Trig: Triglyceride
a: p<0.05 compared with start.
d: p<0.05; e: p<0.01 compared with bezafibrate group.
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Table 4.31: Qualitative parameters in bezafibrate- and placebo groups 8 hours after the test
meal.
Beza:ibrate Placebo
Start end Start end
%VLDL-1/ EVLDL 45.6+3.96 31.9+3.55 b 35.2+4.19 40.4+3.07 a
% VLDL-2/1 VLDL 28.4+1.10 28.1+2.25 31.0+1.03 29.7+0.71
% VLDL-3/ ZVLDL 26.0+3.98 40.0+4.36 b 33.8+4.09 29.9+3.45
%LDL-3/ZLDL 36.5+5.10 29.6+5.05 a 43.1+3.13 44.5+3.33 d
LDL chol/ HDL chol 3.64+0.39 3.00+0.22 4.12+0.44 3.58+0.26
HDL2/HDL3 chol 0.90+0.28 0.75+0.23 0.95+0.32 0.74+0.34
HDL trig/chol 0.53+0.08 0.38+0.06 a 0.29+0.05 d 0.33+0.05
HDL2 trig/chol 0.34+0.04 0.61+0.31 0.19+0.04 d 0.50+0.22
HDL3 trig/chol 0 .6 6 +0 . 1 2 0.47+0.10 a 0.44+0.06 0.37+0.09
All values are mean ± SEM. Chol: Cholesterol; Trig: Triglyceride.
a: p<0.05; b: p<0.01 compared with start; d: p<0.05 compared with bezafibrate group.




0  hours 3 hours 8  hours 0  hours 3 hours 8  hours
%VLDL-1/ 32.0+ 39.0+ 45.6+ 27.7+ 35.7+ 31.9+
EVLDL 4.23 3.60 a 3.96 c 3.18 2 . 8 6  a 3.55
%VLDL-2/ 28.7+ 28.1+ 28.4+ 25.9+ 27.9+ 28.1+
ZVLDL 1.07 0.53 1 . 1 0 1 . 6 6 1 . 2 2 2.25
% VLDL-3/ 39.4+ 32.9+ 26.0+ 46.3+ 36.4+ 40.0+
EVLDL 1.70 3.77 a 3.98 c 4.49 3.60 a 4.36
All values are mean ± SEM.
Fasting levels vs levels at 3 and 8  hours, a: p<0.05; c: p<0 . 0 0 1
Table 4.33. Comparison of paired data (Ohrs vs 3hrs and Ohrs vs 8 hrs) within the placebo
group at the start and end of the study.
Placebo group
Start End
0  hours 3 hours 8  hours 0  hours 3 hours 8  hours
%VLDL-1/ 26.1+ 39.0+ 35.2+ 29.0+ 41.9+ 40.2+
IVLDL 3.44 2.93 a 4.19 2.50 1 . 8 6  b 3.07 a
%VLDL-2/ 27.3+ 28.9+ 31.0+ 27.9+ 28.6+ 29.7+
EVLDL 1.89 0.57 1.03 1.18 1 .1 1 0.71
%VLDL-3/ 46.6+ 32.1+ 33.8+ 43.1+ 29.5+ 29.9+
EVLDL 4.86 3.19 c 4.08 b 2.96 2.15 c 3.45 b
All values are mean ± SEM.
Fasting levels vs levels at 3 and 8  hours, a: p<0.05; b: p<0 .0 1 ; c: p<0 . 0 0 1
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4.4. DISCUSSION
This study demonstrates that bezafibrate significantly reduces fasting and 
postprandial levels of triglyceride-rich lipoproteins and small dense LDL in patients with 
NIDDM. Several studies have reported that bezafibrate therapy effectively reduces serum 
triglyceride concentrations in NIDDM (Seviour et al., 1988; Niort et al., 1992; Rovellini et 
al., 1992). Reductions in postprandial triglyceride response and chylomicron remnants 
have been demonstrated in NIDDM following gemfibrozil treatment (Syvanne et al., 1993).
Reductions in levels of serum triglyceride, triglyceride-rich lipoproteins and 
triglyceride-rich lipoprotein subtractions were on the whole more highly significant in the 
postprandial state. Fasting and postprandial chylomicrons and VLDL-1 were more 
substantially reduced than the smaller VLDL subfractions. Additionally, the proportion of 
large VLDL (VLDL-1) was reduced following bezafibrate therapy, particularly in the 
postprandial state and was reflected by an increase in the proportion of VLDL-3. In this 
way, the VLDL subfraction profile was reversed towards that of non-diabetic 
normolipidaemic population (see chapter 3). Furthermore, the postprandial trend in VLDL- 
3 levels (Fig. 11) before and after bezafibrate treatment resembles that of the diabetic 
patients and non-diabetic controls (in chapter three) respectively. As discussed in chapter 
three, it appears that in diabetic patients (before therapy), the production by the liver of 
small VLDL-3 has been reduced in favour of larger triglyceride-rich VLDL. This would 
occur when the triglyceride accumulation compared to apo B synthesis is very high and in 
this way more triglyceride has to be packaged into each VLDL particle. Reduced levels of 
small VLDL could also arise from slower degradation of large VLDL and chylomicron 
remnants. In patients after bezafibrate therapy and in the controls in chapter three, the 
accumulation of triglyceride is less allowing a greater proportion of small VLDL to be 
produced.
Although concentrations of triglyceride-rich lipoproteins were substantially reduced, 
often as much as 50%, levels were still higher than those of the non-diabetic 
normolipidaemic controls in chapter 3, suggesting that bezafibrate treatment was not 
sufficient to achieve full normalisation. An exception to the aforementioned was AUC for 
chylomicrons which was reduced by bezafibrate treatment to levels below that of the non­
diabetic controls in chapter three, thus further emphasising the efficacy of the drug on the 
larger triglyceride-rich lipoproteins, particularly in the postprandial state. Reductions in 
VLDL triglyceride of similar magnitude have been reported in NIDDM patients with 
hyperlipidaemia (-56%) (Niort et al., 1993) and non-diabetic patients with hyperlipidaemia
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(-66%) (Homma et al., 1994), following bezafibrate therapy. Furthermore, reductions in 
cholesterol and triglyceride in large VLDL after bezafibrate therapy has been demonstrated 
to be more apparent than in small VLDL in LDDM patients with combined hyperlipidaemia 
(Winocour et al., 1992).
It is recognised that the hypotriglyceridaemic effect of bezafibrate is mainly 
mediated by stimulus of LPL and to some extent HL (Vessby et al., 1980; Vessby et al., 
1982; Heller et al., 1983; Eisenberg et al., 1984) leading to accelerated degradation of 
VLDL. Such an effect is consistent with the reduction of triglyceride-rich lipoproteins in 
the present study. An increase in the fractional catabolic rate of triglyceride-rich particles 
has been reported in patients with NIDDM following bezafibrate therapy (Seviour et al.,
1988). Reduction in VLDL, especially the large triglyceride-rich species, decreases their 
atherogenic potential because large VLDL is less readily converted to LDL (Stalenhoef et 
al., 1984; Packard et al., 1984), and less available to provide surface components for HDL. 
In addition, triglyceride-rich VLDL are susceptible to cholesterol ester transfer from HDL 
and LDL in exchange for triglyceride by the actions of CETP (Tall, 1986). Triglyceride- 
rich LDL becomes substrate for lipases resulting in the production of small dense LDL 
(Auwerx et al., 1988; Levy et al., 1990; Zambon et al., 1993). VLDL becomes cholesterol 
ester enriched, a modification that provokes clearance via the scavenger pathway 
(Goldstein, 1980). Kinetic studies of LDL metabolism suggest that small dense LDL (LDL- 
3) are derived from large triglyceride-rich VLDL in the hypertriglyceridaemic state, whereas 
in the normotriglyceridaemic state, the liver produces small VLDL particles which give rise 
to larger, more buoyant LDL (LDL-1 and -2) (Caslake et al., 1992).
Percentage esterified cholesterol (in terms of total mass) was reduced and % 
triglyceride increased, in fasting VLDL-1 and -2, and % cholesterol reduced and % 
triglyceride increased in postprandial VLDL-2 after bezafibrate treatment. Since these 
VLDL subfractions were not triglyceride-enriched following treatment (as denoted by 
triglyceride/apo B ratios), the increase in % triglyceride is more likely to be a reflection of 
reduced % cholesterol. This may be the result of decreased residence time of triglyceride- 
rich lipoproteins in the blood for cholesterol ester transfer with LDL and HDL. Bezafibrate 
has been reported to reduce the activity of CETP in patients with IDDM (Homma et al., 
1994). The size of VLDL particles within each subfraction, as denoted by non-apo B 
protein/ apoB and triglyceride/apo B ratios, appeared to be unaffected as a result of 
bezafibrate treatment.
The proportion of small, dense LDL in total LDL mass was significantly reduced 
after bezafibrate treatment, which is consistent with reductions in triglyceride-rich
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lipoproteins, and further evidence of reduced cholesterol ester transfer. This effect of the 
drug was not apparent from measurements of total and LDL cholesterol. The LDL profile 
was less polydisperse, with closer resemblance to that of the non-diabetic controls (see 
chapter three), but the proportion of LDL-3 in total LDL was not normalised to the levels 
seen in the non-diabetic controls. Previous studies have reported that fibrate therapy 
reduces the density of LDL in type II hyperlipidaemic subjects (Tsai et al., 1992), in 
NIDDM (Lahdenpera et al., 1993) and in patients with hyperlipidaemia (Homma et 
al.,1994), an effect which has great potential in reducing atherogenic risk. The 
predominance of small, dense LDL is a strong marker for the risk of developing premature 
CHD in the non-diabetic population (Austin et al., 1988), and in view of their atherogenic 
potential, small, dense LDL are more readily oxidised (Tribble et al., 1992) and have been 
shown to bind less well to LDL receptors compared to larger LDL species (Kleinman et al., 
1987a; Kleinman et al., 1987b).
Quite surprisingly, there was not a significant fasting or postprandial increase in 
HDL cholesterol, or decrease in HDL triglyceride following bezafibrate therapy. However, 
triglyceride/cholesterol ratio in HDL3 in the postprandial state was significantly decreased 
suggesting that cholesterol ester transfer with triglyceride lipoproteins was reduced. HDL 
cholesterol levels have been shown to be increased by fibrates (Rouffy et al., 1985; Sorisky 
et al., 1987) and also by bezafibrate in patients with NIDDM (Seviour et al., 1988; Rovellini 
et al., 1992; Niort et al., 1992). Increased concentrations of HDL cholesterol are most 
obvious when levels are initially low in patients with hypertriglyceridaemia, treated with 
bezafibrate (Stewart et al., 1982), and response is delayed in comparison with changes in 
total serum cholesterol and triglyceride (Vessby et al., 1980). In the present study, longer 
treatment time may have been required to significantly elevate HDL cholesterol. There is 
uncertainty whether it is HDL2 or HDL3 that is increased in response to bezafibrate (Seviour 
et al., 1988). Lecithin-cholesterol acyl transferase activity in NEDDM patients does not 
appear to be affected by bezafibrate (Prager et al., 1982; Heller et al., 1983) and therefore 
bezafibrate-induced elevated HDL cholesterol is likely to be mediated by increased LPL 
activity and therefore elevated VLDL catabolism, and less cholesterol ester transfer between 
HDL and triglyceride-rich lipoproteins.
In the present study, fasting and postprandial levels of total and LDL cholesterol fell 
after bezafibrate treatment, although not significantly so. As with HDL cholesterol, 
differences in LDL cholesterol levels may have been more apparent with longer treatment 
time. This is consistent with the findings of Rovellini et al. (1992) and Niort et al. (1992), 
who reported that serum cholesterol was significantly reduced in hypertriglyceridaemic
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patients with NIDDM following bezafibrate therapy. However, bezafibrate has been shown 
to have no effect on LDL cholesterol (Olsson et al. 1985; Vessby et al., 1982) and to 
increase LDL cholesterol in patients with hypertriglyceridaemia (Saku et al., 1989) the latter 
being mediated by more normal and rapid conversion of VLDL to LDL resulting in the 
restoration of cholesterol ester-rich LDL which was previously triglyceride-rich due to 
cholesterol ester transfer. In contrast, increased receptor mediated catabolism of LDL has 
been demonstrated in vivo after bezafibrate therapy (Series et al., 1989; Stewart et al., 
1982) resulting in depressed levels of LDL cholesterol. This may be caused by increased 
receptor expression mediated by enhanced secretion of cholesterol into the bile, known to 
occur after fibrate therapy. Alternatively, changes in LDL composition may provoke more 
avid binding to the receptors. Studies have shown statins to be better at reducing LDL 
cholesterol levels and fibrates better at reducing triglyceride levels and increasing HDL 
levels (Crepaldi et al., 1990; Ojala et al., 1990). Fibrates have also been shown to be better 
than statins at reducing postprandial lipaemia (Simo et al., 1993); in hypertriglyceridaemic 
subjects gemfibrozil reduced chylomicron triglyceride and there was a close correlation 
between change in fasting triglyceride and change in postprandial response in subjects 
taking gemfibrozil but not in those taking lovastatin. Also LPL and HL activities were 
increased by gemfibrozil but not by lovastatin.
AUC for NEFA was significantly reduced following bezafibrate therapy, providing 
less substrate for VLDL synthesis and contributing to the reduction in VLDL. Similarly, 
previous studies have reported a reduction of NEFA concentration after bezafibrate therapy 
in patients with NIDDM (Alberti et al., 1990; Jones et al., 1990). A reduction in NEFA 
levels would suggest an increase in insulin sensitivity. Bezafibrate-induced reduction of 
serum triglyceride levels might improve insulin-binding to cell receptors (Bhathena et al.,
1989) and the decrease of plasma NEFA, might mediate an increase in insulin sensitivity by 
increasing insulin-stimulated glucose uptake (Fraze et al., 1985) and by decreasing hepatic 
glucose production (Ferrannini et al., 1983). However there was no significant difference in 
insulin levels, glucose levels or insulin resistance following bezafibrate treatment. Insulin 
levels, and therefore values of insulin resistance and P-cell function, increased in both 
treatment groups and although this is clearly not an effect of bezafibrate, the reason for 
increased insulin levels is less clear. IAUC for glucose was significantly increased following 
bezafibrate treatment, but this change was small (Fig. 8) and perhaps not a good indication 
of the true effect of the drug on glucose concentrations. The effect on bezafibrate on 
glucose concentrations in NIDDM is not fully understood. Riccardi et al. (1989) 
demonstrated that bezafibrate had no effect on fasting glucose concentration, glucose
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tolerance, insulin secretion or peripheral insulin sensitivity in hyperlipidaemic patients with 
and without diabetes. In contrast, previous studies in NIDDM have reported that 
bezafibrate lowers glucose levels (Seviour et al., 1988; Jones and Alberti, 1988; Mikhailidis 
et al.,1990; Rovellini et al., 1992). In some studies, fasting as well as postprandial glucose 
concentrations were reduced (Jones et al., 1990; Smud and Sermukslis, 1987), and dosage 
reductions in glycaemic control medication was necessary in some of the patients (Smud 
and Sermukslis, 1987).
To summarise, bezafibrate therapy resulted in reductions in fasting and postprandial 
triglyceride-rich lipoproteins and small dense LDL towards that of normolipidaemic 
subjects. Reductions were particularly apparent in large VLDL and postprandial 
chylomicrons. Bezafibrate therapy also decreased cholesterol ester content in VLDL 
subffactions, reduced triglyceride content in HDL and increased the proportion of small 
VLDL accompanying a decrease in the proportion of large VLDL. However, there was no 
effect on total, LDL and HDL cholesterol, HDL triglyceride, glucose and insulin levels. 
Bezafibrate clearly improves the VLDL and LDL subfraction profile in patients with 
NIDDM and therefore potentially reduces atherogenic risk.
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CHAPTER 5
DYSLIPIDAEMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS 
AND PSORIATIC ARTHRITIS
5.1. INTRODUCTION
Morbidity and mortality from CHD is common in subjects with systemic lupus 
erythematosus (Urowitz et al., 1976) and rheumatoid arthritis (Isomaki et al., 1975). In 
recent years, dyslipoproteinaemia has been noted in patients suffering from RA (Svenson et 
al., 1987a; Svenson et al., 1987b; Rantapaa-Dahlqvist et al., 1990; Lazarevic et al., 1992), 
PA (Lazarevic et al., 1992; Jones et al., 1993) and SLE (Ilowite et al.,1988; Leong et 
al.,1994). However, these studies have only investigated basic quantitative lipid and 
lipoprotein parameters. The aim of this study was to investigate quality as well as quantity 
of lipids and lipoproteins in patients with PA and SLE compared to healthy normolipidaemic 
controls, because of increasing evidence of the likely importance of these quality changes.
5.2. METHODS
5.2.1. Study population
1. 17 SLE patients and 17 PA were selected at random (by Dr.N.McHugh and Dr. S. Jones, 
Bath Hospital for Rheumatic Disease) from patients attending the Bath Hospital for 
Rheumatic Disease (Table 5.1 and 5.2).
2. 17 age- and gender-matched controls for each patient group were selected from the 




AGE (yrs) ± SEM 42.3± 3.07 43.9+2.93
GENDER 12 female, 5 male 12 female, 5 male
DISEASE ACTIVITY 13 inactive, 4 active





Table 5.1. Demographic data 1or SLE patients and controls.
PA patients Controls
NUMBER 17 17
AGE (yrs)± SEM 42.9+3.89 42.5+3.34
GENDER 10 female, 7 male 10 female, 7 male
DISEASE ACTIVITY 13 active, 4 inactive
THERAPY All patients on non-steroidal 
antiinflammatory drugs
Table 5.2. Demographic data 1or PA patients and controls.
5.2.2. Measurements
Fasting blood samples were taken from all subjects for determination of 
apolipoprotein Al and B in serum and cholesterol and triglyceride in serum and serum 
lipoproteins (HDL, HDL2 and HDL3) (data supplied by C.Stirling and co-workers). 
Measurements for each subfraction included total cholesterol, triglyceride, phospholipid, 
free cholesterol, esterified cholesterol and total protein. The mass of each fraction was 
calculated as the sum of the latter five components. Composition of these fractions was 
expressed as a percentage of total mass. Fasting apo B concentrations were determined in 
VLDL-1, -2 and -3 and LDL-1 fractions only (see Methods 2.3.7). Cholesterol and 
triglyceride values for VLDL and LDL were calculated as the sum of these lipid 
components in VLDL and LDL subfractions respectively. Chylomicron measurements for 
patients and controls were on the whole very low, sometimes undetectable, and therefore 
chylomicron data has not been presented.
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5.2.3. Statistics
Comparisons between patients and controls were made using an unpaired t-test. 
Data for triglycerides was log-transformed prior to analysis. Data are presented as mean ± 
SEM.
5.3. RESULTS
5.3.1. SLE patients and their controls
5.3.1.1. All SLE patients (males and females. n=17)
SLE patients had higher levels of serum and VLDL triglyceride, and lower levels of 
HDL cholesterol (p=0.054) and apo Al compared to controls, contributing to an 
atherogenic lipoprotein profile, although differences did not achieve significance 
(Table 5.3).
Although there were no quantitative differences between SLE patients and controls 
in VLDL and LDL subffactions (Table 5.4), some qualitative differences were seen. SLE 
patients had significantly less % cholesterol in the VLDL subtractions, which was reflected 
in trends to higher % triglyceride in these subtractions (Table 5.5). SLE patients also had 
significantly higher % LDL-3/ZLDL mass ratio compared to controls (Table 5.6). Because 
serum triglycerides were slightly elevated in SLE patients and because of the known 
association between triglyceride and small, dense LDL (Austin 1986, 1988), subjects were 
matched for triglyceride levels. The difference in % LDL-3/XLDL mass ratio no longer 
reached significance (p=0.052) after matching for triglyceride levels (Table 5.7), however 
the mean values remained unchanged and the p value was only marginally greater than 0.05 
suggesting that this lack of significance may be due to the smaller number of patients and 
not the matching of triglyceride levels. LDL/HDL cholesterol and HDL 
triglyceride/cholesterol ratios tended to be higher and HDL2/HDL3 cholesterol ratio tended 
to be lower in SLE patients compared to controls. The VLDL subfraction profile (% of 
VLDL subfractions in total VLDL mass) was similar in both subject groups as was the 
particle size within each subfraction (triglyceride/apo B ratio) (Table 5.6).
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Table 5.3. Lipids, lipoproteins and apolipoproteins in 17 SLE patients and their controls.
SLE patients Controls
Cholesterol (mM) 5.54±0.30 5.46+0.31
Triglyceride (mM) 1.39±0.19 1.12+0.11
VLDL cholesterol (mM) 0.34+0.05 0.34+0.06
VLDL triglyceride (mM) 0.66+0.13 0.44+0.08
LDL cholesterol (mM) 2.71+0.22 2.52+0.15
LDL triglyceride (mM) 0.22+0.03 0.22+0.02
HDL cholesterol (mM) 1.26+0.10 1.61+0.14
HDL2 cholesterol (mM) 0.59+0.10 0.83+0.13
HDL3 cholesterol (mM) 0.68+0.04 0.78+0.07
HDL triglyceride (mM) 0.22+0.02 0.23+0.01
Apo B (mg/dl) 75.6+6.48 70.5+5.38
Apo Al (mg/dl) 154+9.48 170+8.16
All values are mean ± SEM.
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Table 5.4. Concentrations of lipid and protein components of VLDL and LDL subfractions in 17 SLE patients and their controls.
VLDL-1 VLDL-2 VLDL-3 l d :L-l LD L-2 LD L-3

























































































































































































All concentrations are mean ± SEM (mg/dl).
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
Table 5.5. Composition of VLDL and LDL subfractions in 17 SLE patients and their controls.
VLDL-1 VLDL-2 VLDL-3 LD L-l LDL-2 LDL-3

















































































































































All values are mean % of total mass ± SEM.
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
a: p<0.05; b: p<0.01; c: p<0.001
Table 5.6. Qualitative parameters in 17 SLE patients compared to controls.
SLE patients Controls
%VLDL-1/ IVLDL 19.6+2.39 18.4+1.93
% VLDL-2/ IVLDL 26.3+1.73 26.2+1.52
% VLDL-3/ IVLDL 54.1+3.42 55.3+2.25
%LDL-3/ILDL 26.5+2.38 18.9+1.93 a
LDL chol/ HDL chol 2.37+0.28 1.74+0.19
HDL2/HDL3 chol 0.96+0.19 1 .2 1 +0 . 2 0
HDL trig/chol 0.19+0.02 0.16+0.01
VLDL-1 trig/apo B 13.6+1.63 12.8+2.24
VLDL-2 trig/apo B 10.2+2.28 9.64+1.53
VLDL-3 trig/apo B 3.85+0.46 3.66+0.39
All values are mean ± SEM. 
chol: cholesterol; trig: triglyceride, 
a: p<0.05
Table 5.7. Lipid and lipoprotein parameters in 13 SLE patients compared to controls, 
matched for triglyceride.
SLE patients(n= 13) Controls (n=13)
Triglyceride (mM) 1.10+0.08 1.12+0.13
%LDL-3/ILDL 26.2+2.36 18.8+2.70 (p=0.052)
All values are mean ± SEM.
SLE patients and controls were matched for triglyceride by excluding 4 SLE patients with 
the highest triglyceride levels and their age-matched controls.
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5.3.I.2. Female SLE patients (n=12)
For female subjects, there were similar trends in lipid and lipoprotein parameters as 
for all subjects. SLE females had elevated serum and VLDL triglyceride, and lower HDL 
cholesterol and apo Al levels compared to controls (Table 5.8).
The concentration of LDL-3 and most of its lipid and protein components were 
significantly elevated in SLE females (Table 5.9). Percentage esterified cholesterol in 
VLDL-1, -2, -3 and % cholesterol in LDL-1 were significantly lower in SLE females, which 
was reflected in higher (only significant for VLDL-3) % triglyceride in these subtractions 
(Table 5.10).
SLE females had significantly higher % LDL-3/ELDL mass ratio (Table 5.11), 
which persisted when subjects were matched for serum triglyceride (Table 5.12). Mean 
HDL2/HDL3 cholesterol ratio was substantially reduced and LDL/HDL cholesterol and 
HDL triglyceride/cholesterol ratios tended to be raised in SLE females compared to 
controls (Table 5.12). There were no differences in VLDL subtraction profile or particle 
size (Table 5.12). These changes in female patients were quantitatively and qualitatively 
quite similar to those for the whole group, although there were some changes in significance 
levels. The LDL-3 changes were overall more marked in the females compared to the 
whole group.
Table 5.8. Lipids, lipoproteins and apolipoproteins in 12 female SLE patients and their 
controls
SLE patients Controls
Cholesterol (mM) 5.23±0.36 5.40+0.35
Triglyceride (mM) 1.19+0.11 0.99+0.12
VLDL cholesterol (mM) 0.28±0.05 0.32+0.08
VLDL triglyceride (mM) 0.53+0.10 0.36+0.07
LDL cholesterol (mM) 2.46+0.24 2.45+0.16
LDL triglyceride (mM) 0.23+0.04 0 .2 1 +0 . 0 2
HDL cholesterol (mM) 1.31+0.14 1.68+0.17
HDL2 cholesterol (mM) 0.62+0.14 0.99+0.15
HDL3 cholesterol (mM) 0.69+0.05 0.69+0.06
HDL triglyceride (mM) 0 .2 2 +0 . 0 2 0.24+0.02
Apo B (mg/dl) 67.8+5.70 65.0+4.64
Apo Al (mg/dl) 161.3+11.8 175.1+10.9
All values are mean ± SEM.
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Table 5.9. Concentrations of lipid and protein components of VLDL and LDL subfractions in 12 female SLE patients and their controls.
VLDL-1 VLDL-2 VLDL-3 LDL-1 LDL-2 LDL-3



























































































































































































All concentrations are mean ±SEM (mg/dl).
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
a: p<0.05; b: p<0.01; c: p<0.001
Table 5.10. Composition of VLDL and LDL subfractions in 12 female SLE patients and their controls.
VLDL-1 VLDL-2 VLDL-3 l d :L-l l d :L-2 LDL-3

















































































































































All values are mean % of total mass ± SEM.
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
a: p<0.05; b: p<0.01; c: p<0.001
Table 5.11. Qualitative parameters in 12 female SLE patients and their controls.
SLE patients Controls
%VLDL-1/ EVLDL 17.9+2.69 17.3+2.13
%VLDL-2/ ZVLDL 24.5+1.94 25.1+1.91
%VLDL-3/ EVLDL 57.5+3.70 57.6+2.22
%LDL-3/ZLDL 23.6+2.50 15.0+0.92 b
LDL chol/ HDL chol 2.14+0.33 1.58+0.15
HDL2/HDL3 chol 0.99+0.25 1.53+0.22
HDL trig/chol 0.19+0.03 0.16+0.02
VLDL-1 trig/apoB 14.6+1.93 11.2+2.29
VLDL-2 trig/apoB 10.73+3.19 9.64+1.54
VLDL-3 trig/apoB 4.03+0.59 3.34+0.34
All values are mean ± SEM. 
chol: cholesterol; trig: triglyceride, 
b: p<0 . 0 1
Table 5.12. Lipid and lipoprotein parameters in 9 female SLE patients compared to 
controls, matched for triglyceride.
SLE Patients(n=9) Controls (n=9)
Triglyceride (mM) 1.03+0.09 1.08+0.15
%LDL-3/ZLDL 23.9+1.98 15.1+1.23 b
SLE patients and controls were matched for triglyceride by excluding 3 SLE patients with 
the highest triglyceride levels and their age-matched controls.
All values are mean ± SEM. 
b: p<0 . 0 1
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5.3.I.3. Male SLE patients (n=5)
Male SLE patients tended to have higher mean levels of serum and VLDL 
triglyceride, serum and LDL cholesterol and lower mean levels of HDL cholesterol and apo 
AI (p=0.06) compared to controls although differences did not achieve significance (Table 
5.13). HDL3 cholesterol levels were significantly reduced in SLE males (Table 5.13).
There were no significant quantitative (Table 5.14), nor qualitative (Table 5.15) 
differences in VLDL and LDL subfractions between SLE males and controls, although 
mean % LDL-3/ELDL mass ratio again tended to be higher in SLE males (Table 5.16). In 
addition, LDL/HDL cholesterol and HDL triglyceride/cholesterol ratios were non- 
significantly higher in these patients (Table 5.16).
Quantitative and qualitative differences are not dissimilar to the female group, 
although differences in % LDL-3/ELDL mass ratio were less marked in the male group. 
Larger patient numbers are needed to confirm the aforementioned trends, since statistical 
analyses are not reliable with small patient numbers.
Table 5.13. Lipids, lipoproteins and apolipoproteins in SLE patients and controls
SLE patients Controls
Cholesterol (mM) 6.26±0.38 5.59+0.70
Triglyceride (mM) 1.86±0.57 1.40+0.24
VLDL cholesterol (mM) 0.47±0.12 0.39+0.09
VLDL triglyceride (mM) 1.00±0.37 0.64+0.22
LDL cholesterol (mM) 3.32±0.38 2.69+0.35
LDL triglyceride (mM) 0.21+0.05 0.22+0.04
HDL cholesterol (mM) 1.17+0.07 1.44+0.23
HDL2 cholesterol (mM) 0.53+0.12 0.45+0.11
HDL3 cholesterol (mM) 0.64+0.06 0.99+0.13 a
HDL triglyceride (mM) 0.21+0.04 0.20+0.01
Apo B (mg/dl) 99.0+15.4 83.8+13.7
Apo AI (mg/dl) 132.5+6.99 159.0+8.89
All values are mean ± SEM. 
a: p<0.05
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Table 5.14. Concentrations of lipid and protein components of VLDL and LDL subfractions in 5 male SLE patients and their controls.
VLDL-1 VLDL-2 VLDL-3 LD L-l LD.L-2 LD L-3

























































































































































































All concentrations are mean ±SEM (mg/dl).
Contr. Controls; CH: cholesterol; TG.triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
Table 5.15. Composition of VLDL and LDL subfractions in 5 male SLE patients and their controls.
VLDL-1 VLDL-2 VLDL-3 LD L-l LDL-2 LDL-3

















































































































































All values are mean % of total mass ± SEM.
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; FC: free cholesterol; 
Prot: protein.
Table 5.16. Qualitative parameters in 5 male SLE patients and their controls.
SLE patients Controls
%VLDL-1/1 VLDL 23.7±4.86 21.3+4.21
%VLDL-2/1 VLDL 30.5+3.10 28.9+2.22
%VLDL-3/1 VLDL 45.8+6.65 49.8+5.09
%LDL-3/ZLDL 33.5+4.27 28.2+4.88
LDL chol/HDL chol 2.94+0.51 2.14+0.51
HDL2/ HDL3 chol 0.90+0.25 0.44+0.06
HDL trig/chol 0.18+0.03 0.15+0.02
VLDL-1 trig/apoB 11.5+3.12 17.9+5.63
VLDL-2 trig/apoB 9.08+1.77 9.63+3.88
VLDL-3 trig/apoB 3.43+0.71 4.23+1.12
All values are mean ± SEM.
chol: cholesterol; trig: triglyceride.
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5.3.2. Patients with PA and their controls
5.3.2.I. All PA patients (males and females. n=17)
Basic lipid and lipoprotein parameters are shown in Table 5.17. PA patients had 
significantly reduced levels of HDL, HDL2 and HDL3 cholesterol which was accompanied 
by significantly lower serum apo AI concentration.
There were no quantitative differences in VLDL and LDL subfractions between PA 
patients and controls (Table 5.18). However, PA patients had significantly reduced % 
cholesterol in LDL-1, reflected in a non-significant increase in % triglyceride (Table 5.19). 
Percentage triglyceride was increased in LDL-2 in PA patients compared to controls. These 
qualitative differences in LDL subffactions are isolated and only small and weakly 
significant and may therefore be chance differences. However, reduced % cholesterol in 
LDL-1 with a non-significant increase in % triglyceride also occurred in female patients 
(section 5.3.2.2) and increased % triglyceride in LDL-2 also occurred in male patients 
(section 5.3.2.3), suggesting that these differences are genuine.
LDL/HDL cholesterol and HDL triglyceride/cholesterol ratios were significantly 
raised in PA patients (Table 5.20). Other qualitative differences, although not significant, 
include reduced HDL2/HDL3 cholesterol ratio and increased %LDL-3/ZLDL mass ratio 
(p=0.062) in PA patients compared to controls (Table 5.20). VLDL subfraction profile and 
particle size was similar in both subject groups (Table 5.20).
Table 5.17. Lipids, lipoproteins and apolipoproteins in 17 PA patients and their controls
PA patients Controls
Cholesterol (mM) 4.83±0.24 5.20+0.31
Triglyceride (mM) 1.21+0.16 1.12+0.09
VLDL cholesterol (mM) 0.36±0.08 0.33+0.05
VLDL triglyceride (mM) 0.56+0.11 0.46+0.07
LDL cholesterol (mM) 2.36+0.13 2.55+0.21
LDL triglyceride (mM) 0.26+0.02 0.21+0.02
HDL cholesterol (mM) 1.01+0.06 1.52+0.11 c
HDL2 cholesterol (mM) 0.49+0.05 0.69+0.07 a
HDL3 cholesterol (mM) 0.53+0.05 0.83+0.09 b
HDL triglyceride (mM) 0.24+0.02 0.22+0.02
Apo B (mg/dl) 71.3+6.74 66.6+4.92
Apo AI (mg/dl) 122+13.7 161+5.41 a
All values are mean ± SEM. 
a: p<0.05; b: p<0.01; c: pcO.OOl
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Table 5.18. Concentrations of lipid and protein components of VLDL and LDL subfractions in 17 PA patients and their controls.
VLDL-1 VLDL-2 VLDL-3 LDL-1 LDL-2 LDL-3

























































































































































































All concentrations are mean ± SEM (mg/dl).
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; 
FC: free cholesterol; Prot: protein.
Table 5.19. Composition of VLDL and LDL subfractions in 17 PA patients and their controls.
VLDL-1 VLDL-2 VLDL-3 LDL-1 LDL-2 LDL-3

















































































































































All values are mean % of total mass ± SEM.
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; 
FC: free cholesterol; Prot: protein, 
a: p<0.05
Table 5.20. Qualitative parameters in 17 PA patients and their controls.
PA patients Controls
%VLDL-1/ IVLDL 17.9±3.01 17.4+1.45
% VLDL-2/ IVLDL 25.2+1.23 26.6+1.34
% VLDL-3/ IVLDL 56.9+2.85 56.1+1.93
%LDL-3/ILDL 25.3+2.17 19.5+2.12
LDL chol/ HDL chol 2.48+0.20 1 .8 8 +0 . 2 2  a
HDL2/HDL3 chol 1.82+0.94 0.98+0.14
HDL trig/chol 0.25+0.03 0.16+0.02 b
VLDL-1 trig/apoB 16.6+3.54 13.1+1.57
VLDL-2 trig/apoB 9.91+1.05 8.47+1.26
VLDL-3 trig/apoB 3.73+0.26 3.49+0.26
All values are mean ± SEM. 
chol: cholesterol; trig: triglyceride, 
a: p<0.05
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5.3.2.2. Female PA patients (n=10)
Quantitative and qualitative differences in females were not dissimilar to the whole 
group. HDL cholesterol was significantly reduced in female PA patients compared to 
controls, which was reflected in non-significant reductions in HDL2, HDL3 and apo AI 
(Table 5.21).
LDL-3 mass and cholesterol levels were significantly raised in female PA patients 
(Table 5.22). Qualitative changes included significantly reduced % cholesterol in LDL-1 in 
PA patients, reflected by elevated % triglyceride in the same subfraction (Table 5.23) as 
well as significantly elevated %LDL-3/ZLDL mass ratio in PA patients (Table 5.24). In 
addition, LDL/HDL cholesterol and HDL triglyceride/cholesterol were substantially raised 
in SLE patients, whereas VLDL subfraction profile and particle size was similar in both 
subject groups.
Table 5.21. Lipids, lipoproteins and apolipoproteins in 10 female PA patients their controls
PA patients Controls
Cholesterol (mM) 4.72±0.25 4.76+0.27
Triglyceride (mM) 0.95+0.11 0.97+0.09
VLDL cholesterol (mM) 0.22±0.04 0.29+0.06
VLDL triglyceride (mM) 0.36+0.08 0.41+0.07
LDL cholesterol (mM) 2.27+0.12 2.35+0.21
LDL triglyceride (mM) 0.26+0.03 0.22+0.03
HDL cholesterol (mM) 1.10+0.09 1.45+0.10 a
HDL2 cholesterol (mM) 0.56+0.06 0.71+0.08
HDL3 cholesterol (mM) 0.54+0.08 0.74+0.10
HDL triglyceride (mM) 0.25+0.03 0.25+0.02
Apo B (mg/dl) 65.6+6.71 62.1+4.66
Apo AI (mg/dl) 140+13.2 157+4.83
All values are mean ± SEM. 
a: p<0.05
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Table 5.22. Concentrations of lipid and protein components of VLDL and LDL subtractions in 10 female PA patients and their controls.
VLDL-1 VLDL-2 VLDL-3 LDL-1 LDL-2 LDL-3




























































































































































































All concentrations are mean ± SEM (mg/dl).
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; 
FC: free cholesterol; Prot: protein, 
a: p<0.05; b p<0.01
Table 5.23. Composition of VLDL and LDL subfractions in 10 female PA patients and their controls.
VLDL-1 VLDL-2 VLDL-3 LD L-l LD L-2 LD L-3

















































































































































All values are mean % of total mass ± SEM.
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; 
FC: free cholesterol; Prot: protein, 
a: p<0.05
Table 5.24. Qualitative parameters in 10 female PA patients and their controls.
PA patients Controls
%VLDL-1/ IVLDL 17.7±4.52 14.8+1.28
% VLDL-2/ IVLDL 23.7+1.65 26.1+1.96
% VLDL-3/ IVLDL 58.6+3.42 59.1+1.99
%LDL-3/ILDL 21.2+1.51 15.7+0.94 b
LDL chol/ HDL chol 2.20+0.23 1.68+0.16
HDL2/ HDL3 chol 2.56+1.58 1.15+0.22
HDL trig/chol 0.24+0.04 0.18+0.02
VLDL-1 trig/apoB 18.0+6.10 13.3+2.32
VLDL-2 trig/apoB 10.1+1.67 11.0+1.61
VLDL-3 trig/apoB 3.32+0.34 3.95+0.23
All values are mean ± SEM. 
chol: cholesterol; trig: triglyceride, 
b: p<0.01
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5.3.2.3. Male PA patients (n=7)
Male psoriatic patients had significantly reduced levels of HDL and HDL3 
cholesterol and apo AI compared to controls (Table 5.25). In addition serum and VLDL 
triglyceride tended to be higher in PA patients.
Although there were no quantitative differences in VLDL and LDL subfractions 
between male PA patients and controls, there were some qualitative differences (Table 
5.26). Percentage triglyceride in LDL-2 was significantly increased (Table 5.27), and 
triglyceride/apoB ratio in VLDL-2 and -3 was higher in male PA patients than in controls 
(Table 5.28), suggesting that these particles were larger and more triglyceride-rich. 
LDL/HDL cholesterol and HDL triglyceride/cholesterol ratios were raised in SLE patients, 
the latter reaching significance. Percentage LDL-3/ELDL mass ratio was substantially 
higher in male PA patients, although the difference did not reach statistical significance.
Differences in male PA patients were similar to females in that they had reduced 
levels of HDL cholesterol compared to controls. However, males patients tended to have 
higher serum and VLDL triglyceride than controls which may have contributed to the higher 
% LDL-3/ELDL mass ratio in these patients; whereas females tended to have lower serum 
and VLDL triglyceride than controls and still had higher % LDL-3/ELDL mass ratio.
Table 5.25. Lipids, lipoproteins and apolipoproteins in 7 male PA patients and their controls
PA patients Controls
Cholesterol (mM) 5.00+0.47 5.83+0.60
Triglyceride (mM) 1.58+0.33 1.33+0.17
VLDL cholesterol (mM) 0.57+0.17 0.39+0.08
VLDL triglyceride (mM) 0.84+0.22 0.53+0.14
LDL cholesterol (mM) 2.50+0.26 2.83+0.40
LDL triglyceride (mM) 0.27+0.03 0.21+0.03
HDL cholesterol (mM) 0.89+0.08 1.63+0.25 a
HDL2 cholesterol (mM) 0.38+0.07 0.67+0.12
HDL3 cholesterol (mM) 0.50+0.03 0.96+0.14 a
HDL triglyceride (mM) 0.22+0.02 0.17+0.02
Apo B (mg/dl) 79.4+13.4 73.0+9.93
Apo AI (mg/dl) 95.6+25.3 168+11.3 a
All values are mean ± SEM. 
a: p<0.05
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Table 5.26. Concentrations of lipid and protein components of VLDL and LDL subfractions in 7 male PA patients and their controls.
VLDL-1 VLDL-2 VLDL-3 LD L-l LDL-2 LD L-3

























































































































































































All concentrations are mean ± SEM (mg/dl).
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; 
FC: free cholesterol; Prot: protein.
Table 5.27. Composition of VLDL and LDL subfractions in 7 male PA patients and their controls.
VLDL-1 VLDL-2 VLDL-3 LD L-l LD.L-2 LD L-3

















































































































































All values are mean % of total mass + SEM.
Contr: Controls; CH: cholesterol; TG:triglyceride; PL: phospholipid; EC: esterified cholesterol; 
FC: free cholesterol; Prot: protein, 
a: p<0.05; b: p<0.01
Table 5.28. Qualitative parameters in 7 male PA patients and their controls
PA patients Controls
%VLDL-1/ IVLDL 18.2+3.83 21.0+2.51
% VLDL-2/ IVLDL 27.3±1.65 27.3+1.80
% VLDL-3/ IVLDL 54.5+5.10 51.7+3.20
%LDL-3/ILDL 31.3+3.95 24.8+4.38
LDL chol/ HDL chol 2.89±0.30 2.17+0.50
HDL2/HDL3 chol 0.77+0.13 0.73+0.10
HDL trig/chol 0.27+0.03 0.13+0.03 b
VLDL-1 trig/apoB 14.8+2.66 12.8+2.07
VLDL-2 trig/apoB 9.61+1.09 5.25+1.25 a
VLDL-3 trig/apoB 4.32+0.29 2.83+0.39 a
All values are mean ± SEM. 
chol: cholesterol; trig: triglyceride, 
a: p<0.05
5.4. DISCUSSION
The number of patients, especially gender specific patients, was relatively small in 
this study. It was therefore necessary to select closely age-matched controls. Additionally, 
careful statistical interpretation is required for individual differences, since isolated 
differences, which are not in agreement with other differences nor consistent in both 
genders, may be present by chance.
Results presented in this study showed that SLE patients had significantly elevated 
% LDL-3/ELDL mass, which is potentially atherogenic since small dense LDL is associated 
with atherosclerosis and CHD risk. Other trends contributing to atherogenic potential in 
SLE patients included raised serum and VLDL triglyceride, LDL/HDL cholesterol and 
HDL triglyceride/cholesterol ratios, together with depressed HDL cholesterol, HDL2/HDL3 
cholesterol ratio and serum apo AI.
These differences were particularly apparent in female SLE patients, who had highly 
significantly elevated %LDL-3/ELDL mass, not apparent from serum and LDL cholesterol 
measurements, and other trends included raised serum and VLDL triglyceride, LDL/HDL 
cholesterol and HDL triglyceride/cholesterol ratios, and reduced HDL cholesterol, 
HDL2/HDL3 cholesterol ratio and apo AI. Differences between male patients and controls 
were not dissimilar to the female group; serum and VLDL triglyceride and %LDL-3/ZLDL 
mass ratio were elevated and HDL cholesterol and apo AI were reduced.
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Previous studies have demonstrated some of this dyslipidaemia in SLE. Elevated 
VLDL cholesterol and triglyceride and depressed HDL cholesterol and apo AI due to 
disease activity, and raised serum and VLDL cholesterol and triglyceride due to 
corticosteroid therapy have been reported in SLE patients (Ilowite et al., 1988). In another 
study, (Leong et al., 1994), SLE patients on corticosteroid therapy had raised serum 
cholesterol and triglyceride and LDL, and low HDL, but there was no dyslipidaemia 
attributed to the active disease. SLE patients on hydroxychloroquine, an antiinflammatory 
agent used to treat SLE, have been reported to have reduced serum, VLDL LDL and HDL 
triglyceride and VLDL cholesterol (Hodis et al., 1992). It is apparent therefore that 
dyslipidaemia in SLE may be dependent on the type of therapy as well as disease activity. 
In the present study, there were non-significant trends towards raised serum and VLDL 
triglyceride and reduced HDL cholesterol in SLE patients. Although these trends are 
similar to those found by Ilowite and Leong in SLE patients, it was not possible to attribute 
these differences to disease activity or steroid therapy because of the relatively small patient 
numbers. Patients in this study were stable with little or no disease activity, but some 
patients were being treated with corticosteroids, hydroxychloroquine or both.
Previous studies have only compared basic lipid and lipoprotein parameters, whereas 
this study has also demonstrated some important qualitative differences in VLDL and LDL 
subfractions between SLE patients and controls. In SLE patients, and in females especially, 
%LDL-3/ZLDL mass was elevated. Prevalence of small dense LDL is often reported to be 
associated with elevated triglyceride (Austin and Krauss, 1986; Austin et al., 1988) levels 
and is believed to be produced by cholesterol ester transfer from LDL and HDL to 
triglyceride-rich lipoproteins in exchange for triglyceride resulting in cholesterol ester- 
depleted, triglyceride-rich LDL (Tall, 1986). Triglyceride is hydrolysed from this LDL 
producing small, dense LDL (Auwerx et al., 1988; Levy et al., 1990; Zambon et al., 1993). 
Elevated serum and VLDL triglyceride in SLE patients, may contribute to the prevalence of 
small dense LDL. In females, non-significant increases in triglyceride-enrichment of HDL 
and LDL-2 are indicative of increased CETP activity. Contradicting this, however, % 
cholesterol ester in VLDL subfractions was reduced in these patients, a result which appears 
to be genuine rather than a reflection of triglyceride enrichment, as also cholesterol 
ester/apo B ratios tended to be lower (data not shown). This finding is difficult to explain, 
but, as this was not present in PA patients, factors specific to SLE and therapeutic drugs 
may play a role. However, the elevated %LDL-3/ELDL mass persists in SLE patients, 
significantly so in female SLE patients, when they are matched with controls for serum 
triglyceride, suggesting that other factors specific to the disease may be responsible.
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Explanations for dyslipidaemia in SLE in previous studies have included the role of 
mediators of inflammation and corticosteroids on lipoprotein metabolism. Mediators of 
inflammation such as interleukin-1 and tumour necrosis factor have been reported to inhibit 
LPL activity (Beutler et al., 1985; Fried and Zechner, 1989; Ogawa et al., 1989). These 
cytokines, elevated in SLE could inhibit LPL activity leading to raised VLDL and reduced 
HDL. In addition, VLDL production is stimulated by steroids. The explanation for an 
elevated proportion of LDL-3/ZLDL in SLE patients is far less clear, although elevated 
triglyceride, mediators of inflammation and steroids could all play a role.
In conclusion, SLE patients had an atherogenic lipoprotein profile including raised 
%LDL-3/ELDL mass, a parameter which was not apparent from simple lipoprotein 
measurements. This is clearly a preliminary study which warrants further investigation into 
the effects of disease activity and antiinflammatory drug therapy on the LDL profile in SLE 
patients.
Results comparing all PA patients and controls, showed that patients had 
significantly reduced HDL, HDL2 and HDL3 cholesterol and apo AI, significantly raised 
LDL/HDL cholesterol and HDL triglyceride/cholesterol ratios and a non-significant increase 
in %LDL-3/ELDL mass ratio compared to controls (p=0.06), contributing to an 
atherogenic lipoprotein profile. Similarly, female PA patients had significantly reduced 
HDL cholesterol and elevated LDL-3 mass and cholesterol and %LDL-3/ZLDL despite 
having slightly lower serum and VLDL triglyceride. Male patients also had significantly 
lower HDL cholesterol, and in addition, they had significantly lower HDL3 cholesterol, apo 
AI and raised HDL triglyceride/cholesterol ratio compared to controls. Furthermore, both 
male and female patients tended to have lower levels of serum and LDL cholesterol. 
Although male patients had substantially, but non-significantly, higher %LDL-3/ELDL 
mass, unlike with the female group, this may be due to elevated serum and VLDL 
triglyceride and significantly raised triglyceride/apoB ratio in VLDL-2 and -3, contributing 
to the formation of small dense LDL.
Lazarevic and co-workers (1992) reported that patients with severe PA had reduced 
serum, LDL and HDL cholesterol and serum triglyceride compared to patients with mild 
activity, suggesting that disease activity was responsible for hypocholesterolaemia in PA 
patients. Similarly, in the present study, PA patients, most of whom had active disease, 
showed signs of hypocholesterolaemia with significantly lower HDL cholesterol and non­
significant reductions in serum and LDL cholesterol compared to controls.
Depressed levels of HDL, as described for SLE patients, may be due to inhibition of
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LPL activity by cytokines. It is interesting to note that while triglycerides were lower in 
female PA patients, there were non-significant increases in triglyceride-enrichment of HDL 
and LDL-2, indicative of enhanced CETP activity. None of the patients were on steroid 
therapy or any therapy that may affect lipid metabolism, suggesting that the prevalence of 
small dense LDL in female patients may be due to mediators of inflammation specific to the 
disease, although the mechanism is unclear.
For both SLE and PA patients percentage LDL-3/ELDL mass ratio was significantly 
raised, particularly in the female groups, and this difference was not associated with 
elevated triglyceride levels. However, in both the male groups this difference did not 
achieve significance, which may well be due to small patient numbers. Reduced HDL 
cholesterol levels compared to controls were apparent in both patient groups. Whereas this 
was a trend in SLE patients, the difference was significant for PA patients. SLE patients 
tended to have elevated serum and VLDL triglyceride levels in both males and females, 
whereas, in PA patients this trend was only observed in the male group. Furthermore, 
reduced serum and LDL cholesterol was apparent in male and female PA patients, a trend 
not seen in SLE patients. Perhaps similarities in dyslipidaemia in SLE and PA patients are 
caused by mediators of inflammation, whereas differences are caused by the different 
activities of the disease in the patient groups, as well as the influence of therapy in the SLE 
group.
The prevalence of reduced HDL cholesterol and elevated proportion of small dense 




ANTI-XANTHINE OXIDASE ANTIBODIES IN HEALTHY SUBJECTS
6.1. INTRODUCTION
In a previous study (Harrison et al.,1990), IgM anti-BXO antibodies were found to 
be present in the serum of all subjects examined and levels were raised in patients who had 
suffered an MI, compared to controls. There were no such differences in IgG and IgA anti- 
BXO antibodies. Such antibodies could originate in response to ingested bovine milk 
(Oster et al 1971; Rzucildo et al.,1979; Deeth 1983), or they could be autoantibodies in 
response to endogenous XO, known to be present in the capillary endothelium of a variety 
of tissues (Jarasch et al., 1986).
In order to learn more about the distribution and origin of anti-XO antibodies in 
normal subjects, IgG and IgM antibodies to BXO and HXO were compared in serum 
samples obtained from carefully matched groups of human donors.
6.2. METHOD
6.2.1. Study population
Serum samples were collected from the Bath Clinic. Subjects were normal 




AGE ± SEM (yrs) 46.7 ±0.93 (20-72) 46.8 ±0.92 (19-72)
Table 6.1: demographic data for males and females.
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6.2.2. Measurements
The anti-BXO IgM and IgG antibodies were measured by ELISA using freshly prepared 
bovine XO prepared by the method of Nakamura and Yamazaki (1982) (supplied by 
J.Khan, Bath University). The anti-HXO IgM and anti-HXO IgG results were obtained 
from A.Gleeson (Bath University). Antibody levels, measured as a percentage of a high 
titre standard serum (Al), were converted to actual concentration of antibody by using 
values of total antibody concentration and XO-specific antibody concentrations in the 
standard serum (supplied by M.Benboubetra, Bath University). These values are as follows: 
3.0 mg/ml total IgM, 15.04 mg/ml total IgG, 53.0 |ug/ml BXO-specific IgM, 64.0 pg/ml 
HXO-specific IgM, 8.0 pg/ml BXO-specific IgG, and 4.2 |ug/ml HXO-specific IgG. 
Comparisons of anti-BXO and anti-HXO IgM and IgG antibodies were made using all the 
serum samples. In addition comparisons were made between males and females.
6.2.3. Statistics
Comparisons were made using the Kolmogorov-Smirnov test.
6.3. RESULTS
Table 6.2 shows the mean concentrations of IgM and IgG class anti-BXO and anti- 
HXO antibodies in the serum samples from 258 human subjects, as well as their 
concentration expressed as a percentage of total IgM and IgG antibody level. Distributions 
profiles of the concentrations of IgM anti-BXO and anti-HXO antibodies and the 
concentrations of IgG anti-BXO and anti-HXO antibodies are shown in Fig. 6.1 and Fig. 
6.2 respectively. IgM anti-HXO antibody levels were significantly higher than IgM anti- 
BXO antibody levels and IgG anti-BXO antibody levels were significantly higher than IgG 
anti-HXO antibody levels. However, as shown in Table 6.2, IgM anti-BXO and anti-HXO 
antibodies were present at higher levels than the corresponding IgG levels, and were also 
higher in terms of percentage of total antibody of its own class.
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anti-BXO anti-HXO anti-BXO anti-HXO
Number of 
subjects
258 258 258 258
Age in years 
(mean ± SEM)











Mean % of 
class total
0.80 1.42 0.05 0.02
Dmax 0.353 (35.3%) 0.376 (37.6%)
p value <0.001 <0.001
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Fig. 6.2. Comparison of IgG anti-BXO and anti-HXO antibody levels in 258 males and 
females. p<0.001.
Comparisons of IgM and IgG anti-BXO antibodies for males and females, above and 
below 50 years, are shown in Tables 6.3 and 6.4 respectively. The corresponding 
comparisons for anti-HXO antibodies are shown in Tables 6.5 and 6.6. The distribution 
profiles show that IgM anti-BXO antibodies were significantly higher in females compared 
to males (Fig. 6.3), particularly in subjects below 50 years (Fig. 6.4), and higher in females 
below 50 years compared to females above 50 years (Fig. 6.5). There were no differences in 
these antibodies between males and females above 50 years, or between males above and 
below 50 years. There were also no differences in IgG anti-BXO antibodies between the 
aforementioned subject groups. An identical pattern of results was observed for IgM and 
IgG anti-HXO antibodies (Tables 6.5 and 6.6).
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Dmax 0.21 0.29 0 . 10 0 . 14 0.44
p value <0.01 <0.005 >0.1 >0.1 <0.001
Fern: Female, for this Table and subsequent Tables.



































































































Dmax 0.10 0.15 0. 10 0.05 0.17
p value >0.1 >0.1 >0.1 >0.1 >0.1
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Dmax 0.16 0.24 0. 10 0.09 0.24
p value <0.05 <0.025 >0.1 >0.1 <0.05



































































































Dmax 0.13 0.17 0 . 15 0.21 0 . 10
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Fig. 6.3. Comparisons of IgM anti-BXO antibody levels in 129 males and age-matched 
females. p<0.01.
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Fig. 6.5. Comparisons of IgM anti-BXO antibody levels in females above and below 50 
years of age. p<0.001.
6.4. DISCUSSION
The levels of IgM anti-XO antibodies found in normal human serum was 
surprisingly high, with IgM class anti-HXO antibodies (mean titre 42.6 pg/ml) making up
1.4 % of total IgM. In view of the proposed involvement of XO in the generation of 
reactive oxygen species during ischaemia-reperfusion (Sussman and Buckley, 1990), the 
origin and role of these antibodies is clearly of interest.
Concerning their origin, levels of IgM anti-HXO antibodies, were significantly 
(p<0.001) higher than those of IgM anti-BXO antibodies suggesting that endogenous HXO, 
rather than ingested BXO is the immunogen.
In the course of initial studies, it quickly became apparent that female subjects in 
general, show higher titres than do males, and the subject population was accordingly 
chosen to allow precise gender and age-matching. Comparison of IgM anti-BXO antibody 
titres in 129 male and 129 female subjects showed those of the latter to be significantly 
(p<0.01) higher; a difference that can clearly be attributed to the higher titres in women 
under 50 years, which are not only higher than those of age-matched men (p<0.005) but 
also than those of older women (p<0.001). Men, on the other hand, showed no significant 
age-dependent differences. Similar results were obtained for anti-HXO antibodies.
176
Similar findings have been reported by Lewis and Ng (1991), who compared serum 
IgM anti-BXO antibody levels in 105 males and 106 females, all under 50 years, and found 
titres in the females to be significantly higher (p<0.01). Antibody levels in 54 females 
under 50 years were significantly (p<0.005) higher than in 47 older females. Lewis and Ng 
(1991) suggested that higher titres in younger women may occur because pre-menopausal 
females might be cyclically re-immunised by XO released during ischaemic events preceding 
menstruation. This, of course, assumes that the immunogen is HXO rather than BXO, an 
assumption that was reinforced by the fact (Lewis and Ng, 1991) that no differences in 
titres were observed between European and Chinese subjects, despite marked differences in 
bovine milk product consumption between the two population groups.
In contrast to IgM anti-XO class antibodies, those of IgG class showed no variations 
with gender with gender and age and represented a much lower proportion of their total 
class. Levels of IgG anti-HXO antibodies (mean titre 2.68 pg/ml) represent only 0.02% 
total IgG while anti-BXO antibodies (mean titre 7.27 pg/ml) make up 0.05% of total IgG. 
Anti-BXO antibody levels determined in the present study are of the same order as those 
represented by Ng et al. (1990) who found average values for IgM anti-BXO antibodies of
11.9 jig/ml (cf. 24.1pg/ml, Table 6.2) and for IgG anti-BXO antibodies of 14.7 pg/ml (cf. 
7.27 jug/ml, Table 6.2). Lewis and Ng (1991), like myself, found no sex or age dependency 
of IgG anti-BXO levels.
The work of Bruder et al. (1984) should also be considered. In striking contrast to 
both the present data and those of Ng et al. (1990), they found only IgG class antibodies in 
human serum. This conclusion was based on affinity purification of anti-XO antibodies 
from serum, followed by analyses in SDS-PAGE, when y and but not p antibody chains 
were detected. Using an ELISA, they compared anti-BXO and anti-HXO antibody levels in 
the sera of 74 human subjects, based on detection of antibodies by protein A, which they 
took to be specific for IgG. Their findings, based on apparent IgG, show many similarities 
to my conclusions with IgM anti-XO antibodies. Bruder et al. (1984) also found anti-HXO 
class antbodies to be higher than those of anti-BXO, although their absolute levels were 
higher than mine. Their values of 0.2-1.5 % and 0.5-3.0 % total IgG for anti-BXO and 
anti-HXO antibodies respectively represent 30-226 pg/ml and 75-451 pg/ml (cf. Table 6.2). 
The two studies could be partially reconciled if the protein A-based ELISA of Bruder and 
co-workers had, in fact, been detecting IgM, possibly in addition to IgG. Binding of protein 
A to human IgM can indeed occur and the above explanation may be valid.
My findings of high levels of IgM anti-XO antibodies in human serum clearly raise 
many questions. The suggestion, from both the present study and that of Lewis and Ng
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(1991), is that the antibodies arise in response to endogenous HXO, rather than to ingested 
BXO. In this case, the autoantibodies could be seen as protective, acting to neutralise and 
clear pathologically-derived XO from the blood and tissues. The presence of elevated IgM 
anti-XO antibodies in MI patients (Harrison et al.,1990) can be seen as consistent with this 
idea. Harrison et al. (1990) presented evidence that elevated anti-XO antibody levels are 
not merely a consequence of the MI itself. They can be seen as a result of chronic lesions of 
capillary endothelium exposing XO to the immune system, possibly over a period of many 
months prior to clinical manifestations (Harrison et al.,1990). In this context, raised levels 
of IgM anti-XO antibodies in human serum would be seen as a marker of CHD, rather than 
as a positive risk factor. A protective role for IgM anti-XO antibodies is consistent with the 
sex- and age- linked differences reported in the present Chapter. Younger women have a 
lower incidence of myocardial infarction than men of similar age (Heller, 1978). This 
advantage is largely lost after the age of the onset of the menopause, when, according to my 
present findings, levels of IgM anti-XO antibodies fell significantly. It is relevant, at this 
stage to refer ahead to Chapter 7, in which it is shown that patients dying within 6 months 
after an MI have significantly higher IgM anti-XO levels than ‘survivors’. In the absence of 
any positive correlation between antibody titre and extent of MI (as judged by CPK levels; 
Chapter 7, Table 7.14), it can be agreed that those MI patients most at risk of death are 
those with most extensive capillary endothelial damage as evidenced by higher IgM anti-XO 
antibody levels.
The situation regarding IgG class anti-XO antibodies in human serum is quite 
different from that for those of IgM class. Levels of the former were found to be lower 
(Table 6.2), although Ng et al. (1990) reported similar average titres for anti-BXO 
antibodies of IgG (14.7 pg/ml) and IgM (11.9pg/ml) class. Neither the present study or 
that of Lewis and Ng (1991) found any association of IgG anti-XO levels with age or 
gender, nor did Harrison et al. (1990) find any correlation of such levels with MI. 
Moreover, levels of IgG anti-BXO antibodies are significantly (p<0.001) higher than IgG 
anti-HXO antibodies (Table 6.2); the reverse of that found in the case of IgM antibodies. 
There are no ready explanations for the differences between IgG and IgM class antibodies. 
If it is assumed that the basic situation involves IgM anti-HXO antibodies with a protective 
function, then possibly one could imagine that B-lymphocyte clones providing strongly 
cross-reactive antibodies could be induced to class switch from IgM and IgG by exposure to 
ingested BXO fragments. Clearly such an explanation is highly speculative but is offered in 
the absence of a better.
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CHAPTER 7
ANTI-XANTHINE OXIDASE ANTIBODIES AND 
MYOCARDIAL INFARCTION
7.1. INTRODUCTION
Harrison et al. (1990) found raised levels of IgM anti-BXO levels in patients with 
MI compared to controls. They also noted indications that levels were higher in patients 
who had died within 6 months of the MI compared to survivors.
The aim of this study was to investigate this latter suggestion and further to assess 
the extent to which antibody levels simply reflect the severity of the MI, as judged by serum 
creatinine phosphokinase (CPK) levels. Indirect evidence suggests that the endothelium of 
hypercholesterolaemic vessels is a source of ROS, probably via XO activation (Ohara et al., 
1993). In view of the associations between atherosclerotic lesions and elevated lipid levels, 
antibody levels were correlated with serum and lipoprotein cholesterol and triglyceride.
7.2. METHODS
7.2.1. Study population
Serum samples were collected from subjects (MI patients and controls), all of whom 
had been admitted to the Coronary Care Unit (CCU), Bath Royal United Hospital. 
Controls had no signs of heart disease or family history of heart disease. ‘Deaths’ refer to 
patients who died within 6 months after an MI and ‘survivors’ refer to patients who 
survived at least 6 months after an MI. Some controls, used in an early study were from a 
study clinic in the community in Trowbridge (supplied by Dr. J.Lloyd, Royal United 
Hospital, Bath); they were healthy volunteers who had not been admitted to the CCU. All 
subjects were male.
7.2.2. Measurements
All blood samples were taken from subjects within 24 hours of admission to the 
CCU, and serum was stored at -70°C prior to assay. Serum samples from the Trowbridge
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study were also stored at -70°C prior to assay. Anti-BXO IgM antibodies were measured 
in each sample and expressed as a percentage of a high titre standard serum (Al). The 
enzyme used in the ELISA was supplied by Biozyme Ltd. CPK, cholesterol and 
triglyceride levels were obtained from the CCU admission file where possible. For a 
randomly selected group of 60 MI patients, cholesterol and triglyceride were also measured 
in plasma and serum lipoproteins (VLDL, LDL, HDL, HDL2, and HDL3) for correlation 
analysis.
7.2.3. Statistics
Comparisons involving antibody levels and CPK levels were made by using the 
Kolmogorov-Smirnoff test. Comparisons involving cholesterol and triglyceride (log- 
transformed) were made using an unpaired Student’s t-test. Correlations between antibody 
levels and CPK, lipid and lipoprotein measurements were made using Spearman’s rank 
correlation test. All values are mean ± SEM.
7.3. RESULTS
7.3.1. Comparison of antibody levels between MI patients and controls (36 
Trowbridge controls and 16 CCU controls).
IgM anti-BXO antibody levels were significantly higher in controls compared to MI 
patients (Table 7.1., Fig. 7.1) At the point of maximum cumulative difference 48% of MI 
patients had been represented compared to 21% of the controls.
Table 7.1. Comparison of antibody levels between 52 MI patients and 52 age-matched 
controls (36 Trowbridge controls and 16 CCU controls).
MI patients Controls
NUMBER 52 52
AGE (yrs) ± SEM 56.1±1.3 56.1±1.3
Mean titres ± SEM 18.3±1.78 25.0±2.30
Dmax 0.269 (26.9%)
p value p<0.05
Titres are mean ± SEM (% of Al standard).
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Fig. 7.1. Comparison of IgM anti-BXO antibody levels in 52 MI patients and their age- 
matched controls. p<0.05.
7.3.2. Comparison of antibody levels between Trowbridge controls and age-matched 
CCU controls
In a previous study (Harrison et al., 1990), where it was reported that MI patients 
had significantly higher IgM anti-BXO antibody levels than controls, the entire control 
group was selected from the CCU. In order to investigate whether the two control groups 
(Trowbridge controls and CCU controls) differed in terms of IgM anti-BXO antibody 
levels, a comparison was made between 36 Trowbridge controls and 36 age-matched CCU 
controls. No significant differences were found between IgM anti-BXO antibody levels in 
Trowbridge controls and CCU controls (Table 7.2, Fig. 7.2). However, the mean antibody 
titre was higher in the Trowbridge control group and at the point of maximum cumulative 
difference 58% of CCU controls had been represented compared to 36% of the Trowbridge 
controls. A Dmax difference of 33% was needed for statistical significance.
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AGE (yrs) ± SEM 59.3±1.2 59.3±1.2
Mean titres ± SEM 45.0±4.00 37.4±3.60
Dmax 0.220 (22%)
p value >0.1
Titres are mean ± SEM (% of Al standard).
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Fig. 7.2. Comparisons of IgM anti-BXO antibody levels in 36 controls from the CCU and 
36 age-matched controls. p>0.1.
7.3.3. Comparison of antibody levels between MI patients and controls.
In view of the results of section 7.3.2, above, CCU controls were considered to be 
more appropriate than Trowbridge controls (see Discussion). Accordingly a comparison of 
IgM anti-BXO antibody levels was made between MI patients and CCU controls. Again, 
there was no significant difference between the two subject groups (Table 7.3, Fig. 7.3). 
However this time, MI patients had a higher mean titre than the control group, and at the
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point of maximum cumulative difference, 53% of the control group had been represented 
compared to 42% of the MI patients. A Dmax value of 13.4% would have been required 
for the difference to have reached statistical significance.




AGE (yrs) ± SEM 53.8 ±0.51 51.7 ± 0.89
Mean titres ± SEM 31. 1±1.30 26.6±1.29
Dmax 0.105 (10.5%)
p value >0.1
Titres are mean ± SEM (% of Al standard).
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Fig. 7.3. Comparison of IgM anti-BXO antibodies in 311 MI patients and 154 age-matched 
controls. p>0.1.
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7.3.4. Comparison of antibody levels between patients who had died within 6 months
from a MI (‘deaths*) and patients who had survived at least 6 months after a MI 
(‘survivors*).
Table 7.4 and Fig. 7.4 show that IgM anti-BXO antibody levels were significantly 
higher in ‘deaths’ than in ‘survivors’. At the point of maximum cumulative difference 30% 
o f ‘deaths’ had been represented compared to 47% o f ‘survivors’.
Table 7.4. Comparison of antibody levels between 94 patients who had died within 6 




Previous MI (% of patients) 4.3 6.0
AGE (yrs) ± SEM 66.3 ±0.95 64.2+0.51
Mean titres ± SEM 29.5+2.04 27.4+1.43
Dmax 0.172
p value <0.05
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Fig. 7.4. Comparisons of IgM anti-BXO antibody levels in 94 patients who died within 6 
months of an MI and in 234 age-matched patients who survived at least 6 months. P<0.05.
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7.3.5. Comparison of antibody levels between patients who had died within 6 months
from a M I and controls.
In view of ‘deaths’ having significantly higher antibody titres than ‘survivors’, and 
MI patients having higher titres than controls (although differences did not reach 
significance), it seemed logical that ‘deaths’ would have higher antibody titres than controls. 
The latter comparison is shown in Table 7.5.
Table 7.5. A comparison of anti-BXO IgM antibodies between 47 patients who had died 
from a MI (deaths) and 79 age-matched controls.
Deaths Controls
NUMBER 47 79
AGE (yrs) ± SEM 59.3 ±1.16 60.2 ± 0.72
Mean titres ± SEM 31.7+3.55 25.1+1.73
Dmax 0.179 (17.9%)
p value >0.1
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Fig. 7.5. Comparisons of IgM anti-BXO antibody levels in 47 patients who have died 
within 6 months of a MI and 79 age-matched controls. p>0.1.
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Table 7.5 and Fig. 7.5 confirm that ‘deaths’ had higher antibody titres than controls, 
although this difference did not reach statistical significance. At the point of maximum 
cumulative difference, 35% of ‘deaths’ had been represented compared to 52% of the 
controls. A Dmax of 25% would have been required for the difference to have reached 
statistical significance.
7.3.6. Plasma and lipoprotein cholesterol and triglyceride concentrations and their 
relationship with IgM anti-BXO antibodies.
A comparison of plasma cholesterol and triglyceride concentrations was made 
between MI patients and controls (Table 7.6), between ‘deaths’ and ‘survivors’ (Table 7.7), 
and between ‘deaths’ and controls (Table 7.8). MI patients had significantly elevated 
cholesterol levels compared to control patients. There were no significant differences in 
cholesterol and triglyceride between the other subject groups.
Table 7.6. Comparisons of cholesterol and triglyceride levels between MI patients and 
controls.















Table 7.7. Comparisons of cholesterol and triglyceride levels between ‘deaths’ and 
‘survivors’.















Table 7.8. Comparisons of cholesterol and triglyceride levels between ‘deaths’ and controls.
















Correlations of lipid levels and antibody levels in ‘deaths’, ‘survivors’, and controls, 
as individual groups and as one collective group, are shown in Table 7.9. In addition, 
cholesterol and triglyceride levels for VLDL, LDL, HDL, HDL2 and HDL3 were correlated 
with antibody levels in a group of MI patients (Table 7.10). There were no significant 
correlations between IgM anti-BXO antibody levels and lipid and lipoprotein levels in any 
of the subject groups.
Table 7.9. Correlations between IgM anti-BXO antibodies and plasma cholesterol and 
triglyceride levels.





















Rs: Spearman’s rank correlation coefficient.
Table 7.10. Correlations between IgM anti-BXO antibody levels and lipids and lipoprotein 




Serum cholesterol 0.183 >0.1
Serum triglyceride -0.093 >0.1
VLDL cholesterol -0.027 >0.1
VLDL triglyceride -0.078 >0.1
HDL cholesterol 0.143 >0.1
HDL triglyceride -0.020 >0.1
HDL2 cholesterol 0.015 >0.1
HDL2 triglyceride 0.156 >0.1
HDL3 cholesterol 0.127 >0.1
HDL3 triglyceride -0.143 >0.1
h d l 2/h d l 3
cholesterol ratio
-0.032 >0.1
LDL cholesterol 0.176 >0.1
LDL triglyceride -0.033 >0.1
Rs: Spearman’s rank correlation coefficient.
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7.3.7. CPK levels and their relationship with IgM anti-BXO antibodies.
CPK levels were compared between MI patients and controls (Table 7.11), between 
‘deaths’ and ‘survivors’ (Table 7.12), and between ‘deaths’ and controls (Table 7.13). CPK 
levels were significantly higher in MI patients compared to controls, and also in ‘deaths’ 
compared to controls. There were no significant differences between ‘deaths’ and 
‘survivors’, although mean titres were higher in ‘deaths’.

















mean ± SEM 20481194 18541103 >0.1
(iu/1)







mean 1 SEM 21121305 12619.2 <0.001
(iu/l)
CPK levels were correlated with antibody levels in ‘deaths’, ‘survivors’ and 
controls, as individual groups and as one collective group (Table 7.14). There was a 
significant negative correlation between antibody levels and CPK levels in ‘deaths’. No 
other significant correlations were observed in the other subject groups.
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Table 7.14. Correlations between IgM anti-BXO antibody levels and CPK levels.
Antibody levels in 
the below groups
CPK
Deaths Rs= -0.250 
p=0.021 (n=88)
Survivors Rs= 0.070 
p >0.1 (n=227)






Rs: Spearman’s rank correlation coefficient.
7.4. DISCUSSION
In a preliminary study, MI patients were found to have significantly reduced 
antibody levels compared to controls. This result was unexpected in view of previous 
findings reported in the literature. Davies et al. (1969, 1974) and Oster et al. (1971) 
reported that levels of antibodies to whole dried cow’s milk were elevated in patients who 
had suffered an MI. More recently, Harrison et al. (1990) reported that IgM anti-(XO) 
antibodies were significantly (p<0.001) raised in MI patients compared to controls.
In all of the aforementioned studies, the patients and controls were selected from a 
similar location and environment. Harrison et al. (1990) took blood samples from both MI 
patients and controls after their admission to a coronary care unit in hospital. The majority 
of the controls used in my initial study were from the Trowbridge community study, and the 
question arose as to whether titres in these controls differed from those used by Harrison et 
al. (1990). IgM anti-BXO antibody levels were accordingly compared in the two types of 
controls. Although the difference did not reach significance, the mean antibody titre was 
higher in the Trowbridge controls and the Dmax value was sufficiently large to suggest that 
with greater numbers this difference may have reached statistical significance.
Clearly, possible differences between types of control are important and an 
explanation was sought. A likely answer relates to differences in posture of the donors. 
Survey of the literature revealed that posture is known to affect the apparent concentration 
of blood constituents, altering the concentration of some indices by up to 15% (Fawcett et 
al.,1960; Dimmit, 1990). Changing from a horizontal position to a vertical position
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increases the concentration of blood constituents because of an increase in hydrostatic 
pressure in dependant parts, resulting in a net movement of plasma water across the blood 
vessel wall. A reversal of posture results in a reversal of plasma water movement across the 
blood vessel wall. These changes, certainly for lipids, appear after 5 min and peak between 
20-30 min (Tan et al., 1973). In the present study, the difference in mean antibody titres 
between the control groups was 17% which may well result from their different postures on 
blood sampling. Trowbridge controls were healthy volunteers who walked to the clinic and 
assumed a sitting position immediately prior to blood sampling. CCU controls, on the other 
hand, were lying down and had been doing so for many hours, as indeed, had the MI 
patients. Overall, it is clear that MI patients and CCU controls experienced essentially 
identical psychological effects and treatment prior to sampling and that the CCU controls 
are the most suitable for comparisons with MI patients.
In fact, IgM anti-BXO antibody levels in MI patients were found to be higher than 
those in CCU controls. Although this difference did not reach statistical significance, the 
Dmax value was 10.5%; 13.4% being needed for statistical significance. It is interesting to 
note that in a preliminary study comparing antibody levels in 50 MI patients with 50 CCU 
controls (results not shown), MI patients also had higher mean antibody titres than controls, 
with a Dmax value of 12%. IgM anti-BXO are consistently higher in MI patients, albeit 
marginally so, and although such an argument is far from statistical rigour, the impression is 
that larger subject numbers would show statistical significance. Certainly the data of 
Harrison et al. (1990) seem convincing and it may well be that with relatively small 
differences in titre between the two populations, chance in subject selection is a factor; a 
factor which will become less important as the populations increase in size, In this context, 
choice of controls and attention to their posture is clearly critical; a lesson that should 
perhaps be heeded in many clinical studies.
Patients who had died within 6 months of an MI had significantly raised levels of 
antibodies compared to patients who had survived at least 6 months. This finding is in 
agreement with Davies et al 1974, who, using a haemagglutination assay (see General 
Introduction, Chapter 1) found significantly higher levels of antibody to whole dried cows’ 
milk in patients who had died within 6 months of a MI compared to survivors. Harrison et 
al. (1990) also noted higher levels of IgM anti-XO antibody in 12 patients who died within 
6 months of an MI compared to 81 survivors, although not surprisingly, with such small 
numbers of subjects, differences did not reach statistical significance. In the present study, 
as expected ‘deaths’ had higher antibody levels than controls. Although this difference did 
not reach statistical significance, the Dmax value was greater than that found between
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‘deaths’ and ‘survivors’, suggesting that larger numbers might produce statistical 
significance.
The findings of significantly higher IgM anti-BXO antibody levels in patients dying 
within 6 months of MI, compared with ‘survivors’ is important and potentially of prognostic 
value. Higher antibody levels did not reflect occurrence of previous MI (Table 7.4) and it 
would clearly be less interesting if higher antibody levels simply reflect a bigger MI. In 
order to address this possibility, correlations were sought between CPK levels and IgM 
anti-BXO antibody titres in MI patients. CPK is released into the bloodstream after 
myocardial cell death and serum levels are widely used as markers for occurrence and extent 
of MI. As expected, CPK were very much higher in MI patients compared to controls. 
Levels were also slightly higher in ‘deaths’ compared with ‘survivors’, albeit not 
significantly so. CPK levels showed no positive correlation with IgM anti-BXO antibody 
levels, indicating that the latter do not depend on the extent of the MI, and incidentally 
reinforcing the conclusions of Harrison et al. (1990) that IgM anti-BXO antibody levels are 
not a consequence of the MI itself. In fact, a negative correlation was found between CPK 
and antibody levels among the deaths; a finding that is difficult to explain. These antibodies, 
therefore, maybe the result of chronic lesions of the capillary endothelium exposing xanthine 
oxidase to the immune system, possibly over many months. The lack of positive correlation 
between CPK and antibody levels in MI patients supports the potential of IgM anti-BXO 
antibody levels as an independent indicator of survival chances following MI. It may well 
be that a routine assay of serum from MI patients would allow a threshold antibody level to 
be defined, above which special attention is indicated.
Indirect evidence suggests that the endothelium of hypercholesterolaemic vessels is a 
source of superoxide anions, probably via XO activation (Ohara et al., 1993). Because the 
association of atherogenesis and plasma levels of certain lipids/lipoproteins, it was of 
interest to seek correlations between such levels and those of IgM anti-BXO antibodies. 
Not surprisingly, plasma cholesterol concentrations were significantly higher in MI patients 
compared with controls, in line with the generally accepted association of raised cholesterol 
levels with increased risk of MI (Keys, 1980; Nichamen et al., 1975; Martin et al.,1986; 
Stamler et al., 1986; Shaper et al., 1986). Interestingly, levels, while higher in ‘deaths’ 
compared with controls, were not significantly so, possibly reflecting the smaller numbers of 
subjects involved (see above). It is also noteworthy, that levels of cholesterol, far from 
indicating risk of death in MI were actually lower in ‘deaths’ than in ‘survivors’.
There were no significant correlations of antibody level with plasma and lipoprotein 
cholesterol and triglyceride levels in any of the subject groups. However it is interesting to
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notice that in a group of 60 MI patients (Table 7.10), although there were no significant 
correlations, the strongest correlations (denoted by large Rs values) were with total 
cholesterol, LDL cholesterol and HDL3 cholesterol. Total and LDL cholesterol are known 
risk factors for CHD because of their association with atherogenesis (Grundy, 1986). 
Although HDL cholesterol has an inverse relationship with CHD risk, this is due to reverse 
cholesterol transport via HDL2. A low HDL2/HDL3 ratio is associated with 
angiographically defined coronary sclerosis (Miller et al., 1981). However in view of the 
weakness of these correlations and the lack of correlation with cholesterol in the other 
subject groups (Table 7.9), the association, if any, of these antibodies with lipids, 
lipoproteins and atherosclerosis is far from clear.
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CHAPTER 8
ANTI-XANTHINE OXIDASE ANTIBODIES AND DIABETES MELLITUS
8.1. INTRODUCTION
In view of the possibility, discussed in Chapters 6 and 7, that levels of IgM anti­
xanthine oxidase antibodies might reflect the presence and extent of chronic lesions of 
capillary endothelium, these levels could conceivably be higher in any disease group with a 
high risk of CHD.
Diabetes mellitus patients represent such a group and IgM anti-BXO IgM antibody 
levels were accordingly compared in diabetic patients and non-diabetic controls. Diabetic 
patients were subdivided into patients with NIDDM and IDDM and both diabetic patients 
and controls were subdivided into groups with and without CHD. Patients were from a 




Fasting blood samples were obtained from 187 diabetic patients and 187 non­
diabetic subjects (Table 8.1).
DIABETICS CONTROLS
NUMBER 187 (98 male, 89 female) 187 (98 male, 89 female)
AGE (yrs) ± SEM 54.9+0.87 (Range: 18-70) 55.4+0.88 (Range: 18-70)
Table 8.1. Demographic data :'or diabetic patients and non-diabetic controls.
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Comparisons of levels of IgM anti-BXO antibodies were made:
1. between diabetic patients (NIDDM, IDDM, males and females) and their age- and 
gender-matched non-diabetic controls.
2. between NIDDM and EDDM patients.
3. between subjects with and without CHD in both diabetic and non-diabetic patients.
8.2.2. Measurements
IgM anti-BXO antibodies were measured for each subject and expressed as a 
percentage of a standard serum (Al). The enzyme used for the ELISA was supplied by 
Biozyme Ltd.
8.2.3. Statistics
Comparisons involving anti-BXO IgM antibody levels were made using the 
Kolmogorov-Smirnov test. All values are mean ± SEM.
8.3. RESULTS
Comparisons of IgM anti-BXO antibodies between diabetic patients and controls are 
tabulated in Tables 8.2-8.7. There were no significant differences in antibody levels 
between diabetic patients (Table 8.2), NIDDM patients (Table 8.3), IDDM patients (Table 
8.4) and their non-diabetic controls. However, mean antibody titres were considerably 
higher in IDDM patients compared to controls in both males and females. Table 8.5 shows 
that mean antibody titres were higher, although not significantly so, in IDDM patients 
compared to NIDDM patients. Fig. 8.1 illustrates the distribution profile for total IDDM 
and NIDDM patients.
Antibody levels were compared in diabetic and control patients with and without 
CHD (Tables 8.6 and 8.7 respectively). There were no significant differences between 
subjects with CHD and subjects without CHD.
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N 187 187 98 98 89 89
Age (Yrs) 
±SEM
54.9±0.87 55.4±0.88 54.9+1.07 57.6+1.10 52.6+1.38 52.9+1.34
Titre
±SEM
36.7±1.70 38.7±2.29 34.0+2.08 33.4+2.28 39.7+2.72 44.5+4.02
Dmax 0.037 0.082 0.079
P value >0.1 >0.1 >0.1
Titres are mean ± SEM (% of Al standard).
Dmax is the maximum cumulative difference for this Table and subsequent Tables.














N 143 143 76 76 67 67
Age (Yrs) 
+SEM
58.3+0.77 58.4+0.82 59.8+0.89 59.8+1.02 56.6+1.27 56.8+1.29
Titre
+SEM
33.6+1.81 38.3+2.86 31.8+2.27 33.2+2.78 35.5+2.86 44.0+5.17
Dmax 0.070 0.079 0.235
P value >0.1 >0.1 >0.1
Titres are mean ± SEM (% of Al standard).














N 44 44 22 22 22 22
Age (Yrs) 
+SEM
43.7+1.97 45.6+2.05 47.1+2.81 49.1+2.90 40.3+2.64 41.3+2.67
Titre
+SEM
46.3+3.84 40.1+2.92 41.5+4.71 34.2+3.54 52.4+6.12 46.1+4.41
Dmax 0.1 82 0.227 0.136
P value >0.1 >0.1 >0.1
Titres are mean ± SEM (% of Al standard).
195














N 34 44 19 22 15 22
Age (Yrs) 
+SEM
46.1+1.35 43.7±1.97 49.3±1.60 47.1+2.81 42.1+1.86 40.3±2.64
Titre
±SEM
36.2±3.70 46.3±3.84 35.3+5.69 41.5+4.71 37.3+4.54 52.4±6.12
Dmax 0.205 0.191 0.273
P value >0.1 >0.1 >0.1
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Fig. 8.1. Comparison of anti-BXO IgM antibodies between patients with NIDDM and 
IDDM. P>0.1.














N 59 77 27 49 32 28
Age (Yrs) 
±SEM
60.2±1.03 61.0±0.60 60.1+5.20 61.7+0.57 60.1+1.50 59.3+5.29
Titre
±SEM
30.2±2.49 34.6+2.62 30.4+2.50 32.8+2.56 30.1+2.95 37.6+5.28
Dmax 0.139 0.164 0.1 43
P value >0.1 >0.1 >0.1
Titres are mean ± SEM (% of Al standard).
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N 27 89 19 50 8 39
Age (Yrs) 
+SEM
63.2±1.37 62.9+0.47 63.3+1.72 63.0+0.63 63.3+2.35 62.3+2.26
Titre
±SEM
32.8±4.45 36.8+4.00 34.3+5.64 32.2+3.55 29.4+7.18 42.6+7.86
Dmax 0.106 0.1 48 0.266
P value >0.1 >0.1 >0.1
Titres are mean ± SEM (% of Al standard).
8.4. DISCUSSION
Harrison et al. (1990) showed that elevated levels of anti-BXO IgM antibodies in 
MI patients persisted for several weeks after the infarction, suggesting that the antibodies 
were not due to the infarct itself, but produced in response to numerous immunisation 
events prior to the infarct. This finding was supported by the lack of correlation found 
between CPK levels, a marker for the extent of the MI, and antibody levels (Chapter 7). 
Diabetes is a major risk factor for morbidity and mortality from macrovascular disease, the 
prevalence of which is increased 3-4 fold (Garcia et al., 1974). It could follow that patients 
with diabetes, at greater risk of suffering a myocardial infarction, could be producing higher 
levels of anti-BXO antibodies in response to exposure of xanthine oxidase in atherosclerotic 
lesions.
Levels of anti-BXO IgM antibodies did not differ significantly between diabetic, 
patients and their age and gender matched controls. Low patient numbers and possibly 
small extent of atheroma in diabetic patients may account for differences not being 
comparable to those involving MI patients (Chapter 7). Mean antibody levels in male and 
female IDDM patients were considerably higher than age and gender matched NIDDM 
patients. However, this difference is unlikely to be due to CHD risk, since antibody levels 
were not raised in diabetic and non-diabetic patients with CHD. It may be due to self­
immunisation of exposed enzyme as a result the destruction of P-cells in the pancreas by 




This section provides a general discussion with concluding remarks for each results 
Chapter.
Elevated fasting levels of triglyceride-rich lipoproteins were exaggerated and 
prolonged postprandially in hypertriglyceridaemic patients with NIDDM. This was in 
agreement with the finding that postprandial response was proportional to fasting 
triglyceride in both diabetic and control subjects. Raised concentrations of triglyceride-rich 
lipoproteins were particularly evident for chylomicrons and the large VLDL-1 subfraction. 
Not only was the proportion of large VLDL greater in NIDDM, but particle size within 
each VLDL subfraction was also larger, indicative of triglyceride-enrichment. Reduced 
levels of HDL and increased LDL-3 concentrations persisted postprandially in NIDDM, 
consistent with the known association between these indices and triglyceride. Low HDL 
cholesterol and raised levels of small, dense LDL are strong markers for CHD (Miller and 
Miller, 1987; Austin et al., 1988). Large VLDL is less readily catabolised than small VLDL 
(Stahlenhoef et al., 1984; Packard et al., 1984), thus providing less surface component for 
HDL production. In addition longer residence time of large VLDL allows cholesterol ester 
transfer with HDL and LDL by CETP in exchange for triglyceride (Tall, 1986). Hydrolysis 
of triglyceride in LDL results in the production of small, dense LDL (Auwerx et al.,1988; 
Levy et al.,1990; Zambon et al., 1993). Evidence of this cholesterol ester transfer process is 
provided by the triglyceride enrichment of HDL and LDL-2 in NIDDM as well as the 
predominance of LDL-3. Excess cholesterol ester transfer from HDL to triglyceride-rich 
lipoproteins also accounts for low HDL cholesterol levels in NIDDM. Instead of 
cholesterol ester returning to the liver via triglyceride-rich lipoproteins or HDL directly, it 
resides in VLDL, which now excessively cholesterol ester-enriched, is less readily 
catabolised and cleared by the liver, but more prone to removal by the scavenger pathway, 
thus leading to atherogenesis (Goldstein et al., 1980; Mahley et al., 1984).
Raised concentrations of insulin, NEFA and glucose were more apparent 
postprandially in NIDDM and are indicative of insulin resistance and relative insulin lack. 
This is consistent with the finding that (3-cell function was reduced and insulin resistance 
was raised (although not significant) in these patients. Insulin resistance and relative insulin 
lack can lead to low LPL activity which would account for accumulation of triglyceride-rich
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lipoproteins and HDL cholesterol. In addition, high levels of NEFA can stimulate hepatic 
triglyceride and VLDL synthesis (Sniderman et al., 1993).
While this study provides a detailed analysis of fasting and postprandial lipoprotein 
subtraction distribution and composition in NIDDM, investigations to assess the activities 
of LPL, HL and CETP would provide further insight to lipoprotein metabolism in NIDDM. 
Furthermore, a comparison between diabetic patients and non-diabetic patients matched for 
triglycerides would illustrate the effects of diabetes, independent of hypertriglyceridaemia, 
on lipoprotein metabolism. In addition, it would be interesting to determine the relative 
contribution of chylomicron remnants to the postprandial VLDL subfraction profile. 
Retinyl palmitate is incorporated into chylomicrons during absorption and therefore 
concentrations of retinyl palmitate provides a measure of chylomicrons and their remnants. 
This method has the disadvantage that retinyl palmitate may be exchanged with other 
lipoproteins (Krasinski et al., 1990). More recently, the determination of apo B48 using a 
specific monoclonal antibody has been developed (Peel et al., 1993).
Bezafibrate therapy reduced fasting and postprandial triglycerides and triglyceride- 
rich lipoproteins in NIDDM towards that of normolipidaemic subjects. This was 
particularly evident in the postprandial state, and in chylomicrons and VLDL-1, which 
decreased by 55% and 49% respectively. The proportion of small, dense LDL was reduced 
following bezafibrate therapy, consistent with reductions in large triglyceride-rich 
lipoproteins. Clearly these effects of bezafibrate reduce atherogenic potential in NIDDM. 
These effects are probably mediated by reductions in LPL activity (Vessby et al., 1980; 
Vessby et al., 1982; Heller et al., 1983; Eisenberg et al., 1984), NEFA concentrations 
(Alberti et al., 1990; Jones et al., 1990) and CETP activity (Homma et al., 1994).
There were no significant alterations in P-cell function and insulin resistance after 
bezafibrate therapy, although postprandial NEFA response was reduced, indicative of 
suppressed lipolysis. In addition, there were no changes in HDL and LDL cholesterol. An 
increase in HDL cholesterol would be consistent with a reduction in triglyceride-rich 
lipoproteins and furthermore, has been previously reported to be elevated following 
bezafibrate therapy in NIDDM (Seviour et al., 1988; Rovellini et al., 1992; Niort et al., 
1992). Therefore, longer treatment time may have been required to have seen such an 
effect in the present study.
Although bezafibrate treatment resulted in substantial reductions in triglyceride-rich 
lipoproteins and small, dense LDL, these levels remained elevated compared to 
normolipidaemic non-diabetic subjects. Other means of improving dyslipidaemia include
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diet and exercise. Weight reduction in NIDDM can reduce triglycerides and increase HDL 
cholesterol (Ginsberg and Grundy, 1982). Weintraub et al. (1988) showed that lipaemic 
response to an oral fat load containing mainly polyunsaturates was significantly lower than 
that caused by a fat load containing more saturated fats. Regular exercise has been reported 
to have beneficial effects on glucose levels, insulin sensitivity and dyslipidaemia in NIDDM 
(American Diabetes Association, 1990a; American Diabetes Association, 1990b). Short 
term exercise has been shown to enhance clearance of postprandial triglycerides (Annuzzi et 
al., 1987; Schlierf et al., 1987) and further improvements have been achieved by long term 
exercise (Merrill et al., 1989, Weintraub et al., 1989; Mankowitz et al., 1992). This effect 
has been shown to be mediated by elevated chylomicron lipolysis by LPL, rather than 
enhanced receptor-mediated uptake (Weintraub et al., 1989). Exercise-induced and diet- 
induced weight loss has also been shown to reduce the mass of small, dense LDL with a 
shift toward large, buoyant LDL particles (Williams et al., 1989; Williams et al., 1990).
Atherogenic abnormalities were found in the lipoprotein and lipoprotein subfraction 
profiles patients with SLE and psoriatic arthritis. Elevated proportions of LDL-3 in total 
LDL were found in female SLE and psoriatic patients, but not in males, and were not 
associated with raised triglyceride levels. HDL cholesterol was reduced in psoriatic patients 
and tended to be low in SLE patients compared to controls (although not significant). In 
addition to low HDL cholesterol levels, psoriatic patients tended to have lower serum and 
LDL cholesterol than controls, consistent with the findings of Lazarevic et al. (1992), 
whereas SLE patients tended to have raised serum and VLDL triglyceride, consistent with 
the findings of Ilowite et al. (1988). However there is uncertainty in SLE as to whether 
dyslipidaemia arises from disease activity or corticosteroid therapy (Ilowite et al., 1988; 
Leong et al., 1994). Predominance of small, dense LDL may be due mediators of 
inflammation affecting lipoprotein metabolism, since high percentage of LDL-3 in total LDL 
occured in both patient groups and was not associated with high triglyceride concentrations. 
Clearly further investigations with larger patient numbers are required to study the affect of 
gender and disease activity in both patient groups, and the affect of corticosteroid therapy in 
SLE patients, on LDL subfraction distribution and on the key enzymes and transfer proteins 
involved in lipoprotein metabolism.
In serum samples from normal healthy subjects, levels of IgM anti-HXO antibodies 
were higher than IgM anti-BXO antibodies suggesting that endogenous HXO rather than 
digested BXO is the immunogen. IgM anti-BXO and HXO antibody levels were higher in
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females under 50 years compared to age-matched males and older females. Corresponding 
IgG levels were lower and showed no gender or age differences. Similar age and gender 
differences have previously been reported for IgM anti-BXO antibodies (Lewis and Ng, 
1991), and the authors suggested that elevated levels in younger females may arise from 
cyclical reimmunisation of xanthine oxidase released during ischaemic events prior to 
menstruation.
IgM anti-BXO antibodies were raised in patients who died within six months of an 
MI compared to survivors, and tended to be higher in MI patients compared to controls 
(although not significant). Harrison et al. (1990) demonstrated that these antibodies were 
not raised as a consequence of the MI, but perhaps months prior to clinical manifestations. 
In line with this, in the present study, the extent of the MI (as judged by CPK levels ) did 
not correlate positively with antibody levels. It may be that that IgM anti-XO antibodies are 
produced as a result of an immune response to exposed XO from chronic atherosclerotic 
lesions of the capillary endothelium. Thus, IgM anti-XO antibody levels could potentially 
serve as an independent marker of CHD and indicator of MI risk and survival chances 
following an MI. In view of the role of xanthine oxidase in ischaemia reperfusion injury, 
IgM anti-XO antibodies may play a protective role in neutralising XO from blood and 
tissues. A protective role for the antibody is consistent with younger women having lower 
incidence of CHD compared to age-matched males and older females (Heller, 1978).
Correlations of IgM anti-XO antibodies with certain lipids and lipoproteins were 
made because their association with atherogenesis. However, there were no such 
correlations in MI patients and controls.
In view of the possible association of IgM anti-XO antibodies with the presence and 
extent of lesions of the capillary endothelium, these levels were measured in diabetic 
patients, a disease group with a 3-4 fold risk of CHD. However, possibly due to small 
patient numbers and lack of extensive atheroma, there were no differences in antibody levels 
between diabetics and controls.
The finding of significantly higher IgM anti-XO antibody levels in patients dying 
within 6 months of MI compared to survivors is potentially of prognostic value as an 
indicator of survival chances. Routine assay of serum from MI patients would allow a 
threshold antibody to be defined, above which special attention is indicated. Differences in 
IgM anti-XO antibodies are very subtle and large patient numbers are required for 
population studies. A measure of immune complexes of XO and IgM anti-XO antibodies 
may be more revealing in terms of antibody response to XO.
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